Number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
and O
their O
sensitivity O
to O
hormone O
action O
. O

The O
study O
demonstrated O
a O
decreased O
level O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
peripheral O
blood O
lymphocytes O
from O
hypercholesterolemic O
subjects O
, O
and O
an O
elevated O
level O
in O
patients O
with O
acute O
myocardial O
infarction O
. O

Mutation O
of O
a O
kappa B
B I
core I
sequence I
identified O
in O
the O
IL B
- I
2 I
promoter I
( O
- O
206 O
to O
- O
195 O
) O
partially O
inhibits O
both O
mitogen O
- O
and O
HTLV O
- O
I O
Tax O
- O
mediated O
activation O
of O
this O
transcription B
unit I
and O
blocks O
the O
specific O
binding O
of O
two O
inducible B
cellular I
factors I
. O

Novel O
region O
within O
the O
V B
kappa I
gene I
promoter I
is O
responsible O
for O
tissue O
and O
stage O
- O
specific O
expression O
of O
immunoglobulin B
genes I
in O
human O
lymphoid O
neoplasms O
. O

Immunoglobulin B
gene I
- I
specific I
transacting I
factors I
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue O
- O
specific O
expression O
of O
immunoglobulin B
genes I
. O

Different O
fragments O
of O
unrearranged B
human I
variable I
region I
of O
immunoglobulin B
kappa I
gene I
( O
V B
kappa I
) O
were O
used O
for O
cell O
- O
free O
in O
vitro O
transcription O
and O
DNA O
mobility O
shift O
assays O
. O

This O
region O
is O
located O
within O
the O
920 O
bp O
fragment O
located O
210 O
bp O
upstream O
from O
the O
coding O
region O
and O
this O
fragment O
represents O
a O
possible O
novel O
DNA O
region O
, O
which O
plays O
a O
role O
in O
the O
stage O
- O
and O
tissue O
- O
specific O
expression O
of O
immunoglobulin B
genes I
. O

A O
modified O
method O
for O
the O
determination O
of O
glucocorticoid B
receptors I
in O
human O
lymphocytes O
is O
suggested O
. O

Two O
nuclear B
proteins I
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA B
element I
have O
been O
identified O
. O

Two O
nuclear B
proteins I
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA B
element I
have O
been O
identified O
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

NF B
- I
A1 I
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF B
- I
A2 I
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF B
- I
A2 I
activates O
cell O
- O
type O
- O
specific O
transcription O
of O
the O
Ig B
promoter I
and O
NF B
- I
A1 I
mediates O
the O
other O
responses O
of O
the O
OCTA B
element I
. O

Extracts O
of O
the O
B O
- O
cell O
line O
, O
BJA O
- O
B O
, O
contain O
high O
levels O
of O
NF B
- I
A2 I
and O
specifically O
transcribe O
Ig B
promoters I
. O

In O
contrast O
, O
extracts O
from O
HeLa O
cells O
transcribed O
the O
Ig B
promoter I
poorly O
. O

Surprisingly O
, O
addition O
of O
either O
affinity O
- O
enriched O
NF O
- O
A2 O
or O
NF O
- O
A1 O
to O
either O
a O
HeLa O
extract O
or O
a O
partially O
purified O
reaction O
system O
specifically O
stimulates O
the O
Ig B
promoter I
. O

This O
suggests O
that O
the O
constitutive O
OCTA B
- I
binding I
factor I
NF I
- I
A1 I
can O
activate O
transcription O
of O
the O
Ig B
promoter I
and O
that O
B O
- O
cell O
- O
specific O
transcription O
of O
this O
promoter O
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA B
- I
binding I
protein I
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters B
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters B
. O

Because O
NF B
- I
A1 I
can O
stimulate O
Ig B
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B
promoter I
to O
the O
same O
degree O
as O
the O
snRNA B
promoters I
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B
element I
in O
these O
two O
types O
of O
promoters B
. O

The O
binding B
site I
for O
this O
complex O
activated O
a O
linked O
promoter O
after O
transfection O
into O
antigen O
receptor O
- O
activated O
T O
cells O
but O
not O
other O
cell O
types O
. O

The O
binding B
sites I
were O
extracted O
from O
a O
nuclear O
pellet O
by O
treatment O
with O
0 O
. O
4 O
mol O
/ O
l O
KCl O
and O
sonication O
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
( O
encoding O
regulatory O
protein O
T B
- I
lymphocyte I
1 I
) O
led O
to O
the O
definition O
of O
a O
silencer B
element I
that O
inhibits O
heterologous B
gene I
expression O
in O
certain O
CD4 O
+ O
T O
- O
cell O
lines O
but O
not O
in O
B O
- O
cell O
or O
non O
- O
lymphoid O
cell O
lines O
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4 B
+ I
T I
- I
cell I
gene I
Rpt I
- I
1 I
( O
encoding O
regulatory O
protein O
T B
- I
lymphocyte I
1 I
) O
led O
to O
the O
definition O
of O
a O
silencer B
element I
that O
inhibits O
heterologous B
gene I
expression O
in O
certain O
CD4 O
+ O
T O
- O
cell O
lines O
but O
not O
in O
B O
- O
cell O
or O
non O
- O
lymphoid O
cell O
lines O
. O

Formation O
of O
this O
complex O
was O
selectively O
inhibited O
by O
the O
region O
in O
HIV B
- I
1 I
containing O
a O
silencer B
element I
. O

Coordinate O
regulation O
of O
HLA B
class I
II I
gene I
expression O
during O
development O
and O
coinduction O
of O
class B
II I
genes I
by O
soluble B
factors I
suggests O
that O
common O
trans B
- I
acting I
factor I
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2 O
. O
2 O
. O
5 O
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X B
box I
, O
clear O
alterations O
in O
either O
NFX1 B
. I
1 I
or O
NFX1 B
. I
2 I
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines O
. O

In O
vivo O
responsiveness O
to O
glucocorticoid O
correlated O
with O
glucocorticoid B
receptor I
content O
in O
peripheral O
blood O
leukocytes O
in O
normal O
humans O
. O

Simultaneous O
measurements O
of O
glucocorticoid B
receptor I
content O
by O
whole O
- O
cell O
assay O
revealed O
that O
glucocorticoid B
receptor I
content O
in O
polymorphonuclear O
leukocytes O
linearly O
correlated O
with O
that O
in O
the O
corresponding O
lymphocytes O
( O
r O
= O
0 O
. O
9482 O
, O
p O
less O
than O
0 O
. O
0001 O
) O
. O

Simultaneous O
measurements O
of O
glucocorticoid B
receptor I
content O
by O
whole O
- O
cell O
assay O
revealed O
that O
glucocorticoid B
receptor I
content O
in O
polymorphonuclear O
leukocytes O
linearly O
correlated O
with O
that O
in O
the O
corresponding O
lymphocytes O
( O
r O
= O
0 O
. O
9482 O
, O
p O
less O
than O
0 O
. O
0001 O
) O
. O

There O
were O
also O
significant O
correlations O
between O
the O
maximum O
increase O
in O
polymorphonuclear O
leukocytes O
and O
glucocorticoid B
receptor I
content O
in O
polymorphonuclear O
leukocytes O
( O
r O
= O
0 O
. O
7239 O
, O
p O
less O
than O
0 O
. O
0007 O
) O
, O
and O
between O
the O
maximum O
decrease O
in O
lymphocytes O
and O
glucocorticoid B
receptor I
content O
in O
lymphocytes O
( O
r O
= O
0 O
. O
7703 O
, O
p O
less O
than O
0 O
. O
0002 O
) O
. O

There O
were O
also O
significant O
correlations O
between O
the O
maximum O
increase O
in O
polymorphonuclear O
leukocytes O
and O
glucocorticoid B
receptor I
content O
in O
polymorphonuclear O
leukocytes O
( O
r O
= O
0 O
. O
7239 O
, O
p O
less O
than O
0 O
. O
0007 O
) O
, O
and O
between O
the O
maximum O
decrease O
in O
lymphocytes O
and O
glucocorticoid B
receptor I
content O
in O
lymphocytes O
( O
r O
= O
0 O
. O
7703 O
, O
p O
less O
than O
0 O
. O
0002 O
) O
. O

These O
results O
suggest O
that O
individual O
differences O
are O
preserved O
both O
in O
glucocorticoid O
responsiveness O
and O
in O
glucocorticoid B
receptor I
content O
in O
peripheral O
blood O
leukocytes O
in O
normal O
humans O
. O

Estradiol B
receptors I
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
on O
estradiol B
receptors I
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

Estradiol B
receptors I
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon B
- I
alpha I
( O
IFN B
- I
alpha I
) O
on O
estradiol B
receptors I
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

The O
level O
of O
estradiol B
receptors I
in O
the O
cytosol O
of O
mononuclear O
cells O
was O
significantly O
lower O
in O
asymptomatic O
HBV O
carriers O
and O
patients O
with O
chronic O
hepatitis O
B O
, O
compared O
to O
normal O
controls O
. O

This O
low O
level O
of O
cytosol O
estradiol B
receptors I
in O
patients O
with O
chronic O
hepatitis O
B O
was O
increased O
by O
the O
administration O
of O
IFN B
- I
alpha I
. O

In O
addition O
, O
when O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN B
- I
alpha I
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol B
receptors I
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN B
- I
alpha I
. O

We O
previously O
reported O
that O
the O
response O
of O
mononuclear O
cells O
to O
estrogen O
is O
impaired O
in O
HBV O
carriers O
, O
and O
our O
present O
results O
suggested O
that O
this O
may O
be O
due O
to O
the O
low O
level O
of O
estradiol B
receptors I
in O
the O
cytosol O
of O
mononuclear O
cells O
. O

Association O
of O
increased O
lytic O
effector O
cell O
function O
with O
high O
estrogen B
receptor I
levels O
in O
tumor O
- O
bearing O
patients O
with O
breast O
cancer O
. O

Although O
the O
enhanced O
NK O
cell O
activity O
and O
LDCC O
were O
closely O
associated O
with O
high O
levels O
( O
greater O
than O
31 O
fmol O
/ O
mg O
) O
of O
estrogen B
receptor I
( O
ER B
) O
content O
in O
the O
primary O
tumor O
, O
no O
other O
clinical O
or O
histologic O
correlation O
between O
the O
increase O
in O
either O
parameter O
of O
cytotoxic O
effector O
cell O
function O
could O
be O
found O
. O

Properties O
of O
glucocorticoid B
receptors I
in O
Epstein O
- O
Barr O
virus O
- O
transformed O
lymphocytes O
from O
patients O
with O
familial O
cortisol O
resistance O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B
receptors I
( O
GR B
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B
in O
peripheral O
mononuclear O
cells O
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B
in O
both O
patients O
. O

The O
thermal O
stability O
of O
GR B
and O
thermal O
activation O
of O
cytosolic B
receptors I
in O
both O
patients O
were O
found O
to O
be O
normal O
. O

Octamer O
transcription O
factors O
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional B
elements I
in O
the O
immunoglobulin B
heavy I
- I
chain I
promoter I
. O

Binding O
of O
either O
factor O
to O
the O
octamer B
element I
occurred O
independently O
. O

However O
, O
OTF B
interaction O
with O
the O
heptamer B
sequence I
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif O
and O
occurred O
with O
a O
spacing O
of O
either O
2 B
or I
14 I
base I
pairs I
between O
the O
two O
elements O
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein O
- O
protein O
interactions O
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin B
( I
Ig I
) I
heavy I
and I
light I
chain I
genes I
and O
in O
the O
heavy B
chain I
enhancer I
and O
is O
a O
major O
determinant O
of O
the O
cell O
type O
specific O
expression O
of O
Ig B
genes I
in O
B O
cells O
. O

An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream B
promoter I
or I
enhancer I
element I
in O
a O
variety O
of O
housekeeping B
genes I
such O
as O
the O
histone B
H2B I
and I
U I
snRNA I
genes I
. O

One O
species O
of O
100 O
kd O
, O
designated O
OTF B
- I
1 I
, O
is O
present O
in O
all O
cell O
types O
and O
may O
exert O
its O
activating O
function O
only O
when O
it O
can O
interact O
with O
additional O
adjacent O
transcription B
factors I
. O

The O
lymphoid B
cell I
specific I
octamer I
binding I
protein I
of O
60 O
kd O
( O
OTF B
- I
2A I
) O
specifically O
stimulates O
Ig B
promoters I
which O
consist O
essentially O
of O
a O
TATA B
- I
box I
and O
an O
octamer B
sequence I
upstream O
of O
it O
. O

The O
lymphoid B
cell I
specific I
octamer I
binding I
protein I
of O
60 O
kd O
( O
OTF B
- I
2A I
) O
specifically O
stimulates O
Ig B
promoters I
which O
consist O
essentially O
of O
a O
TATA B
- I
box I
and O
an O
octamer B
sequence I
upstream O
of O
it O
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF B
- I
2B I
( O
but O
not O
OTF B
- I
2A I
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B
enhancer I
, O
we O
propose O
a O
role O
of O
the O
novel B
octamer I
factor I
in O
the O
long O
range O
activation O
by O
the O
IgH B
enhancer I
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF B
- I
2B I
( O
but O
not O
OTF B
- I
2A I
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B
enhancer I
, O
we O
propose O
a O
role O
of O
the O
novel B
octamer I
factor I
in O
the O
long O
range O
activation O
by O
the O
IgH B
enhancer I
. O

Inhibition O
of O
interleukin B
2 I
- O
induced O
proliferation O
of O
cloned O
murine O
T O
cells O
by O
glucocorticoids O
. O

Possible O
involvement O
of O
an O
inhibitory B
protein I
. O

The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin B
2 I
( O
IL B
2 I
) O
- O
induced O
T O
cell O
proliferation O
in O
two O
cytotoxic O
T O
cell O
( O
CTL O
) O
clones O
has O
been O
studied O
. O

The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin B
2 I
( O
IL B
2 I
) O
- O
induced O
T O
cell O
proliferation O
in O
two O
cytotoxic O
T O
cell O
( O
CTL O
) O
clones O
has O
been O
studied O
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL O
2 O
- O
depleted O
cultures O
of O
CTL O
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone B
prior O
to O
the O
addition O
of O
IL B
2 I
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL B
2 I
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL O
2 O
- O
depleted O
cultures O
of O
CTL O
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone B
prior O
to O
the O
addition O
of O
IL B
2 I
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL B
2 I
. O

The O
order O
of O
potency O
observed O
with O
the O
different O
steroids O
indicated O
that O
this O
inhibitory O
effect O
was O
mediated O
through O
binding O
to O
a O
specific O
glucocorticoid B
receptor I
. O

The O
action O
of O
these O
hormones B
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory B
protein I
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA O
synthesis O
. O

Furthermore O
, O
supernatant O
from O
Dx O
- O
treated O
CTL O
contained O
a O
nondialyzable O
factor O
which O
inhibited O
DNA O
synthesis O
and O
cell O
growth O
of O
CTL O
clones O
induced O
by O
IL B
2 I
. O

Blocking O
of O
IL B
2 I
synthesis O
and O
IL B
2 I
receptor I
formation O
have O
been O
proposed O
as O
one O
of O
the O
major O
mechanisms O
of O
glucocorticoid O
- O
induced O
immunosuppression O
. O

Our O
results O
indicate O
that O
these O
hormones B
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL B
2 I
activity O
. O

The O
number O
of O
glucocorticoid B
receptor I
sites O
in O
lymphocytes O
and O
plasma O
cortisol O
concentrations O
were O
measured O
in O
20 O
patients O
who O
had O
recovered O
from O
major O
depressive O
disorder O
and O
20 O
healthy O
control O
subjects O
. O

The O
number O
of O
glucocorticoid B
receptor I
sites O
in O
lymphocytes O
from O
the O
recovered O
depressed O
group O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O

This O
study O
shows O
that O
the O
reduction O
in O
glucocorticoid B
receptor I
numbers O
which O
occurs O
during O
acute O
depressive O
illness O
does O
not O
persist O
on O
recovery O
and O
is O
, O
therefore O
, O
state O
- O
dependent O
. O

Identification O
and O
purification O
of O
a O
human B
lymphoid I
- I
specific I
octamer I
- I
binding I
protein I
( O
OTF B
- I
2 I
) O
that O
activates O
transcription O
of O
an O
immunoglobulin B
promoter I
in O
vitro O
. O

The O
octamer O
sequence O
5 O
' O
- O
ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream B
element I
in O
a O
variety O
of O
promoters B
and O
also O
occurs O
as O
a O
modular B
enhancer I
element I
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin B
genes I
since O
it O
is O
found O
in O
the O
upstream B
regions I
of O
all O
heavy B
and I
light I
chain I
promoters I
and O
in O
the O
heavy B
chain I
enhancer I
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell O
- O
specific O
expression O
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin B
genes I
since O
it O
is O
found O
in O
the O
upstream B
regions I
of O
all O
heavy B
and I
light I
chain I
promoters I
and O
in O
the O
heavy B
chain I
enhancer I
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell O
- O
specific O
expression O
. O

In O
addition O
to O
the O
ubiquitous B
and I
B I
cell I
- I
specific I
octamer I
- I
binding I
factors I
, O
we O
identified O
several O
additional O
proteins O
, O
one O
of O
which O
is O
B O
cell O
- O
specific O
, O
that O
interact O
with O
the O
kappa B
promoter I
. O

To O
explain O
the O
end O
- O
organ O
resistance O
to O
cortisol O
, O
the O
glucocorticoid B
receptors I
( O
GR B
) O
in O
peripheral O
mononuclear O
leukocytes O
and O
cultured O
skin O
fibroblasts O
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O

DNA B
binding O
of O
the O
GR B
complex I
after O
temperature O
- O
induced O
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O

Nuclear O
translocation O
of O
GR B
complexes I
from O
the O
patient O
was O
also O
slightly O
decreased O
. O

These O
results O
suggest O
that O
the O
patient O
' O
s O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the O
receptor O
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR B
complex I
to O
DNA B
. O

We O
show O
that O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B
RNA I
accumulation O
of O
the O
multilineage B
growth I
factor I
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
. O

Inhibition O
of O
GM B
- I
CSF I
expression O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
occur O
independently O
of O
interleukin B
2 I
regulation O
and O
is O
probably O
mediated O
through O
cellular B
1 I
, I
25 I
( I
OH I
) I
2D3 I
receptors I
. O

Altered O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B
receptors I
in O
absence O
of O
cortisol O
: O
a O
proposed O
mechanism O
for O
increased O
thyrotropin O
secretion O
in O
corticosteroid O
deficiency O
states O
. O

Therefore O
, O
a O
possible O
role O
of O
cortisol O
in O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B
receptors I
was O
examined O
at O
the O
level O
of O
circulating O
lymphocytes O
obtained O
from O
patients O
with O
primary O
or O
secondary O
adrenocortical O
failure O
. O

Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 O
and O
was O
not O
changed O
by O
phosphodiesterase B
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate B
cyclase I
- O
phosphodiesterase B
system O
. O

Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti B
- I
CBG I
antibody I
are O
compatible O
with O
a O
role O
both O
of O
high O
- O
affinity O
glucocorticoid B
receptors I
and O
of O
CBG B
in O
mediating O
cortisol O
action O
on O
the O
human O
NK O
cell O
activity O
. O

Transfection O
studies O
have O
established O
that O
this O
octamer O
is O
involved O
in O
the O
lymphoid O
- O
specific O
transcription O
of O
immunoglobulin B
genes I
. O

We O
have O
also O
detected O
a O
DNA O
- O
protein O
interaction O
that O
may O
be O
involved O
in O
the O
cell O
- O
type O
specificity O
of O
immunoglobulin B
expression O
, O
and O
we O
have O
determined O
that O
a O
sequence O
upstream O
of O
the O
octamer O
participates O
in O
an O
interaction O
with O
a O
nuclear B
protein I
( O
s O
) O
. O

T O
cell O
line O
producing O
viral B
proteins I
) O
. O

A O
nuclear B
factor I
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional B
control I
elements I
of O
immunoglobulin B
genes I
. O

A O
nuclear B
factor I
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional B
control I
elements I
of O
immunoglobulin B
genes I
. O

Trans B
- I
acting I
factors I
that O
mediate O
B O
- O
cell O
specific O
transcription O
of O
immunoglobulin B
genes I
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin B
gene I
recombinants I
in O
lymphoid O
and O
non O
- O
lymphoid O
cells O
. O

This O
element O
directs O
lymphoid O
- O
specific O
transcription O
even O
in O
the O
presence O
of O
viral B
enhancers I
. O

We O
have O
sought O
nuclear O
factors O
that O
might O
bind O
specifically O
to O
these O
two O
regulatory B
elements I
by O
application O
of O
a O
modified O
gel O
electrophoresis O
DNA O
binding O
assay O
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

We O
report O
here O
the O
identification O
of O
a O
human B
B I
- I
cell I
nuclear I
factor I
( O
IgNF B
- I
A I
) O
that O
binds O
to O
DNA B
sequences I
in O
the O
upstream B
regions I
of O
both O
the O
mouse B
heavy I
and I
kappa I
light I
- I
chain I
gene I
promoters I
and O
also O
to O
the O
mouse B
heavy I
- I
chain I
gene I
enhancer I
. O

This O
sequence O
- O
specific O
binding O
is O
probably O
mediated O
by O
a O
highly O
conserved O
sequence O
motif O
, O
ATTTGCAT O
, O
present O
in O
all O
three O
transcriptional B
elements I
. O

The O
glucocorticoid O
target O
tissues O
that O
have O
been O
examined O
( O
circulating O
mononuclear O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
) O
have O
normal O
concentrations O
of O
glucocorticoid B
receptors I
with O
decreased O
affinity O
for O
dexamethasone O
. O

Transformation O
of O
B O
- O
lymphocytes O
with O
the O
Epstein O
- O
Barr O
virus O
leads O
to O
glucocorticoid B
receptor I
induction O
that O
is O
less O
than O
that O
observed O
with O
cells O
from O
Old O
World O
primates O
. O

Thus O
, O
unlike O
Old O
World O
primates O
, O
cortisol O
in O
New O
World O
primates O
has O
only O
weak O
sodium O
- O
retaining O
potency O
because O
the O
aldosterone B
receptor I
has O
a O
low O
affinity O
for O
cortisol O
. O

Acetylation O
and O
modulation O
of O
erythroid B
Kruppel I
- I
like I
factor I
( O
EKLF B
) O
activity O
by O
interaction O
with O
histone B
acetyltransferases I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation O
region O
. O

T O
cells O
recognizing O
antigens O
encoded O
within O
map O
units O
0 O
. O
67 O
to O
0 O
. O
73 O
of O
HSV B
DNA I
are O
frequently O
recovered O
from O
herpetic O
lesions O
. O

Expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B
protein I
VP22 B
and O
the O
viral B
dUTPase I
, O
encoded O
by O
genes B
UL49 I
and I
UL50 I
, O
respectively O
, O
are O
T B
- I
cell I
antigens I
. O

Expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B
protein I
VP22 B
and O
the O
viral B
dUTPase I
, O
encoded O
by O
genes B
UL49 I
and I
UL50 I
, O
respectively O
, O
are O
T B
- I
cell I
antigens I
. O

Reactivity O
with O
the O
tegument B
protein I
encoded O
by O
UL21 B
was O
identified O
for O
an O
additional O
patient O
. O

Three O
new O
epitopes O
were O
identified O
in O
VP16 B
, O
a O
tegument B
protein I
associated O
with O
VP22 B
. O

These O
cells O
were O
examined O
for O
ER B
mRNA I
by O
reverse O
transcription O
nested O
polymerase O
chain O
reaction O
. O

RESULTS O
: O
In O
all O
cells O
tested O
, O
ER B
mRNA I
was O
expressed O
without O
prior O
in O
vitro O
stimulation O
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B
transcripts I
between O
patients O
and O
healthy O
controls O
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone B
binding I
domain I
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone B
binding I
domain I
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

In O
vitro O
stimulation O
did O
not O
affect O
ER B
mRNA I
expression O
. O

DNA O
damaging O
agents O
induce O
expression O
of O
Fas B
ligand I
and O
subsequent O
apoptosis O
in O
T O
lymphocytes O
via O
the O
activation O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
. O

Apoptosis O
induced O
by O
DNA O
damage O
and O
other O
stresses O
can O
proceed O
via O
expression O
of O
Fas B
ligand I
( O
FasL B
) O
and O
ligation O
of O
its O
receptor O
, O
Fas O
( O
CD95 O
) O
. O

A O
nondegradable B
mutant I
of O
I B
kappa I
B I
blocked O
both O
FasL B
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O

A O
1 O
. O
2 O
kb O
FasL B
promoter I
responded O
to O
DNA O
damage O
, O
as O
well O
as O
coexpression O
with O
p65 B
Rel I
or O
Fos B
/ I
Jun I
. O

A O
1 O
. O
2 O
kb O
FasL B
promoter I
responded O
to O
DNA O
damage O
, O
as O
well O
as O
coexpression O
with O
p65 B
Rel I
or O
Fos B
/ I
Jun I
. O

M O
. O
tuberculosis O
ManLAM O
resulted O
in O
clear O
induction O
of O
the O
luciferase B
gene I
placed O
under O
the O
control O
of O
the O
wild B
- I
type I
, I
but I
not I
the I
kappaB I
- I
mutated I
, I
HIV I
- I
1 I
LTR I
region I
. O

Sequence O
analysis O
of O
nineteen O
LTRs B
cloned O
from O
2 O
adult O
and O
3 O
pediatric O
patients O
revealed O
an O
average O
of O
33 O
nucleotide O
changes O
( O
with O
respect O
to O
the O
sequence O
of O
the O
LAI B
LTR I
) O
within O
the O
455 B
- I
bp I
U3 I
region I
. O

Transient O
expression O
analyses O
in O
cells O
of O
neuroglial O
and O
lymphocytic O
origin O
demonstrated O
that O
some O
of O
these O
LTRs B
had O
activities O
which O
varied O
significantly O
from O
the O
LAI B
LTR I
in O
U O
- O
373 O
MG O
cells O
( O
an O
astrocytoma O
cell O
line O
) O
as O
well O
as O
in O
Jurkat O
cells O
( O
a O
CD4 O
- O
positive O
lymphocyte O
cell O
line O
) O
. O

While O
LTRs B
which O
demonstrated O
the O
highest O
activities O
in O
U O
- O
373 O
MG O
cells O
also O
yielded O
high O
activities O
in O
Jurkat O
cells O
, O
the O
LTRs B
were O
generally O
more O
active O
in O
Jurkat O
cells O
when O
compared O
to O
the O
LAI B
LTR I
. O

Differences O
in O
LTR B
sequence I
also O
resulted O
in O
differences O
in O
transcription O
factor O
recruitment O
to O
cis B
- I
acting I
sites I
within O
the O
U3 B
region I
of O
the O
LTR B
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O

Differences O
in O
LTR B
sequence I
also O
resulted O
in O
differences O
in O
transcription O
factor O
recruitment O
to O
cis B
- I
acting I
sites I
within O
the O
U3 B
region I
of O
the O
LTR B
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B
factor I
binding O
to O
an O
activating B
transcription I
factor I
/ O
cAMP B
response I
element I
binding I
( O
ATF B
/ O
CREB B
) O
binding O
site O
( O
located O
between O
the O
LEF B
- I
1 I
and I
distal I
NF I
- I
kappaB I
transcription I
factor I
binding I
sites I
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV B
- I
1 I
LTR I
. O

These O
findings O
suggest O
that O
LTR B
sequence I
changes O
can O
significantly O
affect O
basal O
LTR O
function O
and O
transcription O
factor O
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

The O
identification O
of O
the O
mammalian B
sex I
- I
determining I
gene I
Sry I
has O
led O
to O
the O
discovery O
of O
a O
large O
family O
of O
related O
( O
' O
HMG B
box I
' O
) O
transcription B
factors I
that O
control O
developmental O
events O
in O
yeast O
, O
C O
. O
elegans O
, O
Drosophila O
and O
vertebrates O
. O

The O
identification O
of O
the O
mammalian B
sex I
- I
determining I
gene I
Sry I
has O
led O
to O
the O
discovery O
of O
a O
large O
family O
of O
related O
( O
' O
HMG B
box I
' O
) O
transcription B
factors I
that O
control O
developmental O
events O
in O
yeast O
, O
C O
. O
elegans O
, O
Drosophila O
and O
vertebrates O
. O

The O
MRP14 B
gene I
was O
not O
expressed O
in O
monoblastic O
ML O
- O
1 O
cells O
, O
promonocytic O
U O
- O
937 O
cells O
, O
or O
promyelocytic O
HL O
- O
60 O
cells O
. O

Among O
several O
known O
transcription B
factor I
binding I
motifs I
, O
nuclear B
protein I
( I
s I
) I
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
- I
binding I
motif I
that O
was O
located O
in O
the O
upstream B
region I
of O
the O
MRP14 B
gene I
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

Among O
several O
known O
transcription B
factor I
binding I
motifs I
, O
nuclear B
protein I
( I
s I
) I
of O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
bound O
to O
the O
CCAAT B
/ I
enhancer I
binding I
protein I
( I
C I
/ I
EBP I
) I
- I
binding I
motif I
that O
was O
located O
in O
the O
upstream B
region I
of O
the O
MRP14 B
gene I
( O
- O
81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility O
- O
shift O
assay O
. O

An O
antibody O
for O
C B
/ I
EBP I
alpha I
super O
- O
shifted O
the O
nucleoprotein B
complex I
in O
THP O
- O
1 O
cells O
but O
not O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
, O
whereas O
an O
antibody O
for O
C B
/ I
EBP I
beta I
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear B
factor I
of O
the O
HL O
- O
60 O
cells O
but O
not O
with O
that O
of O
THP O
- O
1 O
cells O
. O

An O
antibody O
for O
C B
/ I
EBP I
alpha I
super O
- O
shifted O
the O
nucleoprotein B
complex I
in O
THP O
- O
1 O
cells O
but O
not O
in O
the O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
, O
whereas O
an O
antibody O
for O
C B
/ I
EBP I
beta I
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear B
factor I
of O
the O
HL O
- O
60 O
cells O
but O
not O
with O
that O
of O
THP O
- O
1 O
cells O
. O

The O
C B
/ I
EBP I
motif I
in O
the O
MRP14 B
gene I
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3 O
- O
treated O
HL O
- O
60 O
cells O
and O
THP O
- O
1 O
cells O
by O
the O
assay O
. O

It O
is O
a O
pterin B
4alpha I
- I
carbinolamine I
dehydratase I
that O
is O
involved O
in O
the O
regeneration O
of O
the O
cofactor B
tetrahydrobiopterin I
during O
the O
phenylalanine O
hydroxylase O
- O
catalyzed O
hydroxylation O
of O
phenylalanine O
. O

The O
transcription B
factor I
, O
NF B
- I
Y I
, O
plays O
a O
critical O
role O
in O
tissue O
- O
specific O
major B
histocompatibility I
complex I
class I
II I
gene I
transcription O
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

The O
NF B
- I
Y I
complex I
derived O
from O
class O
II O
+ O
mature O
B O
- O
cells O
bound O
with O
high O
affinity O
to O
anion B
exchangers I
, O
and O
eluted O
as O
an O
intact O
trimeric B
complex I
, O
whereas O
, O
NF B
- I
Y I
derived O
from O
class O
II O
- O
plasma O
B O
- O
cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2 O
. O
2 O
. O
5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF B
- I
YA I
and O
NF B
- I
YB I
: I
C I
subunit B
fractions I
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

Recombination O
of O
the O
native B
NF I
- I
YA I
: I
B I
: I
C I
complex I
with O
the O
transcriptional B
cofactor I
, O
PC4 B
, O
likewise O
conferred O
high B
affinity I
NF I
- I
Y I
binding O
to O
anion B
exchangers I
, O
and O
stabilized O
NF B
- I
Y I
interaction O
with O
CCAAT B
- I
box I
DNA I
motifs I
in O
vitro O
. O

This O
arrest O
is O
manifested O
at O
a O
molecular O
level O
as O
a O
reduction O
in O
mRNA O
levels O
of O
secretory O
immunoglobulin O
gene O
products O
such O
as O
mu O
( O
s O
) O
and O
J O
chain O
as O
well O
as O
the O
loss O
of O
the O
transcriptional B
regulator I
BLIMP B
- I
1 I
. O

OBJECTIVE O
: O
Carrier O
identification O
in O
X O
- O
linked O
immunodeficiency O
disorders O
can O
be O
based O
on O
the O
demonstration O
of O
non O
- O
random O
X O
inactivation O
( O
NRXI O
) O
in O
affected O
blood O
cell O
lineages O
when O
growth O
is O
impaired O
in O
cells O
expressing O
the O
abnormal B
gene I
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

METHODOLOGY O
: O
A O
polymerase O
chain O
reaction O
- O
based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B
repeat I
in O
the O
first B
exon I
of O
the O
androgen B
receptor I
gene I
after O
selective O
digestion O
of O
the O
active B
X I
chromosome I
with O
a O
methylation B
- I
sensitive I
enzyme I
, O
HpaII B
to O
distinguish O
between O
the O
paternal B
and I
maternal I
alleles I
and O
to O
identify O
their O
methylation O
status O
. O

Functional O
blocking O
of O
E B
- I
selectin I
, O
intercellular B
cell I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
on O
endothelial O
cells O
with O
the O
corresponding O
mouse B
mAb I
significantly O
inhibited O
glucose O
- O
induced O
increase O
in O
leukocyte O
adhesion O
( O
67 O
+ O
/ O
- O
16 O
, O
83 O
+ O
/ O
- O
12 O
, O
62 O
+ O
/ O
- O
8 O
versus O
144 O
+ O
/ O
- O
21 O
cells O
/ O
mm2 O
) O
. O

Advanced O
glycosylation O
end O
product B
- I
albumin I
significantly O
increased O
the O
number O
of O
adhering O
leukocytes O
in O
respect O
to O
native B
albumin I
used O
as O
control O
( O
110 O
+ O
/ O
- O
16 O
versus O
66 O
+ O
/ O
- O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant B
negative I
( I
DN I
) I
Ikaros I
mutation I
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B
proteins I
exert O
their O
effects O
in O
development O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B
mutations I
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros B

The O
transcription B
factors I
encoded O
by O
the O
E2A B
and O
early B
B I
cell I
factor I
( O
EBF B
) O
genes O
are O
required O
for O
the O
proper O
development O
of O
B O
lymphocytes O
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B
induces O
expression O
of O
EBF B
and O
together O
these O
transcription B
factors I
coordinately O
regulate O
numerous O
B B
lineage I
- I
associated I
genes I
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3 B
. I
6 I
kilobases I
of O
this O
RNA O
, O
which O
represents O
the O
3 B
' I
end I
of O
RXRalpha B
mRNA I
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

Activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha B
protein O
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation O
- O
induced O
loss O
of O
RXRalpha B
mRNA I
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O

The O
decrease O
in O
the O
levels O
of O
RXRalpha B
mRNA I
was O
found O
to O
be O
regulated O
at O
the O
post O
- O
transcriptional O
level O
and O
involved O
new O
protein O
synthesis O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B
D I
, O
type B
IV I
collagen I
, O
laminin B
, O
fibronectin B
, O
EGFR B
, O
c B
- I
erbB I
- I
2 I
oncoprotein I
, O
p53 B
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B
metalloproteinase I
s O
( O
MMPs B
) O
are O
a O
group O
of O
enzymes O
thought O
to O
be O
responsible O
for O
both O
normal O
connective O
tissue O
matrix O
remodelling O
and O
accelerated O
breakdown O
associated O
with O
tumour O
development O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B
metalloproteinase I
3 I
( O
MMP B
- I
3 I
, O
stromelysin B
- I
1 I
) O
in O
correlation O
with O
the O
expression O
of O
Basement B
Membrane I
( I
BM I
) I
antigen I
( O
type B
IV I
collagen I
, O
laminin B
) O
, O
fibronectin B
, O
cathepsin B
D I
, O
p53 B
, O
c B
- I
erbB I
- I
2 I
, O
proliferative O
activity O
( O
Ki B
- I
67 I
, O
PCNA B
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

These O
findings O
suggest O
that O
ST1 B
expression O
in O
breast O
cancer O
tissue O
is O
irrespective O
of O
the O
expression O
of O
the O
extracellular O
matrix O
component O
, O
the O
proteolytic B
enzyme I
cathepsin B
D I
and O
the O
growth O
fraction O
of O
the O
tumour O
, O
and O
that O
it O
could O
be O
a O
potential O
new O
prognostic O
marker O
in O
breast O
cancer O
. O

These O
findings O
suggest O
that O
ST1 B
expression O
in O
breast O
cancer O
tissue O
is O
irrespective O
of O
the O
expression O
of O
the O
extracellular O
matrix O
component O
, O
the O
proteolytic B
enzyme I
cathepsin B
D I
and O
the O
growth O
fraction O
of O
the O
tumour O
, O
and O
that O
it O
could O
be O
a O
potential O
new O
prognostic O
marker O
in O
breast O
cancer O
. O

There O
is O
increased O
activity O
of O
the O
proinflammatory B
cytokine I
, O
tumor B
necrosis I
factor I
( O
TNF B
) O
in O
alcoholic O
liver O
disease O
( O
ALD O
) O
. O

Patients O
with O
ALD O
also O
have O
decreased O
protective B
factors I
for O
cellular O
oxidative O
injury O
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B
factor I
( O
IL B
- I
8 I
) O
and O
a O
protective B
factor I
( O
MnSOD B
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B
factor I
( O
IL B
- I
8 I
) O
and O
a O
protective B
factor I
( O
MnSOD B
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

We O
conclude O
that O
transfected O
liver O
cell O
lines O
can O
be O
used O
to O
evaluate O
mechanisms O
for O
increased O
injurious B
factors I
and O
decreased O
protective B
factors I
in O
alcoholic O
liver O
injury O
. O

We O
conclude O
that O
transfected O
liver O
cell O
lines O
can O
be O
used O
to O
evaluate O
mechanisms O
for O
increased O
injurious B
factors I
and O
decreased O
protective B
factors I
in O
alcoholic O
liver O
injury O
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin B
deposition O
is O
a O
result O
of O
expression O
of O
tissue B
factor I
, O
especially O
in O
oxygen B
- I
deprived I
mononuclear I
phagocytes I
( O
MPs B
) O
. O

We O
now O
show O
that O
transcription B
factor I
early I
- I
growth I
- I
response I
gene I
product I
( O
Egr B
- I
1 I
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription O
and O
expression O
of O
tissue B
factor I
in O
hypoxic O
lung O
. O

Gel O
- O
shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic B
MPs I
and O
HeLa O
cells O
demonstrated O
increased O
DNA O
- O
binding O
activity O
at O
the O
serum B
response I
region I
( O
SRR O
; O
- O
111 O
/ O
+ O
14 O
bp O
) O
of O
the O
tissue B
factor I
promoter I
at O
Egr B
- I
1 I
motifs I
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B
plasmids I
containing O
wild B
- I
type I
or I
mutant I
SRR I
from O
the O
tissue B
factor I
promoter I
showed O
that O
intact B
Sp1 I
sites I
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr B
- I
1 I
sites I
was O
required O
for O
hypoxia O
- O
enhanced O
expression O
. O

A O
central O
role O
for O
Egr B
- I
1 I
in O
hypoxia O
- O
mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr B
- I
1 I
null O
mice O
; O
wild O
- O
type O
mice O
subjected O
to O
oxygen B
deprivation I
expressed I
tissue I
factor I
and O
showed O
fibrin B
deposition O
, O
but O
hypoxic O
homozygous O
Egr B
- I
1 I
null O
mice O
displayed O
neither O
tissue B
factor I
nor O
fibrin B
. O

These O
data O
delineate O
a O
novel O
biology O
for O
hypoxia O
- O
induced O
fibrin B
deposition O
, O
in O
which O
oxygen O
deprivation O
- O
induced O
activation O
of O
Egr B
- I
1 I
, O
resulting O
in O
expression O
of O
tissue B
factor I
, O
has O
an O
unexpected O
and O
central O
role O
. O

The O
presence O
of O
oxLDL O
is O
associated O
with O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
in O
the O
endothelium O
as O
well O
as O
endothelial O
expression O
of O
intercellular B
adhesion I
molecule I
- I
1 I
. O

Molecular O
mechanisms O
of O
promoter O
regulation O
of O
the O
gp34 B
gene I
that O
is O
trans O
- O
activated O
by O
an O
oncoprotein B
Tax I
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
. O

Molecular O
mechanisms O
of O
promoter O
regulation O
of O
the O
gp34 B
gene I
that O
is O
trans O
- O
activated O
by O
an O
oncoprotein B
Tax I
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
. O

We O
investigated O
the O
molecular O
mechanism O
of O
transcriptional O
activation O
of O
the O
gp34 B
gene I
by O
the O
Tax B
oncoprotein I
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
. O

We O
investigated O
the O
molecular O
mechanism O
of O
transcriptional O
activation O
of O
the O
gp34 B
gene I
by O
the O
Tax B
oncoprotein I
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 B
gene I
was O
activated O
by O
HTLV O
- O
I O
Tax B
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 B
is O
induced O
by O
Tax B
. O

Sequence O
analysis O
demonstrated O
that O
two O
NF B
- I
kappaB I
- I
like I
elements I
( O
1 O
and O
2 O
) O
were O
present O
in O
the O
regulatory B
region I
. O

Chloramphenicol B
acetyltransferase I
assays O
indicated O
that O
NF B
- I
kappaB I
- I
like I
element I
1 I
was O
Tax B
- O
responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native B
promoter I
. O

Chloramphenicol B
acetyltransferase I
assays O
indicated O
that O
NF B
- I
kappaB I
- I
like I
element I
1 I
was O
Tax B
- O
responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native B
promoter I
. O

Chloramphenicol B
acetyltransferase I
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF B
- I
kappaB I
- I
like I
elements I
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate B
and I
noncognate I
core I
promoters I
in O
a O
Tax O
- O
independent O
manner O
. O

Our O
results O
imply O
complex O
regulation O
of O
expression O
of O
the O
gp34 B
gene I
and O
suggest O
implication O
of O
gp34 B
in O
proliferation O
of O
HTLV O
- O
I O
infected O
T O
cells O
. O

Fibrillar B
forms I
of O
beta B
- I
amyloid I
( O
Abeta B
) O
, O
which O
are O
the O
primary O
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate O
tyrosine O
kinase O
- O
dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human O
THP1 O
monocytes O
to O
fibrillar B
Abeta I
results O
in O
the O
tyrosine B
kinase I
- O
dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
superfamily I
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human O
THP1 O
monocytes O
to O
fibrillar B
Abeta I
results O
in O
the O
tyrosine B
kinase I
- O
dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
( I
MAPK I
) I
superfamily I
. O

A O
second O
superfamily B
member I
, O
p38 B
MAPK I
, O
was O
also O
activated O
with O
similar O
kinetics O
. O

A O
second O
superfamily B
member I
, O
p38 B
MAPK I
, O
was O
also O
activated O
with O
similar O
kinetics O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Scavenger B
receptor I
and O
receptor B
for I
advanced I
glycated I
end I
products I
( O
RAGE B
) O
ligands O
failed O
to O
activate O
ERK B
and O
p38 B
MAPK I
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B
receptors I
and O
RAGE B
are O
not O
linked O
to O
these O
pathways O
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B
kinases I
, O
such O
as O
RSK1 B
and O
RSK2 B
, O
as O
well O
as O
transcription B
factors I
. O

Downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B
kinases I
, O
such O
as O
RSK1 B
and O
RSK2 B
, O
as O
well O
as O
transcription B
factors I
. O

Regulation O
of O
cellular B
retinoic I
acid I
binding I
protein I
( O
CRABP B
II I
) O
during O
human O
monocyte O
differentiation O
in O
vitro O
. O

Whereas O
CRABP B
I I
is O
ubiquitously O
expressed O
, O
CRABP B
II I
is O
mainly O
detected O
in O
various O
cell O
types O
of O
the O
skin O
. O

Whereas O
CRABP B
I I
is O
ubiquitously O
expressed O
, O
CRABP B
II I
is O
mainly O
detected O
in O
various O
cell O
types O
of O
the O
skin O
. O

By O
representative O
difference O
analysis O
we O
found O
that O
CRABP B
II I
is O
also O
strongly O
expressed O
in O
human O
monocyte O
- O
derived O
macrophages O
( O
MAC O
) O
but O
not O
in O
freshly O
isolated O
monocytes O
( O
MO O
) O
. O

Adherence O
, O
which O
is O
important O
for O
MO O
differentiation O
, O
induced O
CRABP B
II I
expression O
, O
but O
the O
addition O
of O
10 O
( O
- O
7 O
) O
M O
retinoic O
acid O
inhibited O
the O
upregulation O
of O
CRABP B
II I
expression O
during O
MO O
/ O
MAC O
differentiation O
. O

Adherence O
, O
which O
is O
important O
for O
MO O
differentiation O
, O
induced O
CRABP B
II I
expression O
, O
but O
the O
addition O
of O
10 O
( O
- O
7 O
) O
M O
retinoic O
acid O
inhibited O
the O
upregulation O
of O
CRABP B
II I
expression O
during O
MO O
/ O
MAC O
differentiation O
. O

As O
MO O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP B
II I
in O
MO O
- O
derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS B
, O
IL B
- I
4 I
, O
and O
GM B
- I
CSF I
. O

In O
contrast O
to O
MAC O
, O
MO O
- O
derived O
dendritic O
cells O
showed O
an O
extremely O
low O
expression O
of O
CRABP B
II I
. O

The O
paired B
box I
containing I
gene I
PAX B
- I
5 I
encodes O
the O
transcription B
factor I
BSAP B
( O
B B
- I
cell I
- I
specific I
activator I
protein I
) O
, O
which O
plays O
a O
key O
role O
in O
B O
- O
lymphocyte O
development O
. O

A O
monoclonal B
antibody I
against O
human B
STAT6 I
recognizes O
an O
approximately O
100 B
kDa I
molecule I
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth O
factor O
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O

A O
monoclonal B
antibody I
against O
human B
STAT6 I
recognizes O
an O
approximately O
100 B
kDa I
molecule I
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth O
factor O
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O

This O
presumed O
catfish B
STAT I
binds O
the O
mammalian B
interferon I
- I
gamma I
activation I
site I
, O
a O
known O
motif O
of O
mammalian O
STAT O
binding O
, O
as O
shown O
by O
electromobility O
shift O
assays O
. O

Purification O
of O
the O
proteins O
present O
in O
these O
DNA B
complexes I
confirms O
that O
the O
catfish O
reactive O
molecule O
binds O
to O
the O
interferon B
- I
gamma I
activation I
site I
sequence I
. O

These O
results O
suggest O
that O
STAT B
molecules I
have O
been O
highly O
conserved O
in O
vertebrate O
evolution O
. O

PCNA B
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE B
sequences I
in O
the O
promoter B
and I
CRE I
binding I
proteins I
; O
IL B
- I
2 I
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

In O
L2 O
cells O
, O
IL B
- I
2 I
stimulated O
and O
rapamycin O
inhibited O
the O
following O
: O
cAMP O
- O
independent O
CREB B
kinase I
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
variant O
cells O
, O
CREB B
kinase I
activity O
was O
constitutively O
high O
; O
IL B
- I
2 I
stimulated O
and O
rapamycin O
blocked O
PCNA O
expression O
and O
proliferation O
. O

These O
results O
indicate O
that O
IL B
- I
2 I
induces O
a O
rapamycin O
- O
sensitive O
, O
cAMP O
- O
independent O
CREB B
kinase I
activity O
in O
L2 O
cells O
. O

As O
reactive O
oxygen O
species O
( O
ROS O
) O
are O
implicated O
in O
the O
signaling O
of O
lipopolysaccharide O
( O
LPS O
) O
, O
we O
examined O
whether O
CS O
has O
a O
suppressive O
effect O
on O
inflammatory B
cytokine I
generation O
from O
human O
monocyte O
s O
in O
vitro O
. O

Northern O
blot O
analysis O
showed O
that O
LPS O
- O
induced O
expression O
of O
these O
cytokine B
mRNA I
in O
monocytes O
was O
suppressed O
by O
CS O
. O

These O
findings O
indicate O
that O
CS O
has O
a O
suppressive O
effect O
on O
proinflammatory O
cytokine O
production O
from O
monocytes O
, O
and O
this O
effect O
is O
based O
in O
part O
on O
the O
suppression O
of O
cytokine B
mRNA I
expression O
through O
inhibition O
of O
NF B
- I
kappaB I
activation O
. O

Differentiation B
inhibitory I
factor I
nm23 B
gene I
has O
been O
found O
to O
be O
expressed O
in O
high O
quantities O
in O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
especially O
in O
acute O
monocytic O
leukemia O
( O
AML O
- O
M5 O
) O
and O
is O
suggested O
as O
a O
new O
prognostic O
factor O
in O
AML O
- O
M5 O
. O

We O
report O
an O
example O
of O
elevated O
expression O
of O
nm23 B
mRNA I
in O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
( O
CML O
) O
who O
developed O
monoblastic O
crisis O
. O

These O
findings O
are O
compatible O
with O
our O
previous O
report O
that O
nm23 B
gene I
is O
overexpressed O
in O
monocytic O
leukemia O
. O

In O
our O
TK6i O
- O
G3 O
and O
G9 O
tk O
heterozygous O
cell O
lines O
, O
the O
active O
tk B
allele I
is O
linked O
to O
an O
inducible O
promoter B
element I
. O

In O
our O
TK6i O
- O
G3 O
and O
G9 O
tk O
heterozygous O
cell O
lines O
, O
the O
active O
tk B
allele I
is O
linked O
to O
an O
inducible O
promoter B
element I
. O

Tk B
mRNA I
is O
induced O
following O
treatment O
with O
estrogen O
. O

Mutation O
of O
BCL B
- I
6 I
gene I
in O
normal O
B O
cells O
by O
the O
process O
of O
somatic O
hypermutation O
of O
Ig B
genes I
. O

The O
mutation O
pattern O
was O
similar O
to O
that O
of O
Ig B
genes I
. O

Analysis O
of O
the O
cytoplasmic B
inhibitor I
IkappaBalpha B
indicated O
that O
anti O
- O
CD3 O
+ O
anti O
- O
CD28 O
stimulation O
induced O
a O
long O
- O
lasting O
degradation O
in O
CD45RA O
+ O
cells O
but O
in O
CD45RO O
+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Lymphoma O
cells O
from O
both O
cases O
showed O
the O
mature O
B O
- O
cell O
immunophenotype O
and O
had O
rearrangements O
of O
the O
BCL6 B
gene I
. O

It O
shares O
structural O
similarities O
with O
and O
is O
a O
member O
of O
the O
IkappaB B
family I
of O
proteins O
. O

Bcl B
- I
3 I
in O
nuclear O
extracts O
of O
TF O
- O
1 O
cells O
bound O
to O
a O
kappaB B
enhancer I
in O
the O
c B
- I
myb I
promoter I
together O
with O
NF B
- I
kappaB2 I
/ I
p52 I
and O
this O
binding O
activity O
was O
enhanced O
by O
GM B
- I
CSF I
stimulation O
. O

Inhibition O
of O
CD28 O
/ O
CD3 O
- O
mediated O
costimulation O
of O
naive O
and O
memory O
human O
T O
lymphocytes O
by O
intracellular O
incorporation O
of O
polyclonal B
antibodies I
specific O
for O
the O
activator B
protein I
- I
1 I
transcriptional I
complex I
. O

Cells O
scraped O
off O
poly O
- O
L O
- O
lysine O
in O
the O
presence O
of O
Ig B
FITC I
efficiently O
incorporated O
Ig O
, O
with O
relatively O
uniform O
fluorescence O
. O

Differential O
expression O
of O
Nur77 B
family I
members I
in O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
- O
infected O
cells O
: O
transactivation O
of O
the O
TR3 B
/ I
nur77 I
gene I
by O
Tax B
protein I
. O

We O
analyzed O
the O
differential O
expression O
and O
regulation O
of O
three O
members O
of O
the O
Nur77 B
transcription I
factor I
family I
by O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
. O

Attenuation O
of O
the O
inducible O
transcriptional O
response O
occurs O
during O
heat O
shock O
or O
upon O
recovery O
at O
non O
- O
stress O
conditions O
and O
involves O
dissociation O
of O
the O
HSF1 B
trimer I
and O
loss O
of O
activity O
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

We O
have O
used O
the O
hydrophobic B
repeats I
of O
the O
HSF1 B
trimerization O
domain O
in O
the O
yeast O
two O
- O
hybrid O
protein O
interaction O
assay O
to O
identify O
heat B
shock I
factor I
binding I
protein I
1 I
( O
HSBP1 B
) O
, O
a O
novel O
, O
conserved O
, O
76 B
- I
amino I
- I
acid I
protein I
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B
repeats I
that O
interact O
with O
the O
HSF1 B
heptad I
repeats I
. O

Most O
studies O
on O
the O
control O
of O
cytokine O
gene O
expression O
have O
involved O
the O
functional O
analysis O
of O
proximal B
promoters I
. O

Recent O
work O
has O
identified O
distal B
elements I
that O
mediate O
long O
- O
range O
cytokine O
gene O
regulation O
and O
has O
implicated O
chromatin O
reorganization O
in O
regulation O
of O
cytokine B
gene I
loci I
. O

These O
studies O
have O
begun O
to O
elucidate O
the O
basis O
for O
cell O
- O
specificity O
and O
high O
- O
level O
expression O
of O
cytokine B
genes I
. O

Stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2 O
+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2 B
+ I
- I
calmodulin I
- I
dependent I
protein I
kinase I
IV I
( O
CaMKIV B
) O
, O
a O
nuclear B
enzyme I
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
- I
binding I
protein I
( O
CREB B
) O
. O

Nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
controls O
transcription O
of O
inflammation B
genes I
. O

On O
activation O
, O
NF B
kappa I
B I
is O
rapidly O
released O
from O
its O
cytoplasmic B
inhibitor I
( O
I B
kappa I
B I
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA B
response I
elements I
in O
gene O
promoter O
regions O
. O

Corticosteroids O
strongly O
inhibit O
intestinal O
NF B
kappa I
B I
activation O
in O
IBD O
in O
vivo O
and O
in O
vitro O
by O
stabilising O
the O
cytosolic B
inhibitor I
I B
kappa I
B I
alpha O
against O
activation O
induced O
degradation O
. O

Synergistic O
activation O
of O
MAP B
kinase I
( O
ERK1 B
/ I
2 I
) O
by O
erythropoietin B
and O
stem B
cell I
factor I
is O
essential O
for O
expanded O
erythropoiesis O
. O

By O
using O
purified O
human O
erythroid O
colony O
- O
forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B
and O
EPO B
synergistically O
activate O
MAP B
kinase I
( O
MAPK B
, O
ERK1 B
/ I
2 I
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

Binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
to O
CD4 B
and I
CXCR4 I
receptors I
differentially O
regulates O
expression O
of O
inflammatory B
genes I
and O
activates O
the O
MEK B
/ O
ERK O
signaling O
pathway O
. O

We O
have O
previously O
shown O
that O
binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
virions O
to O
CD4 B
receptors I
stimulates O
association O
of O
Lck B
with O
Raf B
- I
1 I
and O
results O
in O
the O
activation O
of O
Raf B
- I
1 I
kinase O
in O
a O
Ras O
- O
independent O
manner O
. O

The O
activation O
of O
this O
signaling O
pathway O
requires O
functional O
CD4 B
receptors I
and O
is O
independent O
of O
binding O
to O
CXCR4 B
. O

Binding O
of O
the O
natural O
ligand O
stromal B
cell I
- I
derived I
factor I
1 I
( O
SDF B
- I
1 I
) O
to O
CXCR4 B
, O
which O
inhibits O
entry O
of O
T O
- O
cell O
- O
tropic O
HIV O
- O
1 O
, O
activates O
also O
the O
ERK O
/ O
MAP B
kinase I
pathway O
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV B
- I
1 I
envelope I
glycoproteins I
to O
CD4 B
receptor I
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine B
receptor I
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory B
genes I
and O
may O
contribute O
significantly O
to O
HIV O
- O
1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV B
- I
1 I
envelope I
glycoproteins I
to O
CD4 B
receptor I
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine B
receptor I
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory B
genes I
and O
may O
contribute O
significantly O
to O
HIV O
- O
1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV B
- I
1 I
envelope I
glycoproteins I
to O
CD4 B
receptor I
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine B
receptor I
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory B
genes I
and O
may O
contribute O
significantly O
to O
HIV O
- O
1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

Antigen O
receptor O
signaling O
induces O
MAP O
kinase O
- O
mediated O
phosphorylation O
and O
degradation O
of O
the O
BCL B
- I
6 I
transcription B
factor I
. O

Glucocorticoid B
receptors I
are O
differentially O
expressed O
in O
the O
cells O
and O
tissues O
of O
the O
immune O
system O
. O

Cytosolic B
glucocorticoid I
receptor I
( O
GR B
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR B
protein I
than O
the O
spleen O
. O

To O
address O
these O
inconsistencies O
, O
GR B
protein I
was O
assessed O
in O
immune O
cells O
and O
tissues O
using O
cytosolic O
radioligand O
binding O
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene B
products I
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B
, O
but O
not O
HEB B
or O
E2 B
- I
2 I
, O
leads O
to O
a O
complete O
arrest O
in O
B O
- O
lymphocyte O
development O
. O

We O
find O
that O
the O
alternatively O
spliced O
E12 B
and I
E47 I
bHLH I
proteins I
of O
the O
E2A B
gene I
play O
similar O
and O
additive O
roles O
in O
supporting O
B O
lymphopoiesis O
. O

Biased O
dependency O
of O
CD80 B
versus O
CD86 B
in O
the O
induction O
of O
transcription B
factors I
regulating O
the O
human B
IL I
- I
2 I
promoter I
. O

Furthermore O
, O
the O
activity O
of O
transcription B
factors I
regulating O
the O
IL B
- I
2 I
promoter I
- I
enhancer I
region I
including O
activation B
protein I
- I
1 I
, O
CD28 B
response I
element I
and O
nuclear B
factor I
kappaB I
were O
4 O
- O
8 O
times O
higher O
after O
CD80 B
compared O
to O
CD86 B
ligation O
. O

Duplication O
of O
the O
DR3 B
gene I
on O
human B
chromosome I
1p36 I
and O
its O
deletion O
in O
human O
neuroblastoma O
. O

Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 B
gene I
, O
including O
the O
extracellular B
and I
transmembrane I
regions I
but O
not O
the O
cytoplasmic B
domain I
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O

Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 B
gene I
, O
including O
the O
extracellular B
and I
transmembrane I
regions I
but O
not O
the O
cytoplasmic B
domain I
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O

Cycloheximide O
, O
a O
reversible O
protein O
synthesis O
inhibitor O
, O
is O
thought O
to O
block O
DNA O
replication O
in O
normal O
cells O
by O
preventing O
synthesis O
of O
a O
labile B
protein I
. O

Primary O
cortisol O
resistance O
accompanied O
by O
a O
reduction O
in O
glucocorticoid B
receptors I
in O
two O
members O
of O
the O
same O
family O
. O

To O
study O
this O
apparent O
end O
- O
organ O
resistance O
to O
cortisol O
, O
we O
examined O
the O
glucocorticoid B
receptors I
in O
peripheral O
mononuclear O
cells O
. O

Using O
whole O
cell O
assays O
, O
glucocorticoid B
receptors I
in O
both O
patients O
were O
found O
to O
have O
reduced O
total O
binding O
capacity O
. O

We O
conclude O
that O
these O
two O
patients O
, O
members O
of O
the O
same O
family O
, O
have O
primary O
cortisol O
resistance O
accompanied O
by O
a O
reduced O
number O
of O
glucocorticoid B
receptors I
. O

[ O
Glucocorticoid B
receptors I
and O
response O
to O
polychemotherapy O
in O
acute O
lymphatic O
leukemia O
] O

Glucocorticoid B
receptor I
( O
GR B
) O
levels O
were O
quantified O
in O
leukemic O
blasts O
from O
peripheral O
blood O
of O
86 O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

The O
study O
of O
glucocorticoid B
receptors I
in O
leukemic O
cells O
may O
predict O
response O
to O
combination O
chemotherapy O
in O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

Results O
were O
the O
same O
when O
the O
amount O
of O
dexamethasone O
bound O
per O
milligram O
of O
cell B
protein I
was O
measured O
. O

Our O
results O
indicate O
that O
cell O
cycle O
changes O
in O
dexamethasone O
binding O
are O
not O
simply O
related O
to O
changes O
in O
cell B
protein I
or O
cell O
volume O
during O
the O
cell O
cycle O
. O

Presence O
and O
steroid O
inducibility O
of O
glutamine B
synthetase I
in O
human O
leukemic O
cells O
. O

Glutamine B
synthetase I
( O
EC O
6 O
. O
3 O
. O
1 O
. O
2 O
; O
GS O
) O
is O
present O
in O
lymphoblasts O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
as O
well O
as O
in O
normal O
peripheral O
blood O
lymphocytes O
. O

The O
increase O
was O
specific O
for O
glucocorticoid B
receptor I
ligands O
. O

A O
direct O
correlation O
was O
found O
between O
the O
magnitude O
of O
glucocorticoid O
- O
mediated O
increase O
of O
GS O
activity O
and O
the O
cellular O
levels O
of O
specific O
glucocorticoid B
receptors I
assayed O
in O
the O
same O
cell O
specimen O
. O

Binding O
of O
progestins O
to O
the O
glucocorticoid B
receptor I
. O

A O
number O
of O
physiological O
and O
synthetic O
progestins O
were O
tested O
for O
their O
ability O
to O
compete O
with O
[ O
3H O
] O
dexamethasone O
for O
the O
binding O
to O
the O
glucocorticoid B
receptor I
of O
human O
mononuclear O
leukocytes O
and O
their O
ability O
to O
elicit O
glucocorticoid O
- O
like O
effects O
on O
the O
same O
cells O
. O

The O
effective O
binding O
of O
medroxyprogesterone O
acetate O
to O
the O
glucocorticoid B
receptor I
was O
confirmed O
by O
direct O
binding O
studies O
utilizing O
a O
tritiated O
derivative O
of O
this O
steroid O
. O

No O
evidence O
for O
the O
existence O
of O
a O
specific O
progesterone B
receptor I
in O
human O
mononuclear O
leukocytes O
was O
obtained O
as O
judged O
by O
the O
results O
of O
competition O
experiments O
where O
a O
progesterone O
receptor O
- O
specific O
ligand O
[ O
3H O
] O
Org O
2058 O
was O
used O
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T B
- I
cell I
mitogens I
concanavalin B
A I
and O
phytohaemagglutinin B
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed O
mitogen O
- O
stimulated O
cultures O
. O

In O
contrast O
, O
the O
synthetic O
progestins O
related O
structurally O
to O
19 O
- O
nortestosterone O
, O
norethisterone O
and O
d O
- O
norgestrel O
, O
were O
virtually O
devoid O
of O
binding O
affinity O
towards O
the O
glucocorticoid B
receptor I
nor O
did O
they O
measurably O
influence O
the O
in O
vitro O
lymphocyte O
functions O
. O

Ultrastructural O
studies O
demonstrated O
sequential O
changes O
in O
the O
cytoplasm O
, O
including O
swelling O
of O
mitochondria O
and O
cytoplasmic O
decompartmentalizati O
, O
followed O
by O
loss O
of O
surface O
microvilli O
with O
the O
appearance O
of O
` O
` O
holes O
' O
' O
in O
the O
cell O
membrane O
, O
and O
subsequent O
condensation O
of O
nuclear B
chromatin I
. O

It O
is O
suggested O
that O
the O
glucocorticoid O
- O
induced O
lysis O
of O
human O
CLL O
cells O
is O
similar O
to O
the O
phenomenon O
observed O
in O
rat O
or O
murine O
lymphocytes O
and O
is O
mediated O
by O
interaction O
of O
the O
steroid O
molecule O
with O
the O
cytoplasmic B
receptor I
. O

Glucocorticoid B
receptors I
in O
lymphoid O
tumors O
. O

There O
is O
a O
range O
of O
levels O
of O
glucocorticoid B
receptor I
numbers O
seen O
in O
the O
various O
subclasses O
of O
acute O
lymphatic O
leukemia O
( O
ALL O
) O
. O

All O
clinical O
specimens O
from O
patients O
with O
lymphatic O
leukemia O
have O
some O
measurable O
level O
of O
glucocorticoid B
receptors I
; O
therefore O
, O
the O
resistance O
seen O
in O
vivo O
can O
not O
be O
explained O
by O
the O
lack O
of O
receptors O
. O

[ O
Tumor O
histology O
and O
steroid B
receptors I
in O
breast O
carcinoma O
] O

The O
steroid B
receptor I
content O
does O
not O
correlate O
with O
histological O
parameters O

Inhibition O
of O
PA B
in O
both O
cell O
types O
is O
specific O
for O
active O
glucocorticoids O
, O
and O
this O
specificity O
parallels O
the O
ability O
of O
various O
steroids O
to O
bind O
to O
glucocorticoid B
receptors I
. O

Thus O
, O
low O
levels O
of O
glucocorticoid B
- I
inducible I
inhibitors I
may O
contribute O
to O
, O
but O
can O
not O
fully O
account O
for O
, O
Dex O
inhibition O
of O
GM4672A B
PA I
activity O
. O

The O
results O
indicate O
that O
mononuclear O
leukocytes O
could O
be O
useful O
for O
studying O
the O
physiological O
significance O
of O
these O
mineralocorticoid B
receptors I
and O
their O
regulation O
in O
humans O
. O

The O
capacity O
and O
the O
affinity O
of O
dexamethasone O
for O
glucocorticoid B
receptors I
ranged O
in O
the O
normal O
values O
. O

These O
data O
suggest O
a O
possible O
down O
- O
regulation O
of O
mineralocorticoid B
receptors I
in O
humans O
. O

However O
, O
the O
recent O
description O
of O
estrogen B
receptors I
in O
the O
thymus O
and O
in O
some O
lymphocyte O
subpopulations O
, O
as O
well O
as O
a O
deeper O
understanding O
of O
regulating O
factors O
in O
the O
immune O
system O
, O
open O
the O
possibility O
of O
a O
more O
detailed O
understanding O
of O
the O
estrogen O
mechanism O
of O
interference O
. O

Concentrations O
of O
cytosol B
and I
nuclear I
estrogen I
receptors I
( O
ERC B
and O
ERN B
, O
respectively O
) O
and O
progestin B
receptors I
( O
PRC B
and O
PRN B
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

[ O
Glucocorticoid B
receptor I
level O
in O
the O
blood O
leukocytes O
in O
different O
acute O
diseases O
] O

Content O
of O
glucocorticoid B
receptors I
in O
cytosol O
of O
blood O
leukocytes O
, O
concentration O
of O
cortisol O
and O
amount O
of O
leukocytes O
in O
blood O
were O
studied O
in O
20 O
patients O
with O
acute O
impairments O
within O
the O
second O
day O
of O
the O
disease O
. O

In O
acute O
pancreatitis O
content O
of O
the O
leukocyte B
receptors I
was O
not O
altered O
as O
compared O
with O
controls O
. O

The O
role O
of O
glucocorticoid B
receptors I
in O
immunological O
processes O
under O
conditions O
of O
purulent O
complications O
and O
possibility O
to O
regulate O
the O
metabolism O
in O
leukocytes O

Therapeutic O
concentrations O
of O
glucocorticoids O
suppress O
the O
antimicrobial O
activity O
of O
human O
macrophages O
without O
impairing O
their O
responsiveness O
to O
gamma B
interferon I
. O

Interleukin B
2 I
receptor I
( O
Tac B
antigen I
) O
expression O
in O
HTLV O
- O
I O
- O
associated O
adult O
T O
- O
cell O
leukemia O
. O

Resting O
T O
- O
cells O
do O
not O
express O
IL B
- I
2 I
receptors I
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T O
- O
cells O
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal B
antibodies I
with O
the O
antigen B
- I
specific I
T I
- I
cell I
receptor I
complex I
. O

Using O
anti B
- I
Tac I
, O
a O
monoclonal B
antibody I
that O
recognizes O
the O
IL B
- I
2 I
receptor I
, O
the O
receptor O
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 O
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 O
, O
000 O
mature O
form O
. O

Normal O
resting O
T O
- O
cells O
and O
most O
leukemic O
T O
- O
cell O
populations O
do O
not O
express O
IL B
- I
2 I
receptors I
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
associated O
adult O
T O
- O
cell O
leukemia O
expressed O
the O
Tac B
antigen I
. O

In O
human O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B
reading I
frame I
protein I
encoded O
in O
part O
by O
the O
pX B
region I
of O
this O
virus O
may O
act O
as O
a O
transacting B
transcriptional I
activator I
that O
induces O
IL B
- I
2 I
receptor I
gene I
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL B
- I
2 I
receptor I
expression O
with O
adult O
T O
- O
cell O
lymphotropic O
virus O
- O
I O
infection O
of O
lymphoid O
cells O
. O

One O
of O
the O
patients O
had O
6 O
- O
and O
3 O
- O
mo O
remissions O
of O
his O
leukemia O
following O
two O
courses O
of O
therapy O
with O
this O
monoclonal B
antibody I
directed O
toward O
this O
growth B
factor I
receptor I
. O

Lymphocyte O
glucocorticoid B
receptor I
binding O
in O
depressed O
patients O
with O
hypercortisolemia O
. O

This O
hypercortisolemia O
in O
the O
absence O
of O
clinical O
effects O
suggests O
a O
state O
of O
hormone O
resistance O
and O
could O
be O
mediated O
by O
alterations O
in O
the O
glucocorticoid B
receptor I
. O

Earlier O
studies O
have O
shown O
that O
small O
doses O
of O
glucocorticoids O
cause O
a O
decrease O
in O
glucocorticoid B
receptor I
binding O
in O
normal O
human O
lymphocytes O
. O

The O
lack O
of O
a O
change O
in O
lymphocyte O
glucocorticoid B
receptor I
concentration O
in O
the O
presence O
of O
cortisol O
excess O
suggests O
the O
possibility O
that O
hypercortisolemia O
in O
depressive O
illness O
represents O
a O
state O
of O
peripheral O
glucocorticoid O
resistance O
. O

The O
glucocorticoid B
receptor I
is O
an O
intracellular B
protein I
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti B
- I
receptor I
antibodies I
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene O
expression O
. O

The O
glucocorticoid B
receptor I
is O
an O
intracellular B
protein I
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti B
- I
receptor I
antibodies I
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene O
expression O
. O

Some O
of O
these O
factors O
appear O
to O
exert O
their O
effect O
by O
controlling O
critical O
receptor O
properties O
such O
as O
ATP O
- O
dependent O
phosphorylation O
, O
integrity O
of O
thiol B
groups I
, O
and O
exposure O
of O
key B
amino I
acid I
residues I
. O

Glucocorticoid O
antagonists O
are O
steroids O
that O
interact O
with O
the O
receptor O
but O
either O
fail O
to O
produce O
a O
stable B
complex I
or O
produce O
a O
stable B
but I
inefficient I
complex I
. O

The O
transformed B
receptor I
then O
interacts O
with O
chromatin B
( O
state O
D O
) O
. O

Cells O
in O
G0 O
, O
G1a O
and O
G1b O
phases O
, O
where O
the O
G1a O
- O
G1b O
transition O
is O
an O
Interleukin B
2 I
dependent O
event O
, O
were O
quantitated O
by O
flow O
cytometry O
. O

Few O
but O
significant O
numbers O
of O
glucocorticoid B
receptors I
( O
2700 O
/ O
cell O
) O
and O
no O
insulin B
receptors I
( O
- O
1 O
/ O
cell O
) O
were O
found O
in O
the O
resting O
( O
G0 O
) O
phase O
. O

Few O
but O
significant O
numbers O
of O
glucocorticoid B
receptors I
( O
2700 O
/ O
cell O
) O
and O
no O
insulin B
receptors I
( O
- O
1 O
/ O
cell O
) O
were O
found O
in O
the O
resting O
( O
G0 O
) O
phase O
. O

Glucocorticoid B
receptors I
and O
cortico O
- O
sensitivity O
in O
a O
human O
clonal O
monocytic O
cell O
line O
, O
CM O
- O
SM O
. O

DEX O
almost O
completely O
inhibited O
TPA O
activation O
of O
the O
following O
macrophage O
functions O
: O
adherency O
to O
the O
culture O
plate O
, O
expression O
of O
lysosomal B
enzymes I
, O
Fc B
and I
C3 I
receptors I
, O
and O
stimulation O
of O
phagocytosis O
. O

Glucocorticoid B
receptor I
and O
in O
vitro O
sensitivity O
to O
steroid O
hormones O
in O
human O
lymphoproliferative O
diseases O
and O
myeloid O
leukemia O
. O

The O
glucocorticoid B
receptor I
( O
GR B
) O
quantitation O
by O
a O
whole O
- O
cell O
assay O
and O
/ O
or O
cytosol O
technique O
and O
the O
in O
vitro O
sensitivity O
to O
steroids O
have O
been O
assessed O
in O
peripheral O
blood O
cells O
from O
normal O
donors O
and O
patients O
with O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
, O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphosarcoma O
cell O
leukemia O
( O
LSCL O
) O
, O
acute O
nonlymphatic O
leukemia O
( O
ANLL O
) O
, O
and O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

Glucocorticoid B
receptors I
and O
in O
vitro O
corticosensitivity O
of O
peanut O
- O
positive O
and O
peanut O
- O
negative O
human O
thymocyte O
subpopulations O
. O

These O
2 O
cell O
subpopulations O
were O
analyzed O
for O
glucocorticoid B
receptor I
content O
by O
using O
a O
whole O
cell O
assay O
, O
with O
( O
3H O
) O
- O
triamcinolone O
acetonide O
as O
tracer O
. O

Despite O
the O
greater O
number O
of O
glucocorticoid B
receptor I
sites O
, O
the O
peanut O
- O
negative O
thymocyte O
subpopulation O
did O
not O
differ O
from O
the O
peanut O
- O
positive O
one O
in O
its O
sensitivity O
to O
the O
inhibitory O
effects O
of O
triamcinolone O
acetonide O
, O
as O
determined O
by O
measurements O
of O
the O
incorporation O
of O
radiolabeled O
precursors O
of O
protein O
and O
DNA O
. O

Thus O
, O
our O
data O
suggest O
that O
glucocorticoid O
receptor O
density O
and O
corticosensitivity O
are O
not O
directly O
correlated O
and O
that O
the O
number O
of O
glucocorticoid B
receptor I
sites O
may O
be O
dependent O
on O
the O
degree O
of O
immunologic O
maturation O

Glucocorticoid B
receptors I
of O
mononuclear O
leukocytes O
from O
myasthenia O
gravis O
patients O
. O

The O
present O
study O
was O
performed O
to O
analyse O
glucocorticoid B
receptor I
( O
GR B
) O
binding O
in O
peripheral O
blood O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
39 O
myasthenia O
gravis O
( O
MG O
) O
patients O
( O
unoperated O
patients O
( O
n O
= O
13 O
) O
, O
thymectomized O
patients O
( O
n O
= O
14 O
) O
and O
patients O
receiving O
glucocorticoids O
: O
thymectomized O
( O
n O
= O
11 O
) O
and O
unoperated O
( O
n O
= O
6 O
] O
. O

Antisera O
raised O
against O
human B
lymphoid I
glucocorticoid I
receptors I
were O
used O
in O
combination O
with O
the O
glucocorticoid O
receptor O
affinity O
label O
[ O
3H O
] O
dexamethasone O
21 O
- O
mesylate O
[ O
( O
3H O
] O
DM O
) O
to O
identify O
the O
glucocorticoid B
receptors I
of O
the O
human O
B O
- O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
and O
the O
human O
T O
- O
cell O
leukemic O
cell O
line O
CEM O
- O
C7 O
. O

The O
presence O
of O
anti B
- I
human I
glucocorticoid I
receptor I
antibodies I
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B
3H I
] I
TA I
- I
receptor I
- I
antibody I
complexes I
to O
Protein B
A I
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B
3H I
] I
TA I
- I
receptor I
complexes I
on O
sucrose O
gradients O
. O

Effect O
of O
thymosin O
on O
glucocorticoid B
receptor I
activity O
and O
glucocorticoid O
sensitivity O
of O
human O
thymocytes O
. O

The O
glucocorticoid B
receptor I
activity O
in O
normal O
infant O
thymocytes O
was O
found O
to O
be O
2 O
, O
146 O
+ O
/ O
- O
726 O
( O
s O
. O
d O
. O
) O
sites O
per O
cell O
with O
dissociation O
constant O
of O
1 O
. O
4 O
+ O
/ O
- O
0 O
. O
6 O
X O
10 O
( O
- O
8 O
) O
M O
. O

The O
disparity O
of O
results O
between O
endogenous O
and O
exogenous O
hypercorticism O
, O
between O
the O
two O
cell O
types O
, O
and O
between O
the O
present O
studies O
and O
previous O
studies O
suggest O
that O
the O
effects O
of O
glucocorticoid O
excess O
on O
the O
insulin B
receptor I
are O
extremely O
complex O
and O
wide O
- O
ranging O
and O
that O
in O
this O
condition O
, O
extrapolations O
in O
humans O
from O
data O
with O
circulating O
cells O
to O
liver O
and O
muscle O
may O
not O
be O
appropriate O
. O

Specific O
glucocorticoid B
receptors I
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
from O
12 O
patients O
with O
anorexia O
nervosa O
and O
21 O
healthy O
control O
subjects O
. O

Cells O
from O
patients O
were O
found O
to O
contain O
a O
significantly O
( O
p O
less O
than O
0 O
. O
01 O
) O
lower O
level O
of O
glucocorticoid B
receptor I
( O
3830 O
+ O
/ O
- O
210 O
sites O
/ O
cell O
, O
mean O
+ O
/ O
- O
SE O
) O
than O
those O
from O
controls O
( O
4930 O
+ O
/ O
- O
250 O
sites O
/ O
cell O
) O
. O

A O
partial O
glucocorticoid B
receptor I
defect O
may O
well O
explain O
the O
abnormal O
cortisol O
metabolism O
and O
glucocorticoid O
resistance O
commonly O
found O
in O
patients O
with O
anorexia O
nervosa O
. O

Regulation O
of O
the O
glucocorticoid B
receptor I
in O
human O
lymphocytes O
. O

The O
presence O
of O
a O
glucocorticoid B
receptor I
in O
human O
lymphocytes O
is O
well O
established O
, O
but O
factors O
affecting O
its O
regulation O
have O
not O
been O
described O
. O

Moderate O
- O
to O
- O
severe O
intraductal O
epithelial O
hyperplasias O
were O
more O
often O
associated O
with O
immunoglobulin B
G I
localization O
that O
were O
other O
benign O
lesions O

Correlation O
of O
steroid B
receptors I
with O
histologic O
differentiation O
in O
mammary O
carcinoma O
. O

A O
detailed O
histopathologic O
review O
of O
50 O
primary O
breast O
cancer O
tumors O
analyzed O
for O
estrogen B
receptor I
( O
ER B
) O
level O
was O
carried O
out O
and O
a O
variety O
of O
morphologic O
features O
correlated O
with O
ER B
results O
to O
identify O
any O
factors O
that O
will O
improve O
the O
management O
and O
prognosis O
for O
breast O
cancer O
. O

Tumors O
binding O
more O
than O
5 O
fmol O
/ O
mg O
cytosol B
protein I
were O
classified O
as O
ER B
- O
positive O
. O

Progesterone B
receptor I
( O
PR B
) O
level O
was O
analyzed O
in O
some O
specimens O
with O
the O
use O
of O
a O
similar O
method O
. O

Mononuclear O
cells O
infiltrating O
human O
mammary O
carcinomas O
: O
immunohistochemical O
analysis O
with O
monoclonal B
antibodies I
. O

Breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major B
histocompatibility I
antigens I
( O
HLA B
- I
A I
, O
- B
B I
, O
- O
C O
; O
Ia B
- I
like I
) O
. O

Some O
of O
the O
T O
cells O
had O
the O
Ia B
antigen I
and O
were O
thus O
probably O
activated O
. O

A O
few O
monocytes O
were O
heterogeneous O
according O
to O
their O
markers O
( O
OKM B
I I
and O
acid O
phosphatase O
) O
. O

In O
6 O
cases O
only O
there O
was O
a O
strong O
infiltration O
of O
mononuclear O
cells O
positive O
for O
acid B
phosphatase I
. O

A O
case O
of O
male O
pseudohermaphroditis O
with O
normal O
androgen B
receptor I
binding O
and O
47 O
, O
XYY O
karyotype O
. O

To O
directly O
examine O
the O
effect O
of O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
on O
T O
cell O
activation O
in O
the O
absence O
of O
other O
complicating O
interactions O
, O
we O
utilized O
a O
panel O
of O
cloned O
Ia O
- O
restricted O
T O
cell O
hybridomas O
that O
secrete O
IL B
2 I
on O
activation O
by O
cloned O
Ia O
- O
bearing O
stimulator O
cells O
( O
TA3 O
) O
or O
when O
stimulated O
by O
mitogen O
. O

This O
system O
should O
prove O
useful O
in O
studying O
the O
molecular O
mechanisms O
by O
which O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
acts O
to O
inhibit O
T O
cell O
activation O
and O
subsequent O
IL B
2 I
production O
. O

Glucocorticoid B
receptors I
and O
steroid O
sensitivity O
in O
normal O
and O
neoplastic O
human O
lymphoid O
tissues O
: O
a O
review O
. O

Given O
these O
facts O
, O
over O
the O
last O
10 O
years O
, O
several O
investigators O
have O
measured O
the O
number O
of O
glucocorticoid B
receptors I
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
to O
see O
whether O
their O
number O
correlated O
with O
glucocorticoid O
responsiveness O
in O
vitro O
or O
in O
vivo O
. O

No O
clear O
correlation O
could O
be O
established O
between O
the O
level O
of O
glucocorticoid B
receptor I
and O
the O
in O
vitro O
action O
of O
steroids O
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
. O

In O
contrast O
, O
attempts O
to O
correlate O
glucocorticoid B
receptor I
levels O
in O
acute O
lymphocytic O
leukemia O
to O
in O
vivo O
steroid O
responsiveness O
and O
immunological O
type O
using O
the O
whole O
- O
cell O
- O
binding O
assay O
for O
receptor O
determination O
and O
selecting O
the O
patients O
according O
to O
age O
and O
immunological O
criteria O
have O
been O
more O
successful O
. O

[ O
Glucocorticoid B
receptors I
in O
normal O
human O
lymphocytes O
] O

It O
was O
shown O
that O
GC B
receptors I
in O
donors O
' O
lymphocytes O
could O
be O
distributed O
into O
two O
different O
classes O
similarly O
to O
the O
pattern O
seen O
in O
skin O
fibroblasts O
. O

Human O
lymphocytes O
are O
an O
adequate O
object O
for O
studying O
genetically O
determined O
variability O
of O
GC B
receptors I
and O
its O
clinical O
importance O
. O

Scatchard O
' O
s O
analysis O
of O
[ O
3H O
] O
- O
moxestrol O
( O
R2858 O
) O
and O
[ O
3H O
] O
- O
estradiol O
binding O
proves O
the O
existence O
of O
a O
single O
class O
of O
receptor B
sites I
having O
a O
dissociation O
constant O
of O
0 O
. O
18 O
- O
2 O
. O
4 O
X O
10 O
( O
- O
9 O
) O
M O
. O

Administration O
of O
fibroblast B
interferon I
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone B
receptors I
. O

Administration O
of O
fibroblast B
interferon I
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone B
receptors I
. O

Decreased O
glucocorticoid B
receptor I
binding O
in O
adrenal O
insufficiency O
. O

To O
examine O
the O
effect O
of O
glucocorticoid O
deficiency O
on O
the O
glucocorticoid B
receptor I
, O
we O
examine O
the O
binding O
of O
[ O
3H O
] O
dexamethasone O
to O
lymphocytes O
in O
normal O
subjects O
and O
patients O
with O
adrenal O
insufficiency O
before O
and O
after O
glucocorticoid O
replacement O
therapy O
. O

Lymphocytes O
from O
patients O
with O
untreated O
adrenal O
insufficiency O
had O
fewer O
binding B
sites I
( O
3364 O
+ O
/ O
- O
322 O
) O
and O
a O
2 O
- O
fold O
increase O
in O
binding O
affinity O
( O
5 O
. O
4 O
+ O
/ O
- O
0 O
. O
9 O
mM O
) O
. O

Glucocorticoid B
receptor I
concentrations O
and O
terminal O
transferase B
activity O
as O
indicators O
of O
prognosis O
in O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

Activity O
of O
terminal B
deoxynucleotidyl I
transferase I
( O
TdT B
) O
, O
adenosine B
deaminase I
, O
and O
5 B
' I
nucleotidase I
and O
the O
cellular O
concentration O
of O
glucocorticoid B
( I
dexamethasone I
) I
receptor I
were O
determined O
in O
25 O
patients O
with O
acute O
non O
- O
lymphocytic O
leukaemia O
. O

The O
glucocorticoid B
receptor I
concentration O
of O
the O
leukaemic O
blast O
cells O
ranged O
from O
0 O
to O
0 O
. O
94 O
fmol O
/ O
microgram O
DNA O
. O

Thirteen O
patients O
had O
blast O
cells O
with O
a O
glucocorticoid B
receptor I
concentration O
over O
0 O
. O
22 O
fmol O
/ O
microgram O
DNA O
. O

Adenosine B
deaminase I
and O
5 B
' I
nucleotidase I
activities O
both O
varied O
within O
two O
orders O
of O
magnitude O
. O

These O
results O
show O
that O
measurements O
of O
TdT B
activity O
and O
the O
glucocorticoid B
receptor I
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non O
- O
lymphocytic O
leukaemia O

[ O
3H O
] O
cortivazol O
: O
a O
unique O
high O
affinity O
ligand O
for O
the O
glucocorticoid B
receptor I
. O

To O
assess O
the O
interaction O
between O
these O
atypical O
steroids O
and O
the O
glucocorticoid B
receptor I
, O
we O
examined O
the O
binding O
of O
[ O
3H O
] O
CVZ O
to O
cytosol O
from O
glucocorticoid O
- O
sensitive O
and O
- O
resistant O
variants O
of O
the O
human O
leukemic O
cell O
line O
CEM O
C7 O
. O

In O
glucocorticoid O
- O
sensitive O
cells O
[ O
3H O
] O
CVZ O
causes O
a O
2 O
- O
fold O
induction O
of O
glutamine B
synthetase I
and O
binds O
to O
a O
protein O
in O
the O
4 O
. O
6 O
S O
region O
of O
high O
salt O
sucrose O
gradients O
. O

A O
comparison O
of O
the O
CPG O
assay O
to O
dextran O
coated O
charcoal O
and O
a O
whole O
cell O
assay O
demonstrates O
that O
CPG O
and O
dextran O
coated O
charcoal O
give O
equivalent O
measurements O
of O
cytosolic B
receptor I
concentration O
, O
while O
the O
CPG O
and O
whole O
cell O
assays O
provide O
equivalent O
values O
for O
total O
receptor O
content O
. O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre O
- O
plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL O
- O
or O
intermediate O
B O
- O
cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B
transferase I
- O
, O
common O
acute B
lymphocytic I
leukemia I
antigen I
- O
, O
Ia B
+ I
, O
surface B
immunoglobulin I
heavy I
chains I
- O
, O
surface B
kappa I
light I
chains I
+ O
, O

intracytoplasmic B
immunoglobulin I
A I
+ I
and I
G I
+ I
, O
BA B
- I
1 I
+ I
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes B
14 I
and I
17 I
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome B
14 I
( O
q12 O
- O
3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O

The O
functional O
status O
of O
the O
steroid B
receptors I
was O
confirmed O
by O
nuclear O
transfer O
of O
the O
cytoplasmic B
hormone I
- I
receptor I
complex I
upon O
temperature O
activation O
. O

The O
objectives O
of O
this O
study O
were O
to O
determine O
whether O
there O
are O
intrinsic O
structural O
differences O
among O
the O
glucocorticoid B
receptors I
in O
various O
types O
of O
leukemic O
cells O
and O
normal O
lymphocytes O
and O
to O
investigate O
the O
role O
of O
endogenous B
peptidases I
in O
receptor O
degradation O
. O

The O
objectives O
of O
this O
study O
were O
to O
determine O
whether O
there O
are O
intrinsic O
structural O
differences O
among O
the O
glucocorticoid B
receptors I
in O
various O
types O
of O
leukemic O
cells O
and O
normal O
lymphocytes O
and O
to O
investigate O
the O
role O
of O
endogenous B
peptidases I
in O
receptor O
degradation O
. O

In O
hypertonic O
, O
molybdate O
- O
free O
buffer O
, O
these O
oligomeric B
complexes I
were O
dissociated O
into O
subunits O
with O
Rs O
of O
5 O
. O
9 O
+ O
/ O
- O
0 O
. O
3 O
nm O
( O
n O
= O
12 O
) O
and O
a O
/ O
b O
of O
11 O
to O
12 O
, O
as O
observed O
previously O
for O
other O
receptors O
. O

Receptor O
cleavage O
by O
these O
and O
other O
endogenous B
enzymes I
may O
account O
for O
previous O
observations O
of O
` O
` O
abnormal O
' O
' O
receptors O
in O
cytosols O
from O
some O
leukemic O
specimens O
. O

Glucocorticoid B
receptor I
number O
and O
intracellular O
water O
space O
. O

In O
order O
to O
elucidate O
the O
relationship O
between O
cell O
water O
content O
and O
number O
of O
glucocorticoid B
receptors I
, O
eleven O
normal O
and O
malignant O
lymphoid O
or O
myelomonocytic O
cell O
types O
originating O
from O
mouse O
, O
rat O
and O
man O
were O
investigated O
. O

The O
cellular O
water O
space O
was O
measured O
with O
3H2O O
, O
and O
glucocorticoid B
receptor I
number O
was O
measured O
in O
a O
whole O
- O
cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
at O
30 O
and O
37 O
degrees O
C O
. O

The O
intracellular O
water O
phase O
concentration O
of O
glucocorticoid B
receptors I
( O
around O
40 O
nmol O
/ O
l O
cell O
water O
) O
, O
and O
the O
dependence O
of O
receptor O
affinity O
on O
temperature O
were O
similar O
in O
normal O
and O
malignant O
rodent O
and O
human O
cells O
. O

It O
is O
concluded O
that O
comparisons O
of O
glucocorticoid B
receptor I
levels O
are O
best O
made O
on O
the O
basis O
of O
intracellular B
receptor I
concentrations O
. O

It O
is O
concluded O
that O
comparisons O
of O
glucocorticoid B
receptor I
levels O
are O
best O
made O
on O
the O
basis O
of O
intracellular B
receptor I
concentrations O
. O

We O
have O
used O
[ O
3H O
] O
dexamethasone O
- O
21 O
- O
mesylate O
to O
label O
covalently O
glucocorticoid B
receptors I
in O
rat O
thymic O
lymphocytes O
and O
in O
neoplastic O
cells O
obtained O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
and O
malignant O
lymphoma O
. O

The O
covalently O
labeled O
glucocorticoid B
receptors I
were O
identified O
by O
polyacrylamide O
gel O
electrophoresis O
( O
in O
the O
presence O
of O
0 O
. O
1 O
% O
sodium O
dodecyl O
sulfate O
) O
. O

In O
cytosolic O
fractions O
prepared O
from O
rat O
thymic O
lymphocytes O
, O
[ O
3H O
] O
- O
dexamethasone O
- O
21 O
- O
mesylate O
labels O
a O
protein O
( O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
) O
which O
was O
identified O
as O
the O
glucocorticoid B
receptor I
by O
the O
following O
criteria O
: O
( O
a O
) O
labeling O
of O
this O
moiety O
is O
inhibited O
by O
treatment O
with O
a O
100 O
- O
fold O
molar O
excess O
of O
glucocorticoids O
, O
such O
as O
dexamethasone O
and O
triamcinolone O
acetonide O
; O
and O
( O
b O
) O
the O
covalently O
labeled O
Mr O
approximately O
equal O
to O
95 O
, O

Approximately O
35 O
% O
of O
the O
glucocorticoid B
receptors I
can O
be O
labeled O
covalently O
when O
intact O
thymocytes O
are O
treated O
with O
100 O
nM O
[ O
3H O
] O
dexamethasone O
- O
21 O
- O
mesylate O
for O
30 O
min O
at O
4 O
degrees O
. O

Smaller B
moieties I
were O
also O
identified O
by O
competition O
experiments O
; O
these O
may O
represent O
proteolytic B
fragments I
of O
the O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
receptor O
. O

Smaller B
moieties I
were O
also O
identified O
by O
competition O
experiments O
; O
these O
may O
represent O
proteolytic B
fragments I
of O
the O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
receptor O
. O

Thus O
, O
in O
rat O
and O
human O
lymphoid O
cells O
, O
[ O
3H O
] O
dexamethasone O
- O
21 O
- O
mesylate O
can O
be O
used O
to O
label O
covalently O
the O
glucocorticoid B
receptor I
. O

Analysis O
has O
shown O
a O
relative O
interdependence O
between O
the O
steroid B
receptor I
status O
of O
primary O
breast O
cancer O
and O
other O
prognostic O
variables O
such O
as O
histological O
grade O
, O
lymphocytic O
infiltration O
and O
tumour O
elastosis O
. O

Cellularity O
and O
fibrosis O
were O
unrelated O
to O
the O
presence O
or O
absence O
of O
oestrogen B
receptor I
. O

Clinical O
implications O
of O
glucocorticoid B
receptors I
in O
human O
leukemia O
. O

Normal O
lymphoid O
cells O
contain O
glucocorticoid B
receptor I
. O

Similar O
glucocorticoid B
receptors I
can O
be O
detected O
in O
lymphoid O
cells O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
. O

Absence O
of O
the O
glucocorticoid B
receptor I
( O
usually O
found O
in O
treated O
patients O
) O
predicts O
lack O
of O
glucocorticoid O
responsiveness O
. O

Furthermore O
, O
in O
our O
hands O
, O
glucocorticoid B
receptor I
levels O
correlate O
with O
the O
duration O
of O
complete O
remission O
in O
ALL O
( O
though O
not O
in O
other O
forms O
of O
leukemia O
) O
. O

In O
some O
experimental O
conditions O
, O
corticosteroids O
inhibit O
Interleukin B
1 I
production O
by O
monocytes O
. O

The O
cytoplasmic B
receptors I
of O
leukaemia O
and O
lymphoblastoid O
lines O
appeared O
to O
contain O
both O
proteinaceous O
and O
phospholipid O
components O
. O

The O
resistance O
to O
cytolethal O
effects O
can O
not O
be O
ascribed O
to O
a O
failure O
of O
cells O
to O
take O
up O
and O
bind O
steroid O
or O
to O
significant O
differences O
in O
the O
molecular O
species O
of O
cytoplasmic B
receptors I
present O
. O

Differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant O
negative O
( O
DN O
) O
Ikaros O
mutation O
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B
proteins I
exert O
their O
effects O
in O
development O
. O

Overexpression O
of O
Rel B
proteins I
demonstrated O
that O
p65 O
- O
expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B
factor I
kappabeta I
reporter I
construct I
when O
costimulated O
with O
B7 B
- I
1 I
or O
LFA B
- I
3 I
, O
but O
transcription O
of O
IL B
- I
2 I
promoter I
or O
CD28 B
response I
element I
( I
CD28RE I
) I
- I
driven I
reporters I
was O
superior O
in O
B7 O
- O
1 O
- O
costimulated O
cells O
. O

We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav B
( O
vav B
- O
/ O
- O
) O
, O
a O
gene O
that O
encodes O
a O
guanine B
- I
nucleotide I
exchange I
factor I
for O
the O
GTPase B
Rac I
. O

Activation O
of O
Jun B
N I
- I
terminal I
kinase I
or O
stress B
- I
activated I
kinase I
( O
JNK B
or O
SAPK B
) O
and O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
and O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
ATc1 I
and I
egr I
- I
1 I
genes I
was O
normal O
. O

To O
assess O
HUVEC O
activation O
, O
E B
- I
selectin I
expression O
was O
measured O
by O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E B
- I
selectin I
- I
specific I
mRNA I
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF B
- I
kappa I
B I
, O
a O
transcription B
factor I
necessary O
for O
E B
- I
selectin I
gene I
activation O
. O

Two O
different O
monoclonal B
antibodies I
directed O
against O
human B
CD14 I
completely O
inhibited O
B O
. O
fragilis O
outer O
membrane O
- O
induced O
NF B
- I
kappa I
B I
activation O
, O
E O
- O
selectin O
transcription O
, O
and O
E O
- O
selectin O
surface O
expression O
. O

Two O
different O
monoclonal B
antibodies I
directed O
against O
human B
CD14 I
completely O
inhibited O
B O
. O
fragilis O
outer O
membrane O
- O
induced O
NF B
- I
kappa I
B I
activation O
, O
E O
- O
selectin O
transcription O
, O
and O
E O
- O
selectin O
surface O
expression O
. O

TNFalpha B
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl B
- I
2 I
protein I
levels O
in O
HIV O
- O
1 O
- O
infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B
protein I
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B
- O
induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl B
- I
2 I
and O
Bax B
. O

Human O
normal O
peripheral O
blood O
B O
- O
lymphocytes O
are O
deficient O
in O
DNA O
- O
dependent O
protein O
kinase O
activity O
due O
to O
the O
expression O
of O
a O
variant O
form O
of O
the O
Ku86 B
protein I
. O

The O
heterodimeric O
Ku B
protein I
, O
which O
comprises O
a O
86 B
kDa I
( I
Ku86 I
) I
amd O
a O
70 B
kDa I
( I
Ku70 I
) I
subunits I
, O
is O
an O
abundant O
nuclear B
DNA I
- I
binding I
protein I
which O
binds O
in O
vitro O
to O
DNA B
termini I
without O
sequence O
specificity O
. O

The O
heterodimeric O
Ku B
protein I
, O
which O
comprises O
a O
86 B
kDa I
( I
Ku86 I
) I
amd O
a O
70 B
kDa I
( I
Ku70 I
) I
subunits I
, O
is O
an O
abundant O
nuclear B
DNA I
- I
binding I
protein I
which O
binds O
in O
vitro O
to O
DNA B
termini I
without O
sequence O
specificity O
. O

Western O
blot O
analysis O
revealed O
that O
B O
cells O
express O
a O
variant O
form O
of O
the O
Ku86 B
protein I
with O
an O
apparent O
molecular O
weight O
of O
69 O
kDa O
, O
and O
not O
the O
86 B
kDa I
- I
full I
- I
length I
protein I
. O

Although O
the O
heterodimer B
Ku70 I
/ I
variant I
- I
Ku86 I
binds O
to O
DNA B
- I
ends I
, O
this O
altered O
form O
of O
the O
Ku B
heterodimer I
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B
component I
of O
the O
complex O
, O
DNA B
- I
PK I
( I
CS I
) I
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

Although O
the O
heterodimer B
Ku70 I
/ I
variant I
- I
Ku86 I
binds O
to O
DNA B
- I
ends I
, O
this O
altered O
form O
of O
the O
Ku B
heterodimer I
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B
component I
of O
the O
complex O
, O
DNA B
- I
PK I
( I
CS I
) I
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA O
- O
PK O
activity O
in O
B O
cells O
. O

To O
investigate O
whether O
cytokine B
signaling O
defects O
occur O
during O
HIV O
infection O
, O
PHA O
blasts O
from O
healthy O
human O
donors O
were O
infected O
with O
two O
strains O
of O
HIV O
- O
1 O
and O
screened O
for O
the O
expression O
of O
STAT B
proteins I
used O
in O
cytokine B
signaling O
. O

Transcription B
factors I
that O
regulate O
monocyte O
/ O
macrophage O
differentiation O
. O

During O
myelopoiesis O
, O
external O
differentiating O
signals O
regulate O
the O
expression O
of O
a O
set O
of O
transcription B
factors I
. O

The O
combined O
action O
of O
these O
transcription B
factors I
subsequently O
determines O
the O
expression O
of O
myeloid B
- I
specific I
genes I
and O
the O
generation O
of O
monocytes O
and O
macrophages O
. O

We O
review O
the O
contribution O
of O
several O
transcription B
factors I
to O
the O
control O
of O
macrophage O
development O

T O
lymphocytes O
circulate O
in O
a O
quiescent O
state O
until O
they O
encounter O
cognate B
antigen I
bound O
to O
the O
surface O
of O
an O
antigen O
- O
presenting O
cell O
. O

The O
p12 B
( I
I I
) I
protein I
, O
encoded O
by O
the O
pX B
open I
reading I
frame I
I I
of O
the O
human O
T O
- O
lymphotropic O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
, O
is O
a O
hydrophobic B
protein I
that O
localizes O
to O
the O
endoplasmic O
reticulum O
and O
the O
Golgi O
. O

This O
study O
demonstrated O
that O
p12 B
( I
I I
) I
binds O
to O
the O
cytoplasmic B
domain I
of O
the O
interleukin B
- I
2 I
receptor I
( I
IL I
- I
2R I
) I
beta I
chain I
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 B
and I
Jak3 I
kinases I
. O

Single O
dose O
intranasal O
administration O
of O
retinal B
autoantigen I
generates O
a O
rapid O
accumulation O
and O
cell O
activation O
in O
draining O
lymph O
node O
and O
spleen O
: O
implications O
for O
tolerance O
therapy O
. O

BACKGROUND O
/ O
AIMS O
: O
A O
single O
intranasal O
delivery O
of O
retinal B
autoantigen I
suppresses O
effectively O
experimental O
autoimmune O
uveoretinitis O
( O
EAU O
) O
. O

Significant O
proliferative O
responses O
to O
IRBP O
were O
elicited O
by O
48 O
hours O
indicating O
that O
systemic O
priming O
of O
naive O
T O
cells O
to O
retinal B
antigen I
had O
occurred O
. O

However O
, O
at O
24 O
hours O
, O
STAT4 O
heterodimerisation O
with O
STAT B
3 I
was O
only O
observed O
in O
spleen O
. O

Interleukin B
( I
IL I
) I
- I
18 I
has O
been O
well O
characterized O
as O
a O
costimulatory B
factor I
for O
the O
induction O
of O
IL B
- I
12 I
- I
mediated I
interferon I
( I
IFN I
) I
- I
gamma I
production O
by O
T O
helper O
( O
Th O
) O
1 O
cells O
, O
but O
also O
can O
induce O
IL O
- O
4 O
production O
and O
thus O
facilitate O
the O
differentiation O
of O
Th2 O
cells O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone B
acetyltransferases I
( O
HATs B
) O
and O
histone B
deacetylases I
( O
HDACs B
) O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone B
acetyltransferases I
( O
HATs B
) O
and O
histone B
deacetylases I
( O
HDACs B
) O
. O

Identification O
of O
the O
precise O
mechanism O
by O
which O
activated B
GR I
recruits O
HDAC2 B
may O
reveal O
new O
targets O
for O
the O
development O
of O
drugs O
that O
may O
dissociate O
the O
antiinflammatory O
actions O
of O
glucocorticoids O
from O
their O
side O
effects O
that O
are O
largely O
due O
to O
gene O
induction O
. O

Biomechanical O
strain O
induces O
class O
a O
scavenger B
receptor I
expression O
in O
human O
monocyte O
/ O
macrophages O
and O
THP O
- O
1 O
cells O
: O
a O
potential O
mechanism O
of O
increased O
atherosclerosis O
in O
hypertension O
. O

We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B
A I
scavenger I
receptor I
( O
SRA B
) O
, O
an O
important O
lipoprotein B
receptor I
in O
atherogenesis O
. O

Mechanical O
strains O
induced O
SRA B
mRNA I
( O
3 O
. O
5 O
+ O
/ O
- O
0 O
. O
6 O
- O
fold O
at O
3 O
% O
strain O
for O
48 O
hours O
, O
P O
< O
0 O
. O
01 O
) O
and O
SRA B
protein I
in O
THP O
- O
1 O
cells O
in O
an O
amplitude O
- O
dependent O
manner O
. O

Mechanical O
strains O
induced O
SRA B
mRNA I
( O
3 O
. O
5 O
+ O
/ O
- O
0 O
. O
6 O
- O
fold O
at O
3 O
% O
strain O
for O
48 O
hours O
, O
P O
< O
0 O
. O
01 O
) O
and O
SRA B
protein I
in O
THP O
- O
1 O
cells O
in O
an O
amplitude O
- O
dependent O
manner O
. O

To O
examine O
the O
roles O
of O
the O
transcription B
factors I
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
and O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B
and O
CD86 B
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B
receptor I
, O
and O
the O
adhesion B
molecule I
CD54 B
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B
and O
CD86 B
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B
receptor I
, O
and O
the O
adhesion B
molecule I
CD54 B
. O

The O
carboxy B
terminus I
of O
LMP1 B
is O
also O
a O
reliable O
marker O
for O
individual O
EBV O
strain O
identification O
and O
thus O
offers O
new O
possibilities O
in O
tracing O
the O
molecular O
events O
leading O
to O
posttransplant O
lymphoproliferative O
disorders O
( O
PTLDs O
) O
. O

TNF B
- I
alpha I
gene I
expression O
obligates O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP B
- I
2 I
activated O
the O
mouse O
p21 B
( I
CIP1 I
/ I
WAF1 I
) I
promoter I
in O
HS O
- O
72 O
cells O
, O
and O
that O
a O
29 B
- I
base I
pair I
( I
b I
) I
region I
of O
the O
promoter O
( O
- O
1928 O
/ O
- O
1900 O
relative O
to O
the O
TATA B
box I
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP B
- I
2 I
as O
well O
as O
expression O
of O
Smad1 B
, O
Smad4 B
, O
and O
constitutively O
active O
mutants O
of O
BMP B
type I
I I
receptors I
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29 B
- I
b I
region I
was O
found O
to O
be O
associated O
with O
Smad4 B
and O
phosphorylated B
Smad1 I
in O
the O
nuclear O
extract O
of O
BMP B
- I
2 I
- O
stimulated O
HS O
- O
72 O
cells O
. O

Therefore O
CD8 B
alpha I
expression O
DCs O
does O
not O
indicate O
a O
lymphoid O
origin O
and O
differences O
among O
CD8 O
alpha O
+ O
and O
CD8 O
alpha O
- O
DCs O
might O
rather O
reflect O
maturation O
status O
than O
ontogeny O
. O

The O
peroxisome B
proliferator I
- I
activated I
receptors I
( I
PPARs I
) I
alpha I
and I
gamma I
are O
nuclear B
receptors I
that O
play O
important O
roles O
in O
inflammatory O
diseases O
like O
ulcerative O
colitis O
and O
arthritis O
. O

Analysis O
of O
PBMCs O
on O
days O
1 O
, O
3 O
, O
5 O
, O
and O
10 O
after O
trauma O
revealed O
that O
expression O
of O
both O
p65p50 B
heterodimers I
and O
p50p50 B
homodimers I
was O
significantly O
reduced O
compared O
with O
that O
in O
controls O
. O

Analysis O
of O
PBMCs O
on O
days O
1 O
, O
3 O
, O
5 O
, O
and O
10 O
after O
trauma O
revealed O
that O
expression O
of O
both O
p65p50 B
heterodimers I
and O
p50p50 B
homodimers I
was O
significantly O
reduced O
compared O
with O
that O
in O
controls O
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin B
- I
10 I
or O
transforming B
growth I
factor I
- I
beta I
and O
NF B
- I
kappa I
B I
, O
these O
immunosuppressive B
cytokines I
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

Activation O
of O
nuclear B
factor I
- I
kappa I
B I
in O
the O
liver O
promotes O
proinflammatory B
cytokine I
and O
adhesion B
molecule I
synthesis O
. O

Activation O
of O
nuclear B
factor I
- I
kappa I
B I
in O
the O
liver O
promotes O
proinflammatory B
cytokine I
and O
adhesion B
molecule I
synthesis O
. O

These O
results O
indicate O
that O
the O
fly O
and O
mouse O
FOG B
proteins I
function O
similarly O
in O
three O
distinct O
cellular O
contexts O
in O
Drosophila O
, O
but O
may O
use O
different O
mechanisms O
to O
regulate O
genetic O
events O
in O
blood O
vs O
. O
cardial O
or O
eye O
cell O
lineages O

The O
RING B
finger I
protein I
Siah B
- I
1 I
regulates O
the O
level O
of O
the O
transcriptional B
coactivator I
OBF B
- I
1 I
. O

The O
transcriptional B
coactivator I
OBF B
- I
1 I
, O
which O
interacts O
with O
Oct B
- I
1 I
and O
Oct B
- I
2 I
and O
the O
octamer B
site I
DNA I
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

TRAIL B
/ I
Apo2L I
also O
overcame O
the O
survival O
effect O
of O
interleukin B
6 I
on O
MM O
cells O
and O
did O
not O
affect O
the O
survival O
of O
peripheral O
blood O
and O
bone O
marrow O
mononuclear O
cells O
and O
purified O
B O
cells O
from O
healthy O
donors O
. O

The O
status O
of O
the O
TRAIL B
receptors I
( O
assessed O
by O
immunoblotting O
and O
flow O
cytometry O
) O
could O
not O
predict O
TRAIL O
sensitivity O
of O
MM O
cells O
. O

Dox O
up O
- O
regulated O
the O
expression O
of O
the O
TRAIL B
receptor I
death B
receptor I
5 I
( O
DR5 B
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL B
not O
only O
against O
MM O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex O
- O
or O
Dox O
- O
induced O
apoptosis O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL B
- I
12 I
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti O
- O
CD28 O
- O
costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti B
- I
CD28 I
exhibited O
decreased O
levels O
of O
Janus B
kinases I
( O
JAK B
) O
JAK2 B
/ I
TYK2 I
and O
STAT4 B
phosphorylation O
and O
IFN O
- O
y O
production O
following O
IL B
- I
12 I
stimulation O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B
and O
tensin B
homologue I
deleted O
from O
chromosome B
10 I
or O
src B
homology I
2 I
domain I
- I
containing I
5 I
' I
inositol I
phosphatase I
, O
phosphatases B
that O
negatively O
regulate O
the O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI3K B
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B
pathway O
for O
macro O
- O
phage O
survival O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B
/ O
Akt B
- I
1 I
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B
molecule I
Mcl B
- I
1 I
, O
but O
not O
other O
Bcl B
- I
2 I
family I
members I
was O
observed O
, O
and O
Mcl B
- I
1 I
rescued O
macrophages O
from O
LY294002 O
- O
induced O
cell O
death O
. O

Biopsies O
were O
immunostained O
for O
inflammatory O
cell O
markers O
as O
well O
as O
GRbeta B
and O
probed O
for O
various O
cytokine B
mRNA I
. O

Transcriptional O
regulation O
of O
galectin B
- I
10 I
( O
eosinophil B
Charcot I
- I
Leyden I
crystal I
protein I
) O
: O
a O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
controls O
butyric O
acid O
induction O
of O
gene O
expression O
. O

Galectin B
- I
10 I
( O
gal B
- I
10 I
, O
also O
known O
as O
Charcot B
- I
Leyden I
crystal I
protein I
) O
is O
a O
member O
of O
the O
galectin B
family I
of O
beta B
- I
galactoside I
binding I
proteins I
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

Analysis O
of O
the O
minimal B
promoter I
revealed O
nine O
consensus B
- I
binding I
sites I
for O
transcription B
factors I
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B
promoters I
of O
galectins B
- I
1 I
, I
- I
2 I
, I
and I
- I
3 I
. O

Analysis O
of O
the O
minimal B
promoter I
revealed O
nine O
consensus B
- I
binding I
sites I
for O
transcription B
factors I
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B
promoters I
of O
galectins B
- I
1 I
, I
- I
2 I
, I
and I
- I
3 I
. O

Analysis O
of O
the O
minimal B
promoter I
revealed O
nine O
consensus B
- I
binding I
sites I
for O
transcription B
factors I
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B
promoters I
of O
galectins B
- I
1 I
, I
- I
2 I
, I
and I
- I
3 I
. O

The O
decrease O
in O
gal O
- O
10 O
promoter O
activity O
after O
disruption O
of O
either O
the O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
or O
the O
Oct B
site I
( O
- O
255 O
to O
- O
261 O
) O
suggests O
that O
these O
sites O
, O
along O
with O
the O
previously O
characterized O
GATA B
and I
EoTF I
sites I
, O
are O
necessary O
for O
full O
promoter O
activity O
. O

The O
decrease O
in O
gal O
- O
10 O
promoter O
activity O
after O
disruption O
of O
either O
the O
GC B
box I
( O
- O
44 O
to O
- O
50 O
) O
or O
the O
Oct B
site I
( O
- O
255 O
to O
- O
261 O
) O
suggests O
that O
these O
sites O
, O
along O
with O
the O
previously O
characterized O
GATA B
and I
EoTF I
sites I
, O
are O
necessary O
for O
full O
promoter O
activity O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B
factors I
Sp1 B
and O
Oct1 B
to O
the O
consensus B
GC I
box I
and O
the O
Oct B
site I
, O
respectively O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B
factors I
Sp1 B
and O
Oct1 B
to O
the O
consensus B
GC I
box I
and O
the O
Oct B
site I
, O
respectively O
. O

Similar O
to O
gal B
- I
1 I
, O
gal O
- O
10 O
expression O
is O
induced O
by O
butyric O
acid O
, O
an O
effect O
that O
is O
lost O
upon O
ablation O
of O
the O
GC B
box I
. O

Additionally O
, O
we O
demonstrate O
AML3 O
binding O
to O
the O
consensus B
AML I
site I
and O
YY1 B
binding I
to O
the O
Inr B
sequence I
, O
both O
elements O
functioning O
as O
silencers O
in O
the O
gal B
- I
10 I
promoter I
. O

Additionally O
, O
we O
demonstrate O
AML3 O
binding O
to O
the O
consensus B
AML I
site I
and O
YY1 B
binding I
to O
the O
Inr B
sequence I
, O
both O
elements O
functioning O
as O
silencers O
in O
the O
gal B
- I
10 I
promoter I
. O

Evidence O
is O
presented O
that O
if O
they O
are O
to O
grow O
, O
end O
buds O
must O
condition O
proximal O
fatty O
stroma O
by O
recruiting O
white O
blood O
cells O
as O
well O
as O
inducing O
stromal O
cell O
division O
and O
, O
possibly O
, O
estrogen B
receptors I
. O

We O
found O
that O
even O
freshly O
isolated O
blood O
monocytes O
express O
adipophilin B
and O
that O
the O
amount O
of O
adipophilin B
protein I
is O
variable O
in O
monocytes O
from O
different O
healthy O
individuals O
. O

Fatty O
acids O
are O
ligands O
for O
peroxisome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
, O
and O
the O
upregulation O
of O
adipophilin B
mRNA I
by O
PPARgamma B
agonists O
like O
15d O
- O
PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

Unexpectedly O
, O
these O
transcripts O
initiate O
from O
promoter B
III I
of O
the O
CIITA B
gene I
, O
a O
promoter O
that O
is O
mainly O
used O
constitutively O
in O
B O
lymphocytes O
. O

Unexpectedly O
, O
these O
transcripts O
initiate O
from O
promoter B
III I
of O
the O
CIITA B
gene I
, O
a O
promoter O
that O
is O
mainly O
used O
constitutively O
in O
B O
lymphocytes O
. O

Constitutive O
transcription O
of O
CIITA B
from O
promoter B
III I
having O
been O
observed O
in O
unrelated O
melanoma O
cell O
lines O
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma O
cells O

We O
report O
here O
that O
the O
60 B
- I
kDa I
catalytic I
subunit I
of O
calcineurin B
A I
( O
Cn B
A I
) O
was O
partially O
cleaved O
to O
a O
45 B
- I
kDa I
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

We O
report O
here O
that O
the O
60 B
- I
kDa I
catalytic I
subunit I
of O
calcineurin B
A I
( O
Cn B
A I
) O
was O
partially O
cleaved O
to O
a O
45 B
- I
kDa I
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
- O
activated O
Jurkat O
cells O
. O

Cn B
A I
cleavage O
was O
caspase O
mediated O
, O
since O
it O
was O
inhibitable O
by O
pan O
- O
caspase O
inhibitor O
Cbz O
- O
Asp O
- O
CH O
( O
2 O
) O
OC O
( O
O O
) O
- O
2 O
, O
6 O
- O
dichlorobenzene O
( O
Z O
- O
D O
- O
DCB O
) O
. O

Cn B
A I
cleavage O
was O
also O
observed O
when O
purified O
calcineurin B
was O
digested O
in O
vitro O
with O
caspase B
- I
3 I
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I O
- O
activated O
Jurkat O
cells O
, O
dephosphorylation O
of O
calcineurin B
substrate O
NFATc B
( O
a O
transcription B
factor I
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL B
- I
2 I
gene I
) O
, O
was O
also O
suppressed O
by O
Z O
- O
D O
- O
DCB O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
caspase O
- O
mediated O
cleavage O
of O
Cn B
A I
contributes O
to O
IL O
- O
2 O
production O
during O
T O
cell O
activation O
. O

The O
cells O
were O
matured O
by O
addition O
of O
tumor B
necrosis I
factor I
( I
TNF I
) I
- I
a I
, O
IL B
- I
1 I
beta I
, O
and O
prostaglandin B
E2 I
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites O
- O
- O
aminosalicylate O
and O
sulfapyridine O
, O
or O
their O
combinations O
. O

Down O
- O
regulation O
of O
TDT O
transcription O
in O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocytes O
by O
Ikaros B
proteins I
in O
direct O
competition O
with O
an O
Ets B
activator I
. O

Down O
- O
regulation O
of O
TDT O
transcription O
in O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocytes O
by O
Ikaros B
proteins I
in O
direct O
competition O
with O
an O
Ets B
activator I
. O

Ikaros B
is O
a O
unique O
regulator O
of O
lymphopoiesis O
that O
associates O
with O
pericentromeric B
heterochromatin I
and O
has O
been O
implicated O
in O
heritable O
gene O
inactivation O
. O

Binding O
and O
competition O
experiments O
demonstrate O
that O
Ikaros B
dimers I
compete O
with O
an O
Ets B
activator I
for O
occupancy O
of O
the O
lymphocyte B
- I
specific I
TdT I
promoter I
. O

Binding O
and O
competition O
experiments O
demonstrate O
that O
Ikaros B
dimers I
compete O
with O
an O
Ets B
activator I
for O
occupancy O
of O
the O
lymphocyte B
- I
specific I
TdT I
promoter I
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros B
should O
be O
disrupted O
by O
a O
small O
isoform B
that O
retains O
the O
dimerization B
domain I
and O
lacks O
the O
DNA B
- I
binding I
domain I
. O

Rather O
, O
the O
small O
isoform B
assembled O
into O
multimeric B
complexes I
with O
DNA B
- I
bound I
Ikaros I
at O
the O
pericentromeric O
foci O
. O

The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros B
dimers I
bound O
to O
the O
TdT B
promoter I
and O
those O
bound O
to O
pericentromeric B
repeat I
sequences I
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B
gene I
. O

The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros B
dimers I
bound O
to O
the O
TdT B
promoter I
and O
those O
bound O
to O
pericentromeric B
repeat I
sequences I
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B
gene I
. O

The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros B
dimers I
bound O
to O
the O
TdT B
promoter I
and O
those O
bound O
to O
pericentromeric B
repeat I
sequences I
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B
gene I
. O

OX40 B
is O
a O
member O
of O
the O
tumor B
necrosis I
factor I
( I
TNF I
) I
receptor I
superfamily I
and O
known O
to O
be O
an O
important O
costimulatory B
molecule I
expressed O
on O
activated O
T O
cells O
. O

Endogenous O
TNF B
alpha I
( O
TNF B
- I
alpha I
) O
and O
TNF B
- I
beta I
production O
were O
not O
involved O
in O
the O
enhanced O
HIV O
- O
1 O
production O
. O

Peroxizome B
proliferator I
- I
activated I
receptor I
- I
gamma I
( O
PPARgamma B
) O
is O
a O
member O
of O
the O
nuclear B
receptor I
family I
of O
transcription B
factors I
that O
regulate O
adipocyte O
differentiation O
. O

Recent O
studies O
indicate O
that O
liganded B
PPARgamma I
not O
only O
promotes O
differentiation O
but O
also O
inhibits O
the O
activation O
of O
macrophages O
. O

Transcription B
factor I
NF I
- I
kappa I
B I
regulates O
Ig B
lambda I
light O
chain O
gene O
rearrangement O
. O

Accessibility O
within O
a O
given O
locus B
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B
factors I
with O
cognate B
enhancer I
elements I
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene B
segments I
. O

Accessibility O
within O
a O
given O
locus B
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B
factors I
with O
cognate B
enhancer I
elements I
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene B
segments I
. O

As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa B
locus I
is O
regulated O
by O
the O
inducible B
transcription I
factor I
NF B
- I
kappaB I
. O

In O
contrast O
to O
the O
Igkappa B
locus I
, O
known O
transcriptional B
control I
elements I
in O
the O
Iglambda B
locus I
lack O
functional O
NF B
- I
kappaB I
binding I
sites I
. O

In O
contrast O
to O
the O
Igkappa B
locus I
, O
known O
transcriptional B
control I
elements I
in O
the O
Iglambda B
locus I
lack O
functional O
NF B
- I
kappaB I
binding I
sites I
. O

Consistent O
with O
this O
observation O
, O
the O
expression O
of O
assembled O
Iglambda B
genes I
in O
mature O
B O
cells O
has O
been O
shown O
to O
be O
NF B
- I
kappaB I
independent O
. O

In O
contrast O
, O
the O
activities O
of O
known O
Iglambda B
promoter I
and O
enhancer B
elements I
are O
unaffected O
in O
the O
same O
cellular O
background O
. O

In O
contrast O
, O
the O
activities O
of O
known O
Iglambda B
promoter I
and O
enhancer B
elements I
are O
unaffected O
in O
the O
same O
cellular O
background O
. O

Transcription B
factor I
STAT5A B
is O
a O
substrate O
of O
Bruton B
' I
s I
tyrosine I
kinase I
in O
B O
cells O
. O

BTK B
was O
also O
capable O
of O
tyrosine O
- O
phosphorylating O
ectopically O
expressed O
recombinant B
STAT5A I
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus B
kinase I
3 I
- O
independent O
fashion O
. O

BTK B
phosphorylated O
the O
Y665F B
, I
Y668F I
, I
and I
Y682F I
, I
Y683F I
mutants I
but O
not O
the O
Y694F B
mutant I
of O
STAT5A B
. O

In O
BTK B
- O
competent O
chicken O
B O
cells O
, O
anti O
- O
IgM O
- O
stimulated O
tyrosine O
phosphorylation O
of O
STAT5 B
protein I
was O
prevented O
by O
pretreatment O
with O
the O
BTK B
inhibitor O
LFM O
- O
A13 O
but O
not O
by O
pretreatment O
with O
the O
JAK3 O
inhibitor O
HI O
- O
P131 O
. O

Subsequently O
, O
it O
appears O
that O
IL B
- I
12 I
/ O
STAT4 B
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B
signal I
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans B
- I
activator I
, O
prolonging O
IFN B
- I
gamma I
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B
, O
CREB B
- I
binding I
protein I
. O

Thus O
, O
activated B
Stat6 I
is O
necessary O
and O
sufficient O
to O
mediate O
both O
IL B
- I
4 I
- O
driven O
Th2 O
differentiation O
and O
cell O
expansion O
in O
CD4 O
T O
cells O
. O

We O
investigated O
the O
cause O
of O
enhanced O
IL O
- O
2 O
secretion O
and O
found O
that O
the O
HIV B
Tat I
induces O
this O
effect O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric B
activator I
containing O
p65 B
and O
c B
- I
Jun I
binds O
to O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

HIV B
Tat I
enhances O
activation O
of O
NF B
- I
kappaB I
and O
consequently O
, O
activates O
the O
AP B
- I
1 I
( I
IL I
- I
2 I
/ I
d I
) I
site I
. O

Our O
data O
provide O
evidence O
for O
a O
novel O
mechanism O
by O
which O
HIV B
Tat I
dysregulates O
IL O
- O
2 O
production O
and O
therefore O
may O
contribute O
to O
the O
HIV O
- O
1 O
infection O
in O
a O
way O
yet O
to O
be O
clarified O
. O

Invariant B
chain I
induces O
B O
cell O
maturation O
by O
activating O
a O
TAF B
( I
II I
) I
105 I
- I
NF I
- I
kappaB I
- O
dependent O
transcription O
program O
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

Recently O
, O
invariant B
chain I
( O
Ii B
) O
, O
a O
major B
histocompatibility I
complex I
class I
II I
chaperone I
, O
as O
well O
as O
the O
transcription B
factors I
c B
- I
Rel I
and O
p65 B
/ I
RelA I
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen O
- O
independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

To O
investigate O
whether O
the O
observed O
thymolytic O
effects O
were O
due O
to O
the O
presence O
of O
hormone B
receptors I
on O
thymocytes O
, O
cells O
were O
isolated O
from O
the O
thymus O
and O
incubated O
with O
androgens O
or O
oestrogens O
to O
measure O
apoptosis O
. O

Therefore O
, O
upon O
in O
vivo O
androgen O
treatment O
, O
other O
cells O
containing O
androgen B
receptors I
than O
thymocytes O
are O
probably O
involved O
in O
inducing O
the O
increase O
in O
thymic O
apoptosis O
. O

To O
study O
the O
role O
of O
the O
androgen B
receptor I
on O
thymocyte O
apoptosis O
, O
androgen B
receptor I
mutant O
( O
Tfm O
/ O
Y O
) O
mice O
were O
treated O
with O
androgens O
. O

To O
study O
the O
role O
of O
the O
androgen B
receptor I
on O
thymocyte O
apoptosis O
, O
androgen B
receptor I
mutant O
( O
Tfm O
/ O
Y O
) O
mice O
were O
treated O
with O
androgens O
. O

No O
alterations O
of O
thymocyte O
subpopulations O
were O
seen O
, O
suggesting O
that O
changes O
in O
the O
percentage O
of O
CD4 O
+ O
CD8 O
+ O
thymocytes O
after O
administration O
of O
androgens O
depend O
on O
the O
presence O
of O
functional O
androgen B
receptors I
. O

Inhibition O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappaB I
in O
CD4 O
T O
cells O
by O
peroxisome B
proliferator I
- I
activated I
receptor I
gamma I
ligands I
. O

We O
also O
found O
the O
PPARgamma B
ligand I
ciglitizone O
to O
attenuate O
the O
activation O
of O
T O
cells O
by O
inhibiting O
cytokine O
gene O
expression O
and O
anti B
- I
CD3 I
and O
anti B
- I
CD28 I
or O
PMA O
- O
induced O
proliferative O
responses O
. O

Inhibition O
of O
both O
the O
proliferative O
response O
and O
inflammatory O
cytokine O
expression O
in O
CD4 O
T O
cells O
was O
correlated O
with O
suppression O
of O
the O
activated O
transcription B
factors I
AP1 B
and O
NF B
- I
kappaB I
. O

PPARgamma B
ligands I
also O
strongly O
inhibited O
SEA O
- O
induced O
Vbeta3 O
T O
cell O
activation O
in O
vivo O
. O

These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma B
ligands I
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma B
as O
a O
negative B
regulator I
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T O
cells O
. O

These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma B
ligands I
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma B
as O
a O
negative B
regulator I
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T O
cells O
. O

The O
cell B
surface I
glycoprotein I
2B4 I
( O
CD244 B
) O
of O
the O
Ig B
superfamily I
is O
involved O
in O
the O
regulation O
of O
NK O
and O
T O
lymphocyte O
functions O
. O

The O
cytoplasmic B
domain I
of O
2B4 B
associates O
with O
src B
homology I
2 I
domain I
- I
containing I
protein I
or O
signaling B
lymphocyte I
activation I
molecule I
- I
associated I
protein I
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X O
- O
linked O
lymphoproliferative O
syndrome O
. O

Through O
primer O
extension O
analysis O
, O
we O
found O
that O
the O
transcription O
of O
the O
h2B4 B
gene I
initiates O
at O
multiple O
start O
sites O
. O

We O
isolated O
h2B4 B
genomic I
clones I
and O
PCR O
amplified O
the O
5 B
' I
untranslated I
region I
containing O
the O
promoter B
elements I
. O

EMSAs O
with O
Abs B
specific O
for O
various O
protein B
factors I
of O
the O
AP B
- I
1 I
family I
revealed O
that O
multiple O
members O
of O
the O
Jun B
family I
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B
gene I
. O

EMSAs O
with O
Abs B
specific O
for O
various O
protein B
factors I
of O
the O
AP B
- I
1 I
family I
revealed O
that O
multiple O
members O
of O
the O
Jun B
family I
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B
gene I
. O

EMSAs O
with O
Abs B
specific O
for O
various O
protein B
factors I
of O
the O
AP B
- I
1 I
family I
revealed O
that O
multiple O
members O
of O
the O
Jun B
family I
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B
gene I
. O

These O
results O
demonstrate O
a O
significant O
role O
for O
AP B
- I
1 I
in O
the O
transcriptional O
regulation O
of O
the O
h2B4 B
gene I
. O

Because O
hematopoietic O
cells O
derived O
from O
Fanconi O
anemia O
( O
FA O
) O
patients O
of O
the O
C O
- O
complementation O
group O
( O
FA O
- O
C O
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon B
gamma I
( O
IFNgamma B
) O
, O
the O
products O
of O
certain O
IFNgamma B
- I
inducible I
genes I
known O
to O
influence O
hematopoietic O
cell O
survival O
were O
quantified O
. O

In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA O
- O
C O
cells O
overexpress O
IFNgamma B
- I
inducible I
genes I
in O
the O
face O
of O
defective O
STAT1 O
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated B
STAT1 I
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B
IFNgamma I
- I
responsive I
protein I
that O
normally O
modulates O
expression O
of O
other O
IFNgamma B
- I
responsive I
genes I
. O

Thus O
, O
the O
FANCC B
protein I
functions O
to O
modulate O
expression O
of O
a O
family O
of O
genes O
that O
in O
normal O
cells O
are O
inducible O
only O
by O
specific O
environmental O
cues O
for O
apoptosis O
or O
mitogenic O
inhibition O
, O
but O
it O
does O
so O
independently O
of O
the O
classic O
IFN O
- O
STAT1 O
pathway O
and O
is O
not O
the O
direct O
result O
of O
reduced O
ICSBP B
expression O
. O

These O
committed O
lymphoid O
cells O
must O
then O
undergo O
V O
( O
D O
) O
J O
recombination O
at O
the O
immunoglobulin B
gene I
or O
T B
cell I
receptor I
gene I
locus I
resulting O
in O
clonal O
production O
of O
functional O
B O
or O
T O
lymphocytes O
, O
respectively O
. O

The O
basic B
- I
helix I
- I
loop I
- I
helix I
( I
bHLH I
) I
transcription I
factors I
encoded O
by O
the O
E2A B
gene I
are O
involved O
in O
several O
differentiation O
events O
during O
B O
and O
T O
cell O
development O
, O
including O
lineage O
commitment O
, O
initiation O
of O
V O
( O
D O
) O
J O
recombination O
, O
and O
antigen O
receptor O
mediated O
proliferation O
and O
differentiation O
. O

Most O
of O
these O
activities O
have O
been O
largely O
attributed O
to O
the O
inhibitory O
effect O
of O
D609 O
on O
phosphatidylcholine O
- O
specific O
phospholipase B
C I
. O

Inhibition O
of O
AP B
- I
1 I
by O
the O
glucocorticoid O
- O
inducible O
protein B
GILZ I
. O

The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine O
gene O
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid B
receptor I
and O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O

The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine O
gene O
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid B
receptor I
and O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O

Indeed O
, O
transient O
expression O
of O
GILZ B
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter B
construct I
driven O
by O
the O
FasL B
promoter I
. O

Indeed O
, O
transient O
expression O
of O
GILZ B
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter B
construct I
driven O
by O
the O
FasL B
promoter I
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

This O
could O
be O
accounted O
for O
by O
GILZ B
- O
mediated O
inhibition O
of O
Egr B
- I
2 I
and O
Egr B
- I
3 I
, O
NFAT B
/ I
AP I
- I
1 I
- O
inducible O
transcription B
factors I
that O
bind O
a O
regulatory B
element I
in O
the O
FasL B
promoter I
and O
up O
- O
regulate O
FasL O
expression O
. O

Whereas O
homodimerization O
of O
GILZ B
required O
the O
presence O
of O
its O
leucine B
zipper I
, O
the O
interaction O
with O
c B
- I
Fos I
and O
c B
- I
Jun I
occurred O
through O
the O
N B
- I
terminal I
60 B
- I
amino I
acid I
region I
of O
GILZ B
. O

Vaccination O
with O
a O
peptide O
representing O
a O
CTL O
epitope O
from O
the O
human O
papillomavirus O
( O
HPV O
) O
16 O
E7 B
protein I
induces O
a O
specific O
CTL O
response O
that O
prevents O
the O
outgrowth O
of O
HPV16 O
E7 O
- O
expressing O
tumors O
. O

The O
HPV16 O
E7 O
peptide O
kinetics O
correlated O
with O
the O
kinetics O
of O
HPV16 B
E7 I
- O
specific O
CTL O
induction O
. O

In O
contrast O
, O
Ad5 O
E1A O
peptide O
injection O
resulted O
in O
physical O
deletion O
of O
preexisting O
Ad5 B
E1A I
- O
specific O
CTLs B
within O
24 O
h O
after O
injection O
. O

These O
data O
suggest O
that O
ubiquitous O
expression O
of O
the O
tolerizing O
Ad5 O
E1A O
peptide O
within O
a O
short O
period O
of O
time O
causes O
activation O
- O
induced O
cell O
death O
of O
Ad5 B
E1A I
- O
specific O
CTLs B
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

Transforming B
growth I
factor I
( I
TGF I
) I
- I
beta1 I
is O
well O
established O
as O
a O
critical O
IgA B
isotype I
switching I
factor I
and O
Smad B
molecules I
have O
been O
reported O
to O
act O
as O
transducers B
and O
transcriptional B
factors I
in O
the O
expression O
of O
TGF B
- I
beta1 I
- O
targeted O
genes B
. O

We O
examined O
the O
involvement O
of O
Smad B
proteins I
in O
TGF B
- I
beta1 I
- O
induced O
IgA O
expression O
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 B
that O
contains O
the O
TGF B
- I
beta I
- I
responsive I
element I
of O
the O
GLalpha B
promoter I
, O
and O
stimulated O
with O
TGF B
- I
beta1 I
. O

Similar O
to O
endogenous B
GLalpha I
transcripts I
, O
TGF B
- I
beta1 I
induces O
GLalpha B
promoter I
activity O
and O
overexpression O
of O
Smad3 B
markedly O
enhances O
the O
promoter O
activity O
. O

This O
activity O
is O
further O
augmented O
by O
cotransfected B
Smad4 I
. O

On O
the O
other O
hand O
, O
Smad7 B
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3 B
/ I
4 I
on O
GLalpha B
promoter I
activity O
. O

We O
show O
that O
human O
B O
cells O
constitutively O
express O
the O
translesion B
pol I
zeta I
, O
which O
effectively O
extends O
DNA O
past O
mismatched O
bases O
( O
mispair O
extender O
) O
, O
and O
pol B
eta I
, O
which O
bypasses O
DNA O
lesions O
in O
an O
error O
- O
free O
fashion O
. O

Upon O
B B
cell I
receptor I
( O
BCR B
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B
zeta I
, O
downregulated O
pol B
eta I
, O
and O
mutated O
the O
Ig B
and I
bcl I
- I
6 I
genes I
. O

Upon O
B B
cell I
receptor I
( O
BCR B
) O
engagement O
and O
coculture O
with O
activated O
CD4 O
+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B
zeta I
, O
downregulated O
pol B
eta I
, O
and O
mutated O
the O
Ig B
and I
bcl I
- I
6 I
genes I
. O

Inhibition O
of O
the O
pol B
zeta I
REV3 B
catalytic I
subunit I
by O
specific O
phosphorothioate O
- O
modified O
oligonucleotides O
impaired O
Ig O
and O
bcl O
- O
6 O
hypermutation O
and O
UV O
damage O
- O
induced O
DNA O
mutagenesis O
, O
without O
affecting O
cell O
cycle O
or O
viability O
. O

Thus O
, O
pol B
zeta I
plays O
a O
critical O
role O
in O
Ig O
and O
bcl O
- O
6 O
hypermutation O
, O
perhaps O
facilitated O
by O
the O
downregulation O
of O
pol B
eta I
. O

Thus O
, O
pol B
zeta I
plays O
a O
critical O
role O
in O
Ig O
and O
bcl O
- O
6 O
hypermutation O
, O
perhaps O
facilitated O
by O
the O
downregulation O
of O
pol B
eta I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B
- O
induced O
expression O
of O
genes O
for O
cell B
cycle I
regulatory I
molecules I
including O
cyclin B
D2 I
, O
cyclin B
E I
, O
E2F1 B
, O
CDK2 B
, O
CDK4 B
and O
CDK6 B
, O
and O
Tax B
- O
induced O
reduction O
of O
CDK B
inhibitors I
p19 I
( O
INK4d B
) O
and O
p27 B
( I
Kip1 I
) I
. O

Cot B
kinase I
induces O
cyclooxygenase O
- O
2 O
expression O
in O
T O
cells O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
. O

Here O
we O
report O
that O
Cot B
kinase I
, O
a O
mitogen B
- I
activated I
protein I
kinase I
kinase I
kinase I
involved O
in O
T O
cell O
activation O
, O
up O
- O
regulates O
COX B
- I
2 I
gene I
expression O
in O
Jurkat O
T O
cells O
. O

Induction O
of O
COX O
- O
2 O
promoter O
activity O
by O
Cot B
kinase I
occurred O
mainly O
through O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
. O

Mutation O
of O
the O
distal B
( I
- I
105 I
/ I
- I
97 I
) I
and O
proximal B
( I
- I
76 I
/ I
- I
61 I
) I
NFAT B
response I
elements I
in O
the O
COX B
- I
2 I
promoter I
abolished O
the O
activation O
induced O
by O
Cot B
kinase I
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B
inhibited O
Cot B
kinase I
- O
mediated O
COX B
- I
2 I
promoter I
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium B
- I
dependent I
phosphatase I
calcineurin I
synergizes O
with O
Cot B
kinase I
in O
the O
up O
- O
regulation O
of O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
. O

Strikingly O
, O
Cot B
kinase I
increased O
transactivation O
mediated O
by O
a O
GAL4 B
- I
NFAT I
fusion I
protein I
containing O
the O
N B
- I
terminal I
transactivation I
domain I
of O
NFATp B
. O

In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 O
, O
Cot B
kinase I
increases O
both O
COX B
- I
2 I
promoter I
activity O
and O
NFAT B
- O
mediated O
transactivation O
in O
a O
cyclosporin O
A O
- O
independent O
manner O
. O

These O
data O
indicate O
that O
Cot B
kinase I
up O
- O
regulates O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
through O
the O
NFAT B
response I
elements I
, O
being O
the O
Cot B
kinase I
- O
induced O
NFAT B
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

These O
data O
indicate O
that O
Cot B
kinase I
up O
- O
regulates O
COX B
- I
2 I
promoter I
- O
driven O
transcription O
through O
the O
NFAT B
response I
elements I
, O
being O
the O
Cot B
kinase I
- O
induced O
NFAT B
- O
dependent O
transactivation O
presumably O
implicated O
in O
this O
up O
- O
regulation O
. O

These O
effects O
did O
not O
in O
all O
cases O
correlate O
with O
the O
presence O
of O
TCF B
binding I
sites I
in O
the O
respective O
proximal B
promoter I
. O

Therefore O
, O
besides O
TCF B
- I
1 I
binding O
to O
the O
proximal B
promoter I
, O
Ly O
- O
49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF B
- I
1 I
binding O
to O
more O
distant O
cis B
- I
acting I
elements I
and O
/ O
or O
by O
regulating O
the O
expression O
of O
additional O
trans B
- I
acting I
factors I
. O

Consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF B
- I
1 I
for O
Ly B
- I
49 I
receptor I
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF B
site I
in O
certain O
proximal O
Ly B
- I
49 I
promoters I
. O

Ligation O
of O
CD11b B
and O
CD11c B
beta I
( I
2 I
) I
integrins B
by O
antibodies B
or O
soluble B
CD23 I
induces O
macrophage B
inflammatory I
protein I
1alpha I
( O
MIP B
- I
1alpha I
) O
and O
MIP B
- I
1beta I
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B
factor I
- I
kappaB I
. O

Chemokines B
and O
adhesion B
molecules I
such O
as O
integrins B
play O
a O
major O
part O
in O
the O
trafficking O
, O
extravasation O
, O
and O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

We O
found O
that O
ligation O
of O
CD11b B
or O
CD11c B
but O
not O
CD11a B
alpha I
chains I
of O
beta B
( I
2 I
) I
integrins I
by O
antibodies B
or O
soluble B
CD23 I
( I
sCD23 I
) I
fusion I
proteins I
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B
8 I
, O
macrophage B
inflammatory I
protein I
( I
MIP I
) I
1alpha I
, O
and O
MIP B
- I
1beta I
. O

Because O
the O
promoters B
of O
these O
chemokine B
genes I
contain O
kappaB B
binding I
sites I
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Acyl B
- I
coenzyme I
A I
: I
cholesterol I
acyltransferase I
( O
ACAT B
) O
is O
an O
intracellular B
enzyme I
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O

This O
region O
contains O
4 O
Sp1 B
elements I
and O
an O
IFN B
- I
gamma I
activated I
sequence I
( O
GAS B
) O
that O
overlaps O
with O
the O
second O
Sp1 B
element I
. O

This O
region O
contains O
4 O
Sp1 B
elements I
and O
an O
IFN B
- I
gamma I
activated I
sequence I
( O
GAS B
) O
that O
overlaps O
with O
the O
second O
Sp1 B
element I
. O

In O
the O
monocytic O
cell O
line O
THP O
- O
1 O
cell O
, O
the O
combination O
of O
IFN B
- I
gamma I
and O
all O
- O
trans O
- O
retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT B
- I
1 I
P1 I
promoter I
but O
not O
the O
P7 B
promoter I
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B
ligand I
- I
binding I
domain I
of O
RAGE B
, O
with O
anti O
- O
RAGE B
antiserum O
, O
and O
by O
coexpression O
of O
truncated B
receptors I
lacking O
the O
intracellular B
domain I
. O

The O
NF O
- O
kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B
ligand I
- I
binding I
domain I
of O
RAGE B
, O
with O
anti O
- O
RAGE B
antiserum O
, O
and O
by O
coexpression O
of O
truncated B
receptors I
lacking O
the O
intracellular B
domain I
. O

RAGE B
- O
mediated O
NF O
- O
kappaB O
activation O
was O
suppressed O
by O
the O
selective O
p38 B
MAPK I
inhibitor O
SB203580 O
and O
by O
coexpression O
of O
a O
kinase O
- O
dead O
p38 O
dominant O
- O
negative O
mutant O
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

Activation O
of O
NF B
- I
kappaB I
by O
CML B
- I
modified I
albumin I
increased O
secretion O
of O
proinflammatory B
cytokines I
( O
tumor B
necrosis I
factor I
- I
alpha I
, O
interleukin B
- I
1beta I
, O
and O
monocyte B
chemoattractant I
protein I
- I
1 I
) O
severalfold O
, O
and O
inhibition O
of O
p38 B
MAPK I
blocked O
these O
increases O
. O

These O
results O
indicate O
that O
p38 B
MAPK I
activation O
mediates O
RAGE B
- O
induced O
NF B
- I
kappaB I
- O
dependent O
secretion O
of O
proinflammatory B
cytokines I
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

These O
results O
indicate O
that O
p38 B
MAPK I
activation O
mediates O
RAGE B
- O
induced O
NF B
- I
kappaB I
- O
dependent O
secretion O
of O
proinflammatory B
cytokines I
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

T O
cell O
responses O
to O
Ags B
involve O
recognition O
of O
selected O
peptide B
epitopes I
contained O
within O
the O
antigenic B
protein I
. O

T O
cell O
responses O
to O
Ags B
involve O
recognition O
of O
selected O
peptide B
epitopes I
contained O
within O
the O
antigenic B
protein I
. O

With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 B
protein I
, O
a O
major O
Ag B
for O
HSV O
- O
2 O
, O
we O
generated O
a O
panel O
of O
class B
II I
MHC I
tetramers I
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral O
lymphocytes O
of O
an O
HSV O
- O
2 O
infected O
individual O
. O

Although O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0401 O
and O
DRA1 O
* O
0101 O
/ O
DRB1 O
* O
0404 O
are O
structurally O
very O
similar O
, O
nonoverlapping O
VP16 B
epitopes I
were O
identified O
, O
illustrating O
high O
selectivity O
of O
individual O
allele O
polymorphisms O
within O
common O
MHC O
variants O
. O

Here O
we O
report O
upregulation O
of O
NF B
- I
kappaB I
and O
inflammatory B
molecules I
, O
and O
their O
correlation O
with O
local O
pancreatic O
injury O
, O
in O
a O
model O
of O
severe O
pancreatitis O
. O

Furthermore O
, O
we O
show O
the O
existence O
of O
CD45 B
epitopes I
( O
GAP8 B
. I
3 I
) O
, O
which O
are O
active O
and O
critical O
for O
signaling O
in O
quiescent O
lymphocytes O
, O
but O
are O
nonfunctional O
in O
activated O
human O
lymphoblasts O
. O

The O
Pax5 B
gene I
encoding O
the O
transcription B
factor I
BSAP I
is O
required O
for O
progression O
of O
B O
- O
lymphopoiesis O
beyond O
the O
pro O
- O
B O
cell O
stage O
. O

Combinatorial O
regulation O
is O
a O
powerful O
mechanism O
that O
enables O
tight O
control O
of O
gene O
expression O
, O
via O
integration O
of O
multiple O
signaling O
pathways O
that O
induce O
different O
transcription B
factors I
required O
for O
enhanceosome O
assembly O
. O

The O
four O
calcium O
- O
regulated O
transcription B
factors I
of O
the O
NFAT B
family I
act O
synergistically O
with O
AP B
- I
1 I
( I
Fos I
/ I
Jun I
) I
proteins I
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT B
and I
AP I
- I
1 I
binding I
sites I
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

The O
four O
calcium O
- O
regulated O
transcription B
factors I
of O
the O
NFAT B
family I
act O
synergistically O
with O
AP B
- I
1 I
( I
Fos I
/ I
Jun I
) I
proteins I
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT B
and I
AP I
- I
1 I
binding I
sites I
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

Concomitant O
induction O
of O
NFAT B
and O
AP B
- I
1 I
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium O
/ O
calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B
kinase I
C I
( I
PKC I
) I
/ I
Ras I
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B
and I
Jun I
families I
of O
transcription B
factors I
. O

A O
fifth O
member O
of O
the O
NFAT B
family I
, O
NFAT5 B
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B
or O
of O
interaction O
with O
AP B
- I
1 I
. O

Infection O
with O
H3 O
, O
but O
not O
H310A1 O
, O
preferentially O
activates O
Vgamma4 O
Vdelta4 O
cells O
, O
which O
are O
strongly O
positive O
for O
gamma B
interferon I
( O
IFN B
- I
gamma I
) O
, O
whereas O
Vgamma1 O
Vdelta4 O
cells O
are O
increased O
in O
both O
H3 O
and O
H310A1 O
virus O
- O
infected O
animals O
. O

Plasmin B
- O
induced O
expression O
of O
cytokines B
and O
tissue B
factor I
in O
human O
monocytes O
involves O
AP B
- I
1 I
and O
IKKbeta B
- O
mediated O
NF O
- O
kappaB O
activation O
. O

Here O
it O
is O
demonstrated O
that O
plasmin B
induces O
proinflammatory B
cytokine I
release O
and O
tissue B
factor I
( O
TF B
) O
expression O
by O
monocytes O
. O

Here O
it O
is O
demonstrated O
that O
plasmin B
induces O
proinflammatory B
cytokine I
release O
and O
tissue B
factor I
( O
TF B
) O
expression O
by O
monocytes O
. O

A O
constitutive O
activation O
of O
STAT B
factors I
could O
explain O
the O
increased O
proliferation O
of O
P O
. O
vera O
cells O
even O
in O
the O
absence O
of O
growth O
factor O
stimulation O
. O

Identification O
of O
phosphorylation B
sites I
for O
Bruton B
' I
s I
tyrosine I
kinase I
within O
the O
transcriptional B
regulator I
BAP I
/ I
TFII I
- I
I I
. O

Residues O
Tyr357 O
and O
Tyr462 O
are O
contained O
within O
the O
loop B
regions I
of O
adjacent O
helix B
- I
loop I
- I
helix I
- I
like I
repeats I
within O
BAP B
/ I
TFII I
- I
I I
. O

To O
evaluate O
transcriptional O
regulation O
of O
the O
IL B
- I
2 I
gene I
in O
CD8 O
+ O
T O
cells O
, O
we O
stably O
transfected O
reporter B
genes I
into O
Ag B
- O
specific O
CD8 O
+ O
T O
cell O
clones O
. O

Distinct O
BMI B
- I
1 I
and O
EZH2 B
expression O
patterns O
in O
thymocytes O
and O
mature O
T O
cells O
suggest O
a O
role O
for O
Polycomb B
genes I
in O
human O
T O
cell O
differentiation O
. O

T O
cell O
stage O
- O
specific O
PcG O
expression O
profiles O
suggest O
that O
PcG B
genes I
contribute O
to O
regulation O
of O
T O
cell O
differentiation O
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant B
gp350 I
( O
rgp350 B
) O
and O
EBV O
upregulate O
IL B
- I
6 I
mRNA I
synthesis O
in O
B O
cells O
, O
EBV O
- O
induced O
IL O
- O
6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i O
. O
e O
. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B
) O
. O

In O
the O
present O
study O
, O
sequence O
analysis O
was O
conducted O
on O
lacI B
DNA I
and O
hprt B
cDNA I
from O
the O
mutants O
, O
to O
determine O
the O
mutational O
specificity O
of O
N O
- O
OH O
- O
AAF O
in O
the O
rat O
. O

In O
the O
present O
study O
, O
sequence O
analysis O
was O
conducted O
on O
lacI B
DNA I
and O
hprt B
cDNA I
from O
the O
mutants O
, O
to O
determine O
the O
mutational O
specificity O
of O
N O
- O
OH O
- O
AAF O
in O
the O
rat O
. O

Also O
, O
multiplex O
PCR O
analysis O
of O
genomic B
DNA I
from O
the O
hprt O
mutants O
indicated O
that O
12 O
% O
of O
mutants O
from O
treated O
rats O
had O
major O
deletions O
in O
the O
hprt B
gene I
; O
no O
corresponding O
incidence O
of O
large O
deletions O
was O
evident O
among O
lacI O
mutations O
. O

Also O
, O
multiplex O
PCR O
analysis O
of O
genomic B
DNA I
from O
the O
hprt O
mutants O
indicated O
that O
12 O
% O
of O
mutants O
from O
treated O
rats O
had O
major O
deletions O
in O
the O
hprt B
gene I
; O
no O
corresponding O
incidence O
of O
large O
deletions O
was O
evident O
among O
lacI O
mutations O
. O

The O
differences O
between O
N O
- O
OH O
- O
AAF O
mutation O
in O
the O
endogenous B
gene I
and O
transgene B
can O
be O
partially O
explained O
by O
the O
structures O
of O
the O
two O
genes O
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Gads B
is O
distinguished O
from O
Grb2 B
and O
the O
closely O
related O
Grap B
protein I
by O
the O
presence O
of O
a O
120 B
amino I
acid I
unique I
region I
between O
the O
SH2 B
domain I
and O
the O
carboxy B
terminal I
SH3 I
domain I
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

Recruitment O
of O
p300 B
by O
cAMP B
- I
responsive I
element I
- I
binding I
protein I
- I
Rel I
cross O
- O
talk O
at O
the O
composite B
CD28 I
response I
element I
( O
CD28RE B
) O
- O
TRE B
element I
of O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
promoter O
inducibility O
during O
T O
- O
cell O
activation O
, O
and O
CD28RE B
- I
TRE I
is O
the O
exclusive O
target O
of O
the O
human O
T O
- O
cell O
lymphotropic O
virus O
type O
I O
oncoprotein B
Tax I
. O

The O
stress O
response O
( O
SR O
) O
can O
block O
inflammatory O
gene O
expression O
by O
preventing O
activation O
of O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappaB I
) O
. O

T O
- O
cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon B
gamma I
( O
IFNgamma B
) O
in O
response O
to O
MOG B
( I
35 I
- I
55 I
) I
, O
was O
also O
decreased O
by O
the O
HSR O
. O

The O
early O
activation O
of O
transcription B
factor I
NF B
- I
kappaB I
was O
also O
blocked O
by O
the O
HSR O
. O

Core B
- I
binding I
factor I
beta I
( O
CBFbeta B
) O
is O
the O
non B
- I
DNA I
- I
binding I
subunit I
of O
the O
heterodimeric B
CBFs I
. O

Definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full B
- I
length I
Cbfb I
transgenes I
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization B
domain I
of O
CBFbeta B
. O

Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta B
- O
SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC B
portion I
of O
the O
fusion B
protein I
. O

Sequences O
responsible O
for O
the O
inability O
of O
CBFbeta B
- O
SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC B
portion I
of O
the O
fusion B
protein I
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV B
- I
DNA I
, O
EBV B
- I
encoded I
nuclear I
RNA I
( O
EBER B
) O
and O
a O
clonality O
of O
EBV B
- I
DNA I
fragments I
containing O
the O
terminal B
repeats I
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
- I
1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q B
promoter I
, O
whereas O
both O
the O
Q B
promoter I
and O
another O
upstream B
promoter I
( O
Cp B
/ I
Wp I
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
- I
1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q B
promoter I
, O
whereas O
both O
the O
Q B
promoter I
and O
another O
upstream B
promoter I
( O
Cp B
/ I
Wp I
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B
nuclear I
antigen I
( I
EBNA I
) I
- I
1 I
mRNA I
which O
was O
transcribed O
using O
the O
Q B
promoter I
, O
whereas O
both O
the O
Q B
promoter I
and O
another O
upstream B
promoter I
( O
Cp B
/ I
Wp I
) O
were O
used O
in O
EBV O
- O
positive O
cell O
lines O
, O
B95 O
. O
8 O
, O
Raji O
and O
Jiyoye O
. O

Latent B
BHRF1 I
transcripts I
encoding O
bcl B
- I
2 I
homologue I
and O
BCRF1 B
transcripts I
encoding O
viral B
interleukin I
( I
vIL I
) I
- I
10 I
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

[ O
( O
3 O
) O
H O
] O
azPC O
bound O
recombinant B
PPARgamma I
with O
an O
affinity O
( O
K O
( O
d O
) O
( O
( O
app O
) O
) O
approximately O
40 O
nm O
) O
that O
was O
equivalent O
to O
rosiglitazone O
( O
BRL49653 O
) O
, O
and O
competition O
with O
rosiglitazone O
showed O
that O
binding O
occurred O
in O
the O
ligand B
- I
binding I
pocket I
. O

Regulation O
of O
the O
human B
MAT2B I
gene I
encoding O
the O
regulatory B
beta I
subunit I
of O
methionine B
adenosyltransferase I
, O
MAT B
II I
. O

Regulation O
of O
the O
human B
MAT2B I
gene I
encoding O
the O
regulatory B
beta I
subunit I
of O
methionine B
adenosyltransferase I
, O
MAT B
II I
. O

Methionine B
adenosyltransferase I
( O
MAT B
) O
catalyzes O
the O
biosynthesis O
of O
S B
- I
adenosylmethionine I
( O
AdoMet B
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

To O
understand O
the O
mechanism O
by O
which O
the O
beta B
subunit I
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B
gene I
, O
determined O
its O
organization O
, O
characterized O
its O
5 B
' I
- I
flanking I
sequences I
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter B
. O

To O
understand O
the O
mechanism O
by O
which O
the O
beta B
subunit I
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B
gene I
, O
determined O
its O
organization O
, O
characterized O
its O
5 B
' I
- I
flanking I
sequences I
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter B
. O

Transcription O
of O
the O
MAT2B B
gene I
initiates O
at O
position O
- O
203 O
relative O
to O
the O
translation B
start I
site I
. O

Promoter B
deletion I
analysis I
defined O
a O
minimal B
promoter I
between O
positions B
+ I
52 I
and I
+ I
93 I
base O
pairs O
, O
a O
GC B
- I
rich I
region I
. O

The O
Sp1 B
site I
at O
position O
+ O
9 O
was O
key O
for O
the O
formation O
of O
protein O
. O
DNA O
complexes O
. O

Mutation O
of O
both O
the O
Sp1 B
site I
at O
+ O
9 O
and O
the O
TATA B
at O
- O
32 O
reduced O
promoter O
activity O
to O
its O
minimal O
level O
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti B
- I
Sp1 I
antibody I
on O
complex O
formation O
, O
whereas O
the O
anti B
- I
Sp3 I
antibody I
had O
a O
strong O
effect O
on O
protein O
. O
DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 B
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 B
site I
. O

Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 B
and O
Sp3 B
in O
complexes O
formed O
on O
the O
MAT2B B
promoter I
. O

The O
data O
show O
that O
the O
5 B
' I
- I
untranslated I
sequences I
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B
gene I
and O
identifies O
the O
Sp1 B
site I
at O
+ O
9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet B
levels O
. O

The O
data O
show O
that O
the O
5 B
' I
- I
untranslated I
sequences I
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B
gene I
and O
identifies O
the O
Sp1 B
site I
at O
+ O
9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet B
levels O
. O

Molecular O
pathogenesis O
of O
influenza O
A O
virus O
infection O
and O
virus O
- O
induced O
regulation O
of O
cytokine B
gene I
expression O
. O

In O
addition O
of O
upregulating O
cytokine B
gene I
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase B
- I
1 I
enzyme I
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL B
- I
1 I
beta I
and O
proIL B
- I
18 I
into O
their O
biologically O
active O
forms O
. O

Influenza O
A O
virus O
- O
induced O
IFN B
- I
alpha I
/ I
beta I
is O
essential O
in O
host O
' O
s O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral B
Mx I
, O
PKR B
and I
oligoadenylate I
synthetase I
genes I
. O

To O
investigate O
Mad1 B
function O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
that O
express O
a O
Mad1 B
transgene I
in O
T O
lineage O
cells O
under O
the O
control O
of O
the O
proximal B
lck I
promoter I
. O

PU O
. O
1 O
( O
- O
/ O
- O
) O
NK O
cells O
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 B
family I
and O
failed O
to O
proliferate O
in O
response O
to O
IL B
- I
2 I
and O
IL B
- I
12 I
. O

We O
have O
shown O
that O
DEPs O
augmented O
the O
production O
of O
inflammatory B
cytokines I
by O
human O
airway O
epithelial O
cells O
in O
vitro O
. O

Expression O
of O
SART3 B
antigen I
and O
induction O
of O
CTLs O
by O
SART3 O
- O
derived O
peptides O
in O
breast O
cancer O
patients O
. O

This O
study O
investigated O
expression O
of O
the O
SART3 B
antigen I
in O
breast O
cancer O
to O
explore O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
breast O
cancer O
patients O
. O

The O
SART3 B
antigen I
was O
detected O
in O
all O
of O
the O
breast O
cancer O
cell O
lines O
tested O
, O
30 O
of O
40 O
( O
75 O
% O
) O
breast O
cancer O
tissue O
samples O
, O
and O
0 O
of O
3 O
non O
- O
tumourous O
breast O
tissue O
samples O
. O

Therefore O
, O
the O
SART3 B
antigen I
and O
its O
peptides O
could O
be O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
the O
majority O
of O
HLA O
- O
A24 O
- O
positive O
breast O
cancer O
patients O

Autostimulation O
of O
the O
Epstein O
- O
Barr O
virus O
BRLF1 B
promoter I
is O
mediated O
through O
consensus O
Sp1 B
and I
Sp3 I
binding I
sites I
. O

Consistent O
with O
this O
biologic O
function O
, O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
Rta B
protein I
powerfully O
stimulates O
the O
promoter B
of O
its O
own O
gene O
, O
Rp B
, O
in O
EBV O
- O
positive O
B O
cells O
in O
transient O
- O
transfection O
reporter O
- O
based O
assays O
. O

Gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 B
and O
Sp3 B
as O
the O
predominant O
cellular B
proteins I
bound O
to O
Rp B
near O
- O
45 O
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 B
and O
Sp3 B
transcription B
factors I
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B
promoter I
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 B
and O
Sp3 B
transcription B
factors I
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B
promoter I
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2 B
- I
Runx2 I
transgene I
either O
with O
a O
Pim1 B
transgene I
( O
E B
( I
mu I
) I
- I
Pim1 I
) O
or O
with O
the O
p53 B
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B
. O

However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 B
with O
specific O
monoclonal B
antibodies I
. O

Transcription B
factors I
are O
essential O
to O
govern O
differentiation O
along O
the O
lymphoid O
lineage O
from O
uncommitted O
hematopoietic O
stem O
cells O
. O

Although O
many O
of O
these O
transcription B
factors I
have O
putative O
roles O
based O
on O
murine O
knockout O
experiments O
, O
their O
function O
in O
human O
lymphoid O
development O
is O
less O
known O
and O
was O
studied O
further O
. O

Id B
- I
3 I
, O
a O
basic B
helix I
loop I
helix I
factor I
with O
dominant O
negative O
function O
for O
T O
- O
cell O
differentiation O
transcription B
factors I
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T O
- O
cell O
maturation O
. O

The O
TCF B
- I
1 I
isoform I
found O
in O
CD56 O
( O
+ O
bright O
) O
cells O
, O
which O
express O
lectin B
but O
not O
immunoglobulin B
class I
I I
recognizing O
inhibitory B
receptors I
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

Bright B
( O
B B
cell I
regulator I
of I
IgH I
transcription I
) O
is O
a O
B O
cell O
- O
specific O
, O
matrix B
associating I
region I
- I
binding I
protein I
that O
transactivates O
gene O
expression O
from O
the O
IgH B
intronic I
enhancer I
( O
E B
mu I
) O
. O

We O
show O
here O
that O
Bright B
has O
multiple O
contextual O
requirements O
to O
function O
as O
a O
transcriptional B
activator I
. O

Two O
of O
the O
three O
previously O
identified O
binding B
sites I
in O
E B
mu I
are O
required O
for O
full O
Bright B
transactivation O
. O

Two O
of O
the O
three O
previously O
identified O
binding B
sites I
in O
E B
mu I
are O
required O
for O
full O
Bright B
transactivation O
. O

Similar O
to O
one O
group O
of O
high B
mobility I
group I
box I
proteins I
, O
Bright B
distorts O
E B
mu I
binding I
site I
- O
containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E B
mu I
remodeling O
. O

Finally O
, O
we O
show O
that O
overexpression O
of O
Bright B
leads O
to O
enhanced O
DNase O
I O
sensitivity O
of O
the O
endogenous O
E B
mu I
matrix O
associating O
regions O
. O

These O
data O
further O
suggest O
that O
Bright B
may O
contribute O
to O
increased O
gene O
expression O
by O
remodeling O
the O
immunoglobulin B
locus I
during O
B O
cell O
development O
. O

Translocations O
of O
the O
BCL B
- I
6 I
gene I
to O
heterologous B
promoters I
and O
mutations O
of O
its O
5 B
' I
- I
noncoding I
regulatory I
region I
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL B
- I
6 I
expression O
and O
for O
playing O
a O
role O
in O
the O
genesis O
of O
non O
- O
Hodgkin O
lymphoma O
. O

Here O
we O
show O
that O
the O
IL B
- I
2 I
- O
induced O
expression O
of O
Gadd45gamma B
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B
kinase I
Jak3 I
and O
the O
transcription B
factors I
Stat5a B
and O
Stat5b B
( O
signal B
transducer I
and I
activator I
of I
transcription I
) O
. O

Whereas O
expression O
of O
E2A O
mRNA O
and O
protein O
are O
unaltered O
, O
Id3 B
transcripts I
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR B
. O

These O
observations O
directly O
connect O
the O
ERK B
MAPK B
cascade O
and O
HLH B
proteins I
in O
a O
linear O
pathway O
. O

Investigation O
of O
retinoid B
receptor I
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR B
alpha I
, I
RAR I
gamma I
, I
RXR I
beta I
, I
and I
RXR I
gamma I
transcripts I
in O
all O
cell O
lines O
studied O
, O
and O
HMC O
- O
1 O
cells O
were O
the O
only O
line O
lacking O
RXR B
alpha I
. O

Investigation O
of O
retinoid B
receptor I
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR B
alpha I
, I
RAR I
gamma I
, I
RXR I
beta I
, I
and I
RXR I
gamma I
transcripts I
in O
all O
cell O
lines O
studied O
, O
and O
HMC O
- O
1 O
cells O
were O
the O
only O
line O
lacking O
RXR B
alpha I
. O

RAR B
beta I
, O
not O
expressed O
at O
baseline O
, O
was O
induced O
by O
RA O
in O
a O
fashion O
obviously O
correlating O
with O
ICAM B
- I
3 I
up O
- O
regulation O
. O

In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP B
- I
1 I
- O
and O
NF B
- I
kappa I
B I
- O
mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self B
Ag I
expressed O
exclusively O
on O
hepatocytes O
. O

The O
transcription B
factors I
that O
mediate O
these O
processes O
are O
often O
expressed O
broadly O
in O
many O
cell O
types O
. O

The O
emerging O
theme O
is O
one O
of O
cell O
- O
type O
- O
specific O
regulation O
, O
affecting O
not O
only O
the O
functional O
activation O
of O
transcription B
factors I
but O
also O
their O
access O
to O
appropriate O
regions O
of O
DNA O
. O

However O
, O
the O
differentiation O
induced O
by O
the O
ER O
- O
35795 O
was O
not O
antagonized O
at O
all O
by O
the O
RAR B
antagonist O
, O
but O
was O
inhibited O
by O
an O
RXR B
homodimer I
antagonist O
( O
LGD100754 O
, O
( O
2E O
, O
4E O
, O
6Z O
) O
- O
7 O
- O
( O
3 O
- O
n O
- O
propoxy O
- O
5 O
, O
6 O
, O
7 O
, O
8 O
- O
tetrahydro O
- O
5 O
, O
5 O
, O
8 O
, O
8 O
- O
tetramethylnaphthale O
- O
2 O
- O
yl O
) O
- O
3 O
- O
methylocta O
- O
2 O
, O
4 O
, O
6 O
- O
trienoic O
acid O
) O

During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta B
mRNA I
, O
while O
the O
RXR B
had O
no O
effect O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

Similar O
to O
transmembrane B
PTP I
, O
CD45 B
, O
the O
membrane O
- O
associated O
populations O
of O
SHP B
- I
1 I
and O
SHP B
- I
2 I
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B
molecules I
such O
as O
Lck B
, I
linker I
for I
activation I
of I
T I
cells I
, O
and O
CD3 B
zeta I
are O
enriched O
. O

We O
have O
shown O
that O
estrogen B
receptor I
( O
ERalpha B
, O
ERbeta B
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

In O
this O
study O
, O
T O
cell O
nuclear O
extracts O
from O
female O
lupus O
patients O
and O
normal O
donors O
were O
tested O
for O
biologically O
active O
ER B
proteins I
capable O
of O
binding O
to O
the O
human B
estrogen I
response I
element I
( O
hERE B
) O
by O
electrophoretic O
mobility O
shift O
assays O
. O

Together O
, O
these O
results O
suggest O
that O
activated O
human O
T O
cells O
, O
whether O
lupus O
- O
derived O
or O
normal O
- O
derived O
, O
contain O
biologically O
active O
ERalpha B
proteins I
. O

UTI O
decreased O
the O
TNFalpha B
production O
of O
LPS O
- O
stimulated O
monocytes O
, O
but O
did O
not O
inhibit O
the O
TNFalpha B
mRNA I
expression O
. O

Surface B
immunoglobulin I
and O
IL B
- I
4R I
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B
- O
resistance O
that O
differentially O
depend O
on O
PKC B
and O
STAT6 B
, O
respectively O
. O

The O
FAIM B
sequence I
is O
highly O
evolu O
- O
tionarily O
conserved O
, O
suggesting O
an O
important O
role O
for O
this O
molecule O
throughout O
phylogeny O
. O

Stromal B
cell I
- I
derived I
factor I
1 I
alpha I
( O
SDF1 B
alpha I
) O
and O
its O
cognate O
chemokine B
receptor I
CXCR4 I
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic O
progenitor O
cells O
and O
lymphocytes O
. O

However O
, O
the O
molecular O
mechanisms O
regulating O
SDF1 B
alpha I
- O
driven O
cell O
migration O
are O
not O
well O
defined O
. O

In O
this O
study O
, O
we O
have O
explored O
the O
roles O
of O
the O
second O
messenger O
NO O
and O
the O
transcription B
factor I
NF I
- I
kappa I
B I
in O
SDF1 B
alpha I
- O
induced O
T O
cell O
migration O
. O

SDF1 B
alpha I
treatment O
of O
Jurkat O
T O
cells O
increased O
the O
activity O
of O
NO B
synthase I
, O
which O
catalyzes O
the O
generation O
of O
NO O
. O

SDF1 B
alpha I
treatment O
of O
Jurkat O
T O
cells O
increased O
the O
activity O
of O
NO B
synthase I
, O
which O
catalyzes O
the O
generation O
of O
NO O
. O

We O
observed O
that O
pretreatment O
of O
Jurkat O
cells O
or O
activated O
PBLs O
with O
several O
NO O
donors O
significantly O
enhanced O
the O
SDF1 B
alpha I
- O
induced O
migration O
, O
whereas O
various O
inhibitors O
of O
NO B
synthase I
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration O
- O
dependent O
manner O
. O

We O
observed O
that O
pretreatment O
of O
Jurkat O
cells O
or O
activated O
PBLs O
with O
several O
NO O
donors O
significantly O
enhanced O
the O
SDF1 B
alpha I
- O
induced O
migration O
, O
whereas O
various O
inhibitors O
of O
NO B
synthase I
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration O
- O
dependent O
manner O
. O

Furthermore O
, O
we O
observed O
that O
inhibitors O
of O
the O
transcription B
factor I
NF I
- I
kappa I
B I
, O
which O
is O
linked O
to O
NO O
signaling O
pathways O
, O
also O
significantly O
blocked O
the O
SDF1 B
alpha I
- O
induced O
chemotactic O
response O
. O

However O
, O
these O
compounds O
did O
not O
have O
a O
significant O
effect O
on O
SDF1 B
alpha I
- O
induced O
mitogen O
- O
activated O
protein O
kinase O
activity O
. O

In O
addition O
, O
the O
MAP O
/ O
Erk O
kinase O
kinase O
inhibitor O
PD98059 O
did O
not O
abrogate O
SDF1 B
alpha I
- O
induced O
chemotaxis O
. O

AKT B
, O
which O
has O
been O
shown O
to O
mediate O
NO O
production O
, O
was O
also O
phosphorylated O
upon O
SDF1 B
alpha I
stimulation O
. O

These O
studies O
suggest O
that O
NO O
- O
related O
signaling O
pathways O
may O
mediate O
SDF1 B
alpha I
- O
induced O
chemotaxis O
, O
but O
not O
mitogen B
- I
activated I
protein I
kinase I
activation O
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B
transgene I
, O
dominant B
negative I
ras I
/ I
Mek I
proteins I
and O
a O
reporter B
gene I
construct I
with O
AP B
- I
1 I
or I
NF I
- I
kappa I
B I
binding I
sites I
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
but O
not O
AP B
- I
1 I
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

Taken O
together O
the O
results O
suggest O
that O
the O
lack O
of O
PKC B
epsilon I
in O
DP O
thymocytes O
could O
lead O
to O
the O
absence O
of O
NF B
- I
kappa I
B I
activity O
after O
antigenic O
stimulation O
contributing O
to O
negative O
selection O
. O

Although O
cytokine B
receptors I
are O
known O
to O
signal O
through O
STAT B
family I
transcription I
factors I
, O
the O
mechanisms O
by O
which O
other O
cell B
- I
surface I
molecules I
, O
such O
as O
CD2 B
, O
transduce O
signals O
is O
unclear O
. O

In O
contrast O
to O
stimulation O
by O
cytokines B
, O
the O
activation O
of O
STAT1 B
in O
response O
to O
CD2 O
ligation O
is O
delayed O
and O
does O
not O
involve O
Jak B
kinases I
. O

Doubly O
deficient O
T O
cells O
displayed O
cell O
surface O
markers O
of O
activation O
yet O
were O
significantly O
deficient O
in O
the O
development O
of O
multiple O
effector O
functions O
, O
including O
Th B
cytokine I
production O
, O
surface B
effector I
molecule I
expression O
, O
and O
cytolytic O
activity O
. O

The O
PML B
protein I
is O
induced O
by O
interferon B
, O
involved O
in O
major B
histocompatibility I
complex I
class I
I I
presentation O
, O
and O
necessary O
for O
certain O
types O
of O
apoptosis O
. O

Suppression O
of O
nuclear B
factor I
- I
kappaB I
and O
stimulation O
of O
inhibitor B
kappaB I
by O
troglitazone O
: O
evidence O
for O
an O
anti O
- O
inflammatory O
effect O
and O
a O
potential O
antiatherosclerotic O
effect O
in O
the O
obese O
. O

We O
measured O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
inhibitor B
kappaB I
( I
IkappaB I
) I
alpha I
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B
( I
phox I
) I
subunit I
( O
a O
key O
component O
protein O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
oxidase I
) O
in O
MNC O
. O

We O
measured O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
inhibitor B
kappaB I
( I
IkappaB I
) I
alpha I
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B
( I
phox I
) I
subunit I
( O
a O
key O
component O
protein O
of O
nicotinamide B
adenine I
dinucleotide I
phosphate I
oxidase I
) O
in O
MNC O
. O

Plasma B
tumor I
necrosis I
factor I
( I
TNF I
) I
- I
alpha I
, O
soluble B
intercellular I
adhesion I
molecule I
- I
1 I
( O
sICAM B
- I
1 I
) O
, O
monocyte B
chemoattractant I
protein I
- I
1 I
( I
MCP I
- I
1 I
) I
, O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
, O
C B
- I
reactive I
protein I
( I
CRP I
) I
, O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
antiinflammatory B
cytokine I
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B
transcription I
factor I
NFkappaB I
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
IkappaBalpha B
, O
and O
p47 B
( I
phox I
) I
subunit I
and O
ROS O
generation O
were O
determined O
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
IkappaBalpha B
, O
and O
p47 B
( I
phox I
) I
subunit I
and O
ROS O
generation O
were O
determined O
. O

There O
was O
a O
fall O
in O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
and O
p47 B
( I
phox I
) I
subunit I
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha B
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

There O
was O
a O
fall O
in O
intranuclear B
NFkappaB I
, O
total O
cellular B
NFkappaB I
, O
and O
p47 B
( I
phox I
) I
subunit I
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha B
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

Plasma O
IL B
- I
10 I
concentration O
increased O
significantly O
, O
whereas O
plasma B
CRP I
concentrations O
decreased O
. O

The O
involvement O
of O
the O
tyrosine B
kinases I
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases B
. O

Furthermore O
, O
the O
SH2 B
domain I
of O
p56 B
( I
lck I
) I
appeared O
to O
be O
required O
for O
pervanadate O
- O
induced O
NF B
- I
kappa I
B I
activation O
but O
not O
for O
Tyr42 O
phosphorylation O
. O

These O
results O
show O
that O
p56 B
( I
lck I
) I
and O
ZAP B
- I
70 I
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine O
- O
dependent O
NF B
- I
kappa I
B I
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B
kinases I
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF B
- I
kappa I
B I
. O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

These O
mutations O
prevent O
CD40 B
ligand I
( O
CD40L B
) O
- O
mediated O
degradation O
of O
inhibitor O
of O
NF B
- I
kappaB I
alpha I
( O
IkappaB B
- I
alpha I
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM O
- O
ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class O
- O
switch O
recombination O
and O
antigen O
- O
presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF B
- I
kappaB I
- I
regulated I
cytokines I
interleukin B
12 I
( O
IL B
- I
12 I
) O
or O
tumor B
necrosis I
factor I
alpha I
( O
TNF B
- I
alpha I
) O
when O
stimulated O
with O

METHODS O
: O
Expression O
of O
oestrogen B
receptors I
( O
ER B
) O
and O
progesterone B
receptors I
( O
PR B
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O

METHODS O
: O
Expression O
of O
oestrogen B
receptors I
( O
ER B
) O
and O
progesterone B
receptors I
( O
PR B
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O

RESULTS O
: O
Consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4 O
+ O
( O
T O
helper O
/ O
inducer O
) O
, O
CD8 O
+ O
( O
cytotoxic O
/ O
suppressor O
) O
, O
CD68 O
+ O
( O
macrophages O
) O
, O
mast O
cells O
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal B
antibodies I
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast O
cells O
tested O
positive O
for O
ER B
/ O
PR O
labelling O
with O
their O
polyclonal B
and I
monoclonal I
antibodies I
. O

Our O
previous O
studies O
have O
implicated O
the O
nuclear O
transcription O
factor O
kappa O
B O
( O
NF B
kappa I
B I
) O
in O
the O
regulation O
of O
adhesion B
molecule I
expression O
in O
endothelial O
cells O
exposed O
to O
anoxia O
- O
reoxygenation O
( O
A O
/ O
R O
) O
or O
a O
redox O
imbalance O
. O

tyrosine I
phosphatase I
( O
PTPase B
) O
and O
/ O
or O
protein B
kinase I
C I
( O
PKC B
) O
. O

Unlike O
Fas B
- O
mediated O
apoptosis O
, O
the O
initiator B
caspase I
, O
caspase B
- I
8 I
, O
was O
not O
involved O
in O
DMA O
- O
2 O
, O
4 O
- O
D O
- O
induced O
apoptosis O
. O

Interleukin B
6 I
( O
IL B
- I
6 I
) O
is O
a O
cytokine B
produced O
by O
immune O
and O
nonimmune O
cells O
and O
exhibits O
functional O
pleiotropy O
and O
redundancy O
. O

IL B
- I
6 I
upregulates O
suppressor B
of I
cytokine I
signaling I
1 I
( O
SOCS1 B
) O
expression O
in O
activated O
CD4 O
+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B
transducer I
and I
activator I
of I
transcription I
1 I
( O
STAT1 B
) O
phosphorylation O
induced O
by O
interferon B
gamma I
( O
IFNgamma B
) O
. O

Inhibition O
of O
IFNgamma B
receptor O
- O
mediated O
signals O
by O
IL B
- I
6 I
prevents O
autoregulation O
of O
IFNgamma B
gene I
expression O
by O
IFNgamma B
during O
CD4 O
+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Given O
that O
C B
/ I
EBP I
proteins I
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B
factors I
including O
members O
of O
the O
ATF B
/ I
CREB I
family I
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF B
/ I
CREB I
binding I
site I
could O
affect O
C B
/ I
EBP I
protein I
binding O
to O
C B
/ I
EBP I
site I
I I
. O

Thus O
, O
HIV B
- I
1 I
LTR I
ATF B
/ I
CREB I
binding I
site I
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral B
promoter I
through O
the O
C O
/ O
EBP O
pathway O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL O
- O
1 O
- O
dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B
RNA I
( O
mRNA B
) O
for O
the O
chemokines B
monocyte B
chemoattractant I
protein I
1 I
, O
macrophage B
inhibitory I
protein I
2 I
( O
MIP B
- I
2 I
) O
, O
RANTES B
, O
MIP B
- I
1alpha I
, O
and O
MIP B
- I
1beta I
, O
in O
vivo O
and O
in O
vitro O
. O

Positive O
and O
negative O
regulation O
of O
granulopoiesis O
by O
endogenous B
RARalpha I
. O

Whether O
these O
translocations O
relate O
to O
a O
role O
for O
endogenous B
RARalpha I
in O
normal O
granulopoiesis O
remains O
uncertain O
because O
most O
studies O
addressing O
this O
question O
have O
used O
non O
- O
physiological O
overexpression O
systems O
. O

Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha B
fusion B
proteins I
expressed O
in O
APL O
cells O
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded B
RARalpha I
. O

Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha B
fusion B
proteins I
expressed O
in O
APL O
cells O
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded B
RARalpha I
. O

In O
human O
T O
cells O
CBFalpha2 B
is O
usually O
transcribed O
from O
a O
different B
promoter I
( O
distal B
promoter I
) O
than O
in O
myeloid O
cells O
( O
proximal B
promoter I
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

In O
human O
T O
cells O
CBFalpha2 B
is O
usually O
transcribed O
from O
a O
different B
promoter I
( O
distal B
promoter I
) O
than O
in O
myeloid O
cells O
( O
proximal B
promoter I
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

In O
human O
T O
cells O
CBFalpha2 B
is O
usually O
transcribed O
from O
a O
different B
promoter I
( O
distal B
promoter I
) O
than O
in O
myeloid O
cells O
( O
proximal B
promoter I
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

Here O
, O
we O
report O
that O
both O
coding B
and I
noncoding I
sequences I
of O
the O
distal B
5 I
' I
end I
are O
highly O
conserved O
between O
the O
human B
and I
the I
murine I
genes I
, O
and O
the O
distal B
promoter I
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

The O
distal B
N I
- I
terminal I
isoform I
binds O
to O
functionally O
important O
regulatory B
sites I
from O
known O
target B
genes I
with O
two O
- O
to O
threefold O
higher O
affinity O
than O
the O
proximal B
N I
- I
terminal I
isoform I
. O

The O
distal B
N I
- I
terminal I
isoform I
binds O
to O
functionally O
important O
regulatory B
sites I
from O
known O
target B
genes I
with O
two O
- O
to O
threefold O
higher O
affinity O
than O
the O
proximal B
N I
- I
terminal I
isoform I
. O

Neither O
full B
- I
length I
isoform I
alters O
growth O
of O
a O
myeloid O
cell O
line O
under O
nondifferentiating O
conditions O
, O
but O
the O
proximal B
isoform I
selectively O
delays O
mitotic O
arrest O
of O
the O
cell O
line O
under O
differentiating O
conditions O
, O
resulting O
in O
the O
generation O
of O
greater O
numbers O
of O
neutrophils O
. O

Stimulation O
of O
B O
cells O
by O
surface B
immunoglobulin I
( O
sIg B
) O
triggering O
, O
or O
through O
the O
mitogenic O
combination O
of O
phorbol O
ester O
and O
calcium O
ionophore O
, O
is O
accompanied O
by O
activation O
of O
STAT B
transcription I
factors I
. O

The O
mechanism O
responsible O
for O
the O
delayed O
nuclear O
accumulation O
of O
phosphorylated B
STAT3 I
was O
examined O
in O
detail O
, O
focusing O
on O
the O
role O
of O
B B
cell I
- I
derived I
lymphokines I
. O

sIg B
- O
induced O
activation O
of O
STAT3 B
was O
partially O
inhibited O
in O
B O
cells O
obtained O
from O
IL O
- O
6 O
- O
or O
IL O
- O
10 O
- O
deficient O
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B
antibodies I
directed O
against O
either O
of O
these O
lymphokines B
. O

sIg B
- O
induced O
STAT3 O
activation O
was O
completely O
inhibited O
by O
combining O
IL B
- I
6 I
- I
and I
IL I
- I
10 I
- I
specific I
neutralizing I
antibodies I
, O
or O
by O
adding O
individual O
neutralizing B
antibodies I
to O
B O
cells O
obtained O
from O
lymphokine O
- O
deficient O
animals O
. O

This O
work O
indicates O
that O
a O
lymphokine O
pathway O
is O
responsible O
for O
STAT3 O
activation O
that O
occurs O
late O
after O
B O
cell O
stimulation O
, O
and O
points O
out O
differences O
in O
B O
cell O
activation O
that O
result O
from O
stimulation O
through O
the O
antigen B
receptor I
and O
through O
pharmacological O
mimicry O
of O
signaling B
mediators I
. O

This O
work O
indicates O
that O
a O
lymphokine O
pathway O
is O
responsible O
for O
STAT3 O
activation O
that O
occurs O
late O
after O
B O
cell O
stimulation O
, O
and O
points O
out O
differences O
in O
B O
cell O
activation O
that O
result O
from O
stimulation O
through O
the O
antigen B
receptor I
and O
through O
pharmacological O
mimicry O
of O
signaling B
mediators I
. O

Immunoglobulin B
( I
Ig I
) I
- I
kappa I
promoters I
from O
humans O
and O
mice O
share O
conserved B
sequences I
. O

The O
octamer B
element I
is O
common O
to O
all O
Ig B
promoters I
and O
pivotal O
for O
their O
function O
. O

The O
octamer B
element I
is O
common O
to O
all O
Ig B
promoters I
and O
pivotal O
for O
their O
function O
. O

One O
example O
is O
an O
E B
- I
box I
of O
the O
E47 B
/ I
E12 I
type I
( I
5 I
' I
- I
CAGCTG I
- I
3 I
' I
) I
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B
and I
murine I
Ig I
- I
kappa I
gene I
subgroups I
/ I
families I
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine B
families I
. O

Furthermore O
, O
AP B
- I
4 I
, O
unlike O
E47 B
, O
did O
not O
act O
as O
a O
transactivator B
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B
promoters I
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B
element I
has O
been O
mutated O
. O

Furthermore O
, O
AP B
- I
4 I
, O
unlike O
E47 B
, O
did O
not O
act O
as O
a O
transactivator B
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B
promoters I
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B
element I
has O
been O
mutated O
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5 B
' I
- I
CAGCTG I
- I
3 I
' I
motif I
among O
human B
and I
murine I
kappa I
promoters I
, O
we O
propose O
that O
AP B
- I
4 I
is O
the O
major B
ligand I
for O
Ig B
- I
kappa I
promoter I
E I
- I
boxes I
. O

In O
this O
study O
, O
we O
obtained O
PBL O
from O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
IgG B
antibody I
positive O
kidney O
transplant O
recipients O
( O
R O
) O
and O
their O
living O
- O
related O
donors O
( O
LRD O
) O
one O
year O
after O
renal O
transplantation O
. O

Protein B
Kinase I
A I
( O
PKA B
) O
, O
a O
cAMP B
kinase I
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B
cytokine I
activity O
, O
was O
increased O
in O
EBV O
- O
CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

Protein B
Kinase I
A I
( O
PKA B
) O
, O
a O
cAMP B
kinase I
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B
cytokine I
activity O
, O
was O
increased O
in O
EBV O
- O
CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

These O
results O
show O
that O
the O
BMC O
inhibition O
is O
mediated O
by O
soluble B
factors I
( O
cytokines B
) O
and O
that O
cell O
- O
cell O
contact O
in O
this O
autologous O
system O
is O
not O
required O
, O
so O
that O
BMC O
( O
at O
least O
partially O
, O
via O
cytokine O
production O
) O
promote O
TH2 O
polarization O
in O
culture O
. O

Reduction O
in O
DNA O
binding O
activity O
of O
the O
transcription B
factor I
Pax B
- I
5a I
in O
B O
lymphocytes O
of O
aged O
mice O
. O

The O
transcription B
factor I
Pax B
- I
5 I
is O
a O
key O
regulator O
of O
B O
cell O
development O
. O

Pax B
- I
5a I
/ I
B I
cell I
- I
specific I
activator I
protein I
and O
an O
alternatively B
spliced I
isoform I
, I
Pax I
- I
5d I
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation B
domain I
in O
Pax B
- I
5d I
. O

Expression O
of O
the O
Ig B
J I
chain I
and O
the O
secreted O
form O
of O
Ig B
mu I
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax B
- I
5a I
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax B
- I
5a I
but O
not O
Pax B
- I
5d I
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J B
chain I
, O
and O
secretion O
of O
IgM B

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF B
- I
kappaB I
through O
the O
expression O
of O
an O
IkappaBalpha B
( O
inhibitory B
protein I
that O
dissociates O
from O
NF B
- I
kappaB I
) O
mutant O
refractory O
to O
signal O
- O
induced O
degradation O
( O
IkappaBalpha B
( I
DeltaN I
) I
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL B
- I
4 I
as O
well O
as O
IL B
- I
2 I
. O

These O
results O
indicate O
that O
the O
NF O
- O
kappaB O
/ O
Rel O
/ O
IkappaBalpha O
system O
can O
regulate O
cytokine B
receptor I
capacitation O
through O
effects O
on O
the O
induction O
of O
downstream O
signaling O
by O
the O
Stat B
transcription I
factor I
family I
. O

In O
Sprague O
Dawley O
rats O
at O
daily O
oral O
doses O
of O
15 O
, O
60 O
, O
or O
240 O
mg O
/ O
kg O
for O
1 O
month O
, O
BMS O
- O
189453 O
produced O
increases O
in O
leukocyte O
counts O
, O
alkaline B
phosphatase I
and O
alanine B
aminotransferase I
levels O
, O
and O
marked O
testicular O
degeneration O
and O
atrophy O
at O
all O
doses O
. O

In O
Sprague O
Dawley O
rats O
at O
daily O
oral O
doses O
of O
15 O
, O
60 O
, O
or O
240 O
mg O
/ O
kg O
for O
1 O
month O
, O
BMS O
- O
189453 O
produced O
increases O
in O
leukocyte O
counts O
, O
alkaline B
phosphatase I
and O
alanine B
aminotransferase I
levels O
, O
and O
marked O
testicular O
degeneration O
and O
atrophy O
at O
all O
doses O
. O

Sequential O
involvement O
of O
NFAT B
and O
Egr B
transcription B
factors I
in O
FasL O
regulation O
. O

The O
critical O
function O
of O
NFAT B
proteins I
in O
maintaining O
lymphoid O
homeostasis O
was O
revealed O
in O
mice O
lacking O
both O
NFATp B
and O
NFAT4 B
( O
DKO O
) O
. O

The O
transcription B
factors I
Egr2 B
and O
Egr3 B
are O
potent O
activators O
of O
FasL O
expression O
. O

Genomic O
effects O
are O
mediated O
by O
cytosolic B
receptors I
that O
alter O
expression O
of O
specific O
genes O
. O

METHODS O
/ O
RESULTS O
: O
Cells O
exposed O
to O
high O
D O
- O
glucose O
( O
30 O
mmol O
/ O
l O
) O
caused O
an O
increase O
in O
[ O
3H O
] O
- O
thymidine O
incorporation O
and O
cell O
numbers O
at O
24 O
and O
48 O
h O
and O
normalized O
at O
72 O
h O
( O
p O
< O
0 O
. O
05 O
) O
, O
whereas O
these O
changes O
were O
not O
found O
in O
high O
mannitol O
( O
30 O
mmol O
/ O
l O
) O
, O
IL B
- I
1 I
beta I
, O
or O
TNF B
alpha I
- O
stimulated O
mesangial O
cells O
. O

Combined O
corticosteroid O
/ O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G B
- I
CSF I
: O
Activated O
glucocorticoid B
receptors I
synergize O
with O
G B
- I
CSF I
signals O
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G B
- I
CSF I
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular B
domain I
of O
the O
G B
- I
CSF I
receptor I
( O
GCSF B
- I
R I
) O
. O

Proliferation O
of O
32D O
cells O
expressing O
the O
mutated B
receptor I
and O
STAT5 O
activation O
were O
improved O
by O
a O
combination O
of O
G B
- I
CSF I
and O
dexamethasone O
. O

In O
epithelial O
cells O
, O
defensin B
genes I
are O
found O
as O
both O
constitutively O
expressed O
and O
inducible O
. O

In O
vivo O
, O
up O
- O
regulation O
of O
several O
defensin B
genes I
occurs O
in O
both O
infectious O
and O
inflammatory O
states O
. O

Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription B
factors I
such O
as O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
and O
NF B
interleukin I
- I
6 I
. O

Extracellular B
signal I
- I
regulated I
kinase I
, I
CaMKIV I
, O
and O
p38 B
MAPK I
were O
also O
the O
kinases O
involved O
in O
CREB B
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3 B
/ I
CD28 I
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

Notably O
, O
CD28 O
ligation O
activated O
p38 B
MAPK I
and O
CaMKIV B
, O
the O
kinases B
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B
MAPK I
and O
CaMKIV B
. O

The O
murine B
IL I
- I
2 I
promoter I
contains O
distal B
regulatory I
elements I
responsive O
to O
the O
Ah B
receptor I
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH B
- I
PAS I
transcription I
factor I
family I
. O

The O
minimal B
promoter I
necessary O
for O
this O
expression O
lies O
proximal O
, O
between O
- O
300 O
and O
the O
transcription B
start I
site I
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B
receptor I
( O
AHR B
) O
, O
a O
member O
of O
the O
bHLH B
- I
PAS I
family I
of I
transcription I
factors I
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL B
- I
2 I
in O
murine O
fetal O
thymocytes O
. O

Binding O
motifs O
for O
the O
liganded B
AHR I
can O
be O
identified O
in O
the O
distal B
region I
- I
1300 I
to I
- I
800 I
of O
the O
mouse B
IL I
- I
2 I
promoter I
. O

We O
show O
here O
that O
these O
DNA B
motifs I
, O
the O
so O
- O
called O
dioxin B
response I
elements I
, O
after O
binding O
to O
the O
liganded B
AHR I
are O
sufficient O
to O
transactivate O
luciferase O
expression O
in O
a O
reporter O
gene O
system O
. O

We O
show O
here O
that O
these O
DNA B
motifs I
, O
the O
so O
- O
called O
dioxin B
response I
elements I
, O
after O
binding O
to O
the O
liganded B
AHR I
are O
sufficient O
to O
transactivate O
luciferase O
expression O
in O
a O
reporter O
gene O
system O
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B
in O
B O
cells O
responding O
to O
BCR B
cross O
- O
linking O
, O
we O
expressed O
in O
Syk B
- O
deficient O
DT40 O
B O
cells O
a O
fusion B
protein I
consisting O
of O
Syk B
coupled O
to O
green B
fluorescent I
protein I
. O

Syk B
is O
not O
demonstrably O
associated O
with O
the O
internalized B
receptor I
. O

Lyn B
is O
not O
required O
for O
the O
recruitment O
of O
Syk B
to O
the O
cross B
- I
linked I
receptor I
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR B
complexes I
. O

This O
study O
established O
a O
UUO O
model O
in O
angiotensin B
type I
1a I
receptor I
( O
AT1a B
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin B
II I
through O
AT1a B
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK O
) O
. O

The O
relative O
volume O
of O
the O
tubulointerstitium O
was O
measured O
by O
an O
image O
analyzer O
; O
deposition O
of O
collagen B
types I
III I
and I
IV I
and O
monocyte O
/ O
macrophage O
infiltration O
were O
histologically O
examined O
using O
specific B
antibodies I
. O

The O
results O
provide O
direct O
evidence O
that O
angiotensin B
II I
acting O
via O
the O
AT1a B
plays O
a O
pivotal O
role O
in O
the O
development O
of O
tubulointerstitial O
fibrosis O
in O
UUO O
. O

MHC B
tetramers I
, O
which O
constitute O
a O
labeled B
MHC I
- I
peptide I
ligand I
suitable O
for O
binding O
to O
the O
Ag B
- I
specific I
receptor I
on O
T O
cells O
, O
provide O
a O
novel O
approach O
for O
the O
detection O
and O
characterization O
of O
such O
rare O
cells O
. O

In O
this O
study O
, O
we O
utilized O
this O
technology O
to O
identify O
HLA B
DQ I
- O
restricted O
Ag O
- O
specific O
T O
cells O
in O
the O
peripheral O
blood O
of O
human O
subjects O
and O
to O
identify O
immunodominant O
epitopes O
associated O
with O
viral O
infection O
. O

Peptides O
representing O
potential O
epitope B
regions I
of O
the O
VP16 B
protein I
from O
HSV O
- O
2 O
were O
loaded O
onto O
recombinant B
DQ0602 I
molecules I
to O
generate O
a O
panel O
of O
Ag B
- I
specific I
DQ0602 I
tetramers I
. O

Peptides O
representing O
potential O
epitope B
regions I
of O
the O
VP16 B
protein I
from O
HSV O
- O
2 O
were O
loaded O
onto O
recombinant B
DQ0602 I
molecules I
to O
generate O
a O
panel O
of O
Ag B
- I
specific I
DQ0602 I
tetramers I
. O

VP16 B
Ag I
- O
specific O
DQ O
- O
restricted O
T O
cells O
were O
identified O
and O
expanded O
from O
the O
peripheral O
blood O
of O
HSV O
- O
2 O
- O
infected O
individuals O
, O
representing O
two O
predominant O
epitope O
specificities O
. O

Although O
the O
VP16 O
369 O
- O
380 O
peptide O
has O
a O
lower O
binding O
affinity O
for O
DQ0602 B
molecules I
than O
the O
VP16 O
33 O
- O
52 O
peptide O
, O
T O
cells O
that O
recognized O
the O
VP16 O
369 O
- O
380 O
peptide O
occurred O
at O
a O
much O
higher O
frequency O
than O
those O
that O
were O
specific O
for O
the O
VP16 O
33 O
- O
52 O
peptide O
. O

Although O
initial O
studies O
have O
suggested O
crippling O
immunoglobulin O
gene O
mutations O
to O
be O
the O
cause O
of O
absent O
immunoglobulin O
expression O
in O
cHD O
, O
recent O
work O
of O
our O
group O
has O
demonstrated O
an O
impaired O
activation O
of O
the O
immunoglobulin B
promoter I
as O
a O
superior O
mechanism O
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B B
- I
cell I
transcription I
factors I
Oct2 B
and O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription B
factors I
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
tax B
protein I
activates O
transcription O
through O
AP B
- I
1 I
site I
by O
inducing O
DNA O
binding O
activity O
in O
T O
cells O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B
factor I
AP I
- I
1 I
, O
such O
as O
c B
- I
Jun I
, O
JunD B
, O
c B
- I
Fos I
, O
and O
Fra B
- I
1 I
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

Transient O
transfection O
studies O
showed O
that O
Tax B
activated O
the O
expression O
of O
a O
luciferase B
gene I
regulated O
by O
two O
copies O
of O
an O
AP B
- I
1 I
site I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

Tax B
activates O
the O
expression O
of O
viral B
and I
cellular I
genes I
through O
two O
different O
enhancers O
: O
a O
cAMP B
- I
responsive I
( I
CRE I
) I
- I
like I
element I
and O
a O
kappaB B
element I
. O

Two O
Tax B
mutants I
differentially O
activated O
expression O
of O
these O
two O
elements O
. O

Tax703 B
preferentially O
activated O
the O
kappaB B
element I
but O
not O
the O
CRE O
- O
like O
one O
, O
whereas O
TaxM22 B
showed O
the O
reverse O
. O

The O
binding B
complex I
induced O
by O
Tax B
in O
CTLL O
- O
2 O
contained O
JunD B
and O
Fra B
- I
2 I
. O

Our O
results O
suggest O
that O
Tax B
activates O
the O
transcription O
of O
cellular B
genes I
with O
AP B
- I
1 I
sites I
by O
inducing O
the O
DNA O
- O
binding O
activity O
of O
AP B
- I
1 I
proteins I
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE B
- I
like I
and I
kappaB I
elements I
. O

OBJECTIVE O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF O
) O
on O
DNA O
binding O
activity O
of O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
in O
the O
Mono O
Mac O
6 O
monocytic O
/ O
macrophage O
cell O
line O
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O

Incubation O
of O
SF O
with O
neutralizing B
antibodies I
against O
tumor B
necrosis I
factor I
- I
alpha I
( I
TNF I
- I
alpha I
) I
, O
but O
not O
antibodies B
against O
interleukin B
6 I
( I
IL I
- I
6 I
) I
, O
significantly O
reduced O
the O
induction O
of O
p65 O
/ O
p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

The O
slowly O
migrating B
complex I
could O
not O
be O
supershifted O
with O
antibodies B
against O
NF B
- I
kappaB I
, O
Jun B
, O
or O
the O
transcriptional O
coactivators O
p300 B
or O
CBP B
. O

Soluble O
mediators O
in O
SF O
of O
subjects O
with O
RA O
and O
OA O
can O
therefore O
modulate O
binding O
of O
nuclear B
proteins I
to O
the O
NF B
- I
kappaB I
binding I
site I
in O
macrophages O
and O
may O
play O
a O
role O
in O
inflammatory O
gene O
expression O
in O
arthritis O
. O

We O
found O
that O
leukemic O
LGL O
from O
19 O
patients O
displayed O
high O
levels O
of O
activated B
STAT3 I
. O

Activated B
STAT3 I
was O
shown O
to O
bind O
an O
SIE B
- I
related I
element I
in O
the O
murine B
mcl I
- I
1 I
promoter I
. O

Decreased O
immediate O
inflammatory B
gene I
induction O
in O
activating B
transcription I
factor I
- I
2 I
mutant O
mice O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF O
- O
2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B
molecules I
E B
- I
selectin I
, O
P B
- I
selectin I
and O
VCAM B
- I
1 I
as O
well O
as O
the O
cytokines B
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
1beta I
and O
IL B
- I
6 I
compared O
with O
control O
mice O
. O

ATF B
- I
2 I
is O
essential O
for O
maximal O
immediate O
induction O
of O
adhesion B
molecules I
and O
cytokine B
genes I
, O
but O
at O
later O
time O
points O
may O
even O
protect O
against O
overactive O
immune O
responses O
. O

ATF B
- I
2 I
is O
essential O
for O
maximal O
immediate O
induction O
of O
adhesion B
molecules I
and O
cytokine B
genes I
, O
but O
at O
later O
time O
points O
may O
even O
protect O
against O
overactive O
immune O
responses O
. O

LIGHT B
is O
a O
recently O
identified O
member O
of O
the O
TNF B
superfamily I
and O
its O
receptors O
, O
herpesvirus B
entry I
mediator I
and O
lymphotoxin B
beta I
receptor I
, O
are O
found O
in O
T O
cells O
and O
stromal O
cells O
. O

Blockade O
of O
LIGHT B
by O
its O
soluble B
receptors I
, O
lymphotoxin B
beta I
receptor I
- I
Ig I
or O
HVEM B
- I
Ig I
, O
inhibits O
the O
induction O
of O
DC O
- O
mediated O
primary O
allogeneic O
T O
cell O
response O
. O

Our O
results O
suggest O
that O
LIGHT B
is O
a O
costimulatory B
molecule I
involved O
in O
DC O
- O
mediated O
cellular O
immune O
responses O
. O

Activity O
of O
the O
distal B
region I
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long B
terminal I
repeat I
( O
LTR B
) O
, O
which O
contains O
binding B
sites I
for O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

Activity O
of O
the O
distal B
region I
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long B
terminal I
repeat I
( O
LTR B
) O
, O
which O
contains O
binding B
sites I
for O
the O
Ets B
- I
1 I
and I
USF I
- I
1 I
proteins I
, O
is O
integral O
for O
HIV O
- O
1 O
replication O
. O

BACKGROUND O
: O
Eosinophils O
are O
now O
known O
to O
produce O
a O
variety O
of O
proinflammatory B
cytokines I
, O
although O
the O
molecular O
factors O
that O
regulate O
their O
production O
are O
poorly O
understood O
. O

OBJECTIVE O
: O
We O
sought O
to O
characterize O
the O
expression O
of O
different O
NFAT B
proteins I
in O
resting O
and O
activated O
eosinophils O
. O

NFAT B
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA O
- O
binding O
assays O
, O
and O
RT O
- O
PCR O
analysis O
of O
eosinophil B
mRNA I
. O

In O
addition O
, O
eosinophils O
were O
found O
to O
constitutively O
express O
NFATc B
mRNA I
. O

BLyS B
BINDS O
TO O
B O
CELLS O
WITH O
HIGH O
AFFINITY O
AND O
INDUCES O
ACTIVATION O
OF O
THE O
TRANSCRIPTION B
FACTORS I
NF B
- I
kappaB I
AND O
ELF B
- I
1 I
. O

The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled B
BLyS I
to O
its O
cognate B
receptor I
on O
human O
B O
lymphocytes O
and O
examine O
intracellular O
events O
initiated O
by O
BLyS B
binding O
. O

The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled B
BLyS I
to O
its O
cognate B
receptor I
on O
human O
B O
lymphocytes O
and O
examine O
intracellular O
events O
initiated O
by O
BLyS B
binding O
. O

The O
Nef B
protein I
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell B
surface I
proteins I
, O
and O
associate O
with O
many O
intracellular B
proteins I
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O

The O
Nef B
protein I
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell B
surface I
proteins I
, O
and O
associate O
with O
many O
intracellular B
proteins I
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O

One O
of O
the O
challenges O
in O
defining O
the O
molecular O
events O
regulated O
by O
Nef B
has O
been O
obtaining O
good O
expression O
of O
Nef B
protein I
in O
T O
cells O
. O

We O
have O
designed O
a O
Nef B
protein I
that O
is O
readily O
expressed O
in O
T O
- O
cell O
lines O
and O
whose O
function O
is O
inducibly O
activated O
. O

The O
Nef B
- I
ER I
is O
kept O
in O
an O
inactive O
state O
due O
to O
steric O
hindrance O
, O
and O
addition O
of O
the O
membrane O
- O
permeable O
drug O
4 O
- O
hydroxytamoxifen O
( O
4 O
- O
HT O
) O
, O
which O
binds O
to O
the O
ER B
domain I
, O
leads O
to O
inducible O
activation O
of O
Nef B
- I
ER I
within O
cells O
. O

Using O
a O
rat O
model O
of O
acute O
lung O
inflammation O
induced O
by O
intratracheal O
instillation O
of O
sodium O
metavanadate O
( O
NaVO3 O
) O
at O
the O
dose O
of O
200 O
microg O
V O
/ O
kg O
, O
we O
investigated O
the O
relationship O
between O
the O
cytologic O
characterization O
of O
pulmonary O
inflammation O
and O
the O
expression O
of O
chemokine B
mRNA I
. O

The O
promotor B
region I
contains O
consensus B
binding I
sites I
for O
transcription B
factor I
nuclear I
factor I
kappaB I
( O
NF B
- I
kappaB I
) O
and O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
. O

p65 B
( I
Rel I
A I
) I
and O
p50 B
protein I
appears O
to O
be O
involved O
in O
MIP O
- O
2 O
NF B
- I
kappaB I
binding O
. O

Among O
six O
or O
so O
PKC B
isoforms I
expressed O
in O
T O
cells O
, O
only O
PKCtheta B
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR B
with O
Ag B
. O

Moreover O
, O
endogenous O
PKCtheta B
physically O
associates O
with O
activated O
IKK B
complexes I
in O
CD3 O
/ O
CD28 O
- O
costimulated O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

Taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta B
by O
the O
TCR B
and O
CD28 B
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B
complexes I
in O
the O
T O
cell O
membrane O

IFN B
- I
gamma I
induces O
rapid O
degradation O
of O
the O
RANK B
adapter I
protein I
, O
TRAF6 B
( O
tumour B
necrosis I
factor I
receptor I
- I
associated I
factor I
6 I
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B
- O
induced O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
JNK B
. O

Our O
study O
shows O
that O
there O
is O
cross O
- O
talk O
between O
the O
tumour B
necrosis I
factor I
and O
IFN B
families I
of O
cytokines B
, O
through O
which O
IFN B
- I
gamma I
provides O
a O
negative O
link O
between O
T O
- O
cell O
activation O
and O
bone O
resorption O
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans O
- O
Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B
9 I
( O
MMP B
- I
9 I
) O
and O
vascular B
endothelial I
growth I
factor I
( O
VEGF B
) O
by O
these O
cells O
, O
and O
both O
SDF B
- I
1 I
and O
TPO B
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B
and O
vitronectin B
. O

Investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF B
- I
1 I
and O
TPO B
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation O
/ O
activation O
( O
mitogen B
- I
activated I
protein I
kinase I
[ I
MAPK I
] I
p42 I
/ I
44 I
, O
MAPK B
p38 I
, O
and O
AKT B
[ I
protein I
kinase I
B I
] I
) O
and O
some O
that O
were O
distinct O
for O
TPO B
( O
eg O
, O
JAK B
- I
STAT I
) O
and O
for O
SDF B
- I
1 I
( O
eg O
, O
NF B
- I
kappa I
B I
) O
. O

Key O
molecules O
mediating O
TEC O
/ O
thymocytes O
interactions O
include O
cytokines B
and O
growth B
factors I
secreted O
by O
the O
two O
cell O
types O
and O
adhesion B
receptors I
mediating O
cell O
contact O
. O

Key O
molecules O
mediating O
TEC O
/ O
thymocytes O
interactions O
include O
cytokines B
and O
growth B
factors I
secreted O
by O
the O
two O
cell O
types O
and O
adhesion B
receptors I
mediating O
cell O
contact O
. O

We O
found O
that O
adhesion O
of O
unstimulated O
T O
cell O
i O
) O
involved O
beta1 O
, O
but O
not O
beta4 O
integrin O
functions O
at O
the O
surface O
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 B
, O
but O
not O
alpha2beta1 B
heterodimers I
at O
the O
TEC O
surface O
and O
iii O
) O
up O
- O
regulated O
the O
nuclear O
binding O
activity O
of O
NF B
- I
kappaB I
transcription I
factor I
and O
the O
IL O
- O
6 O
secretion O
. O

We O
propose O
that O
alpha3beta1 B
and I
alpha6beta4 I
heterodimers I
are O
induced O
to O
cluster O
at O
the O
TEC O
surface O
recognizing O
yet O
unknown O
cellular B
ligands I
differentially O
expressed O
during O
T O
cell O
development O
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2 O
- O
type O
ZF O
tandemly O
arrayed O
at O
its O
C B
terminus I
and O
N B
- I
terminal I
SCAN B
box I
and O
KRAB B
domains I
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2 O
- O
type O
ZF O
tandemly O
arrayed O
at O
its O
C B
terminus I
and O
N B
- I
terminal I
SCAN B
box I
and O
KRAB B
domains I
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2 O
- O
type O
ZF O
tandemly O
arrayed O
at O
its O
C B
terminus I
and O
N B
- I
terminal I
SCAN B
box I
and O
KRAB B
domains I
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT B
- I
2 I
, O
thus O
SKAT B
- I
2 I
is O
a O
novel O
Th2 B
- I
specific I
gene I
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine B
genes I
in O
T O
cells O
. O

hsp70 B
interacting I
protein I
Hip I
does O
not O
affect O
glucocorticoid B
receptor I
folding O
by O
the O
hsp90 O
- O
based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG B
- I
1 I
. O

Using O
purified B
proteins I
, O
we O
have O
prepared O
a O
five O
- O
protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly O
- O
hsp90 B
and O
hsp70 B
- O
and O
three O
proteins O
that O
act O
as O
co O
- O
chaperones O
to O
enhance O
assembly O
- O
Hop B
, O
hsp40 B
, O
p23 B
[ O
Morishima O
, O
Y O
. O
, O
Kanelakis O
, O
K O
. O
C O
. O
, O
Silverstein O
, O
A O
. O
M O
. O
, O
Dittmar O
, O
K O
. O
D O
. O
, O
Estrada O
, O
L O
. O
, O
and O
Pratt O
, O
W O
. O
B O
. O
( O
2000 O
) O
J O
. O
Biol O
. O
Chem O
. O
275 O
, O
6894 O
- O

Therefore O
, O
deletion O
of O
the O
STAT6 B
gene I
facilitates O
development O
of O
potent O
anti O
- O
tumor O
immunity O
via O
a O
CD4 O
( O
+ O
) O
- O
independent O
pathway O
. O

Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
Tax B
protein I
transforms O
primary O
human O
T O
cells O
in O
vitro O
. O

In O
contrast O
, O
3 O
, O
3 O
' O
, O
4 O
, O
4 O
' O
, O
5 O
- O
PeCB O
, O
a O
congener O
of O
coplanar O
structure O
, O
as O
well O
as O
2 O
, O
3 O
, O
7 O
, O
8 O
- O
TCDD O
did O
not O
induce O
apoptosis O
in O
these O
human O
monocytic O
cells O
, O
although O
they O
potently O
induced O
CYP B
1A1 I
in O
human O
hepatoma O
Hep O
G2 O
cells O
. O

Taken O
together O
, O
the O
data O
indicate O
that O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6 O
' O
- O
PeCB O
induces O
apoptosis O
in O
human O
monocytic O
cells O
through O
a O
mechanism O
that O
is O
independent O
of O
the O
arylhydrocarbon B
receptor I
. O

The O
cytokine O
- O
dependent O
murine O
myeloid O
FDC O
- O
P1 O
and O
human O
erythroleukemic O
TF O
- O
1 O
cell O
lines O
were O
transformed O
to O
grow O
in O
response O
to O
deregulated O
Raf O
expression O
in O
the O
absence O
of O
exogenous B
cytokines I
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

The O
conditionally O
active O
Raf B
proteins I
were O
regulated O
by O
beta O
- O
estradiol O
as O
cDNAs B
containing O
the O
Raf B
catalytic I
, O
but O
lacking O
negative B
- I
regulatory I
domains I
, O
were O
ligated O
to O
the O
hormone B
binding I
domain I
of O
the O
estrogen B
receptor I
( O
deltaRaf B
: I
ER I
) O
. O

Continuous O
deltaRaf B
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous B
cytokines I
and O
altered O
the O
morphology O
of O
the O
FD O
/ O
deltaRaf O
: O
ER O
cells O
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 O
cells O
) O
whereas O
the O
parental O
cytokine O
- O
dependent O
FDC O
- O
P1 O
cells O
grew O
in O
smaller O
grape O
- O
like O
clusters O
( O
< O
10 O
cells O
) O
. O

In O
contrast O
, O
when O
these O
cells O
were O
cultured O
in O
IL B
- I
3 I
, O
higher O
levels O
of O
these O
adhesion B
molecules I
were O
detected O
. O

Expression O
of O
activated O
Raf B
oncoproteins I
also O
abrogated O
cytokine O
dependency O
and O
prevented O
apoptosis O
of O
TF O
- O
1 O
cells O
. O

IL B
- I
4 I
and O
IL B
- I
13 I
are O
pleiotropic B
cytokines I
whose O
biological O
activities O
overlap O
with O
each O
other O
. O

IL B
- I
13 I
receptor I
alpha I
chain I
1 I
( O
IL B
- I
13R I
alpha I
1 I
) O
is O
necessary O
for O
binding O
to O
IL B
- I
13 I
, O
and O
the O
heterodimer O
composed O
of O
IL B
- I
13R I
alpha I
1 I
and O
IL B
- I
4R I
alpha I
chain I
transduces O
IL B
- I
13 I
and O
IL B
- I
4 I
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B
domain I
of O
IL B
- I
13R I
alpha I
1 I
is O
not O
fully O
understood O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B
region I
and O
the O
C B
- I
terminal I
tail I
of O
IL B
- I
13R I
alpha I
1 I
were O
critical O
for O
binding O
to O
Tyk2 B
, O
and O
activation O
of O
Jak1 B
, O
Tyk2 B
, O
the O
insulin B
receptor I
substrate I
- I
1 I
and O
STAT6 B
respectively O
. O

Janus B
tyrosine I
kinase I
( I
Jak I
) I
3 I
and O
transcription B
factors I
Stat5a B
and O
Stat5b B
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV O
- O
1 O
- O
transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV O
- O
1 O
- O
infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3 O
- O
Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

Disruption O
of O
constitutive O
Jak3 O
/ O
Stat5 O
activation O
by O
AG O
- O
490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B
, O
Stat5a B
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B
Ab I
; O
and O
3 O
) O
Stat5a O
/ O
b O
DNA O
binding O
to O
the O
Stat5 B
- I
responsive I
beta I

In O
contrast O
, O
AG O
- O
490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50 B
/ I
p65 I
components I
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
activated O
by O
the O
HTLV B
- I
1 I
- I
encoded I
phosphoprotein I
, I
Tax I
. O

The O
Epstein B
- I
Barr I
virus I
promoter I
initiating O
B O
- O
cell O
transformation O
is O
activated O
by O
RFX B
proteins I
and O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Bandshift O
studies O
indicate O
that O
this O
region O
contains O
three O
factor O
binding O
sites O
, O
termed O
sites B
B I
, I
C I
, I
and I
D I
, O
in O
addition O
to O
a O
previously O
characterized O
CREB B
site I
. O

Here O
we O
show O
that O
site B
C I
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B
family I
of I
proteins I
, O
notably O
RFX1 B
, O
RFX3 B
, O
and O
the O
associated O
factor O
MIBP1 B
, O
whereas O
sites B
B I
and I
D I
both O
bind O
the O
B B
- I
cell I
- I
specific I
activator I
protein I
BSAP I
/ I
Pax5 I
. O

Activation O
of O
the O
Lck B
tyrosine I
protein I
kinase I
by O
the O
Herpesvirus O
saimiri O
tip B
protein I
involves O
two O
binding O
interactions O
. O

The O
Tip B
protein I
of O
Herpesvirus O
saimiri O
strain O
484C O
binds O
to O
and O
activates O
the O
Lck B
tyrosine I
protein I
kinase I
. O

Two O
sequences O
in O
the O
Tip B
protein I
were O
previously O
shown O
to O
be O
involved O
in O
binding O
to O
Lck B
. O

A O
proline B
- I
rich I
region I
, O
residues O
132 O
- O
141 O
, O
binds O
to O
the O
SH3 B
domain I
of O
the O
Lck B
protein I
. O

A O
proline B
- I
rich I
region I
, O
residues O
132 O
- O
141 O
, O
binds O
to O
the O
SH3 B
domain I
of O
the O
Lck B
protein I
. O

Accumulation O
of O
RXR B
alpha I
during O
activation O
of O
cycling O
human O
T O
lymphocytes O
: O
modulation O
of O
RXRE O
transactivation O
function O
by O
mitogen O
- O
activated O
protein O
kinase O
pathways O
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL B
- I
2 I
internalized O
by O
IL B
- I
2R I
that O
were O
comprised O
of O
cytoplasmic B
tailless I
beta B
- I
or I
gamma I
c I
- I
subunits I
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B
is O
independent O
of O
either O
the O
cytoplasmic B
tail I
of O
the O
IL B
- I
2R I
beta B
- I
or I
gamma I
c I
- I
subunits I
and O
their O
associated O
signaling O
components O
. O

We O
report O
the O
results O
of O
studies O
aimed O
at O
understanding O
the O
regulatory O
mechanisms O
controlling O
p45 B
gene I
expression O
in O
erythroid O
cells O
. O

MATERIALS O
AND O
METHODS O
: O
Human B
p45 I
mRNAs I
have O
two O
alternative O
isoforms O
, O
aNF B
- I
E2 I
and O
fNF B
- I
E2 I
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative B
promoters I
. O

For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter B
genes I
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter B
fragments I
were O
transfected O
to O
human O
hematopoietic O
cell O
lines O
. O

For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter B
genes I
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter B
fragments I
were O
transfected O
to O
human O
hematopoietic O
cell O
lines O
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
GATA B
proteins I
, O
which O
govern O
the O
differentiation O
of O
erythroid O
lineage O
cells O
, O
are O
required O
for O
full O
promoter O
activity O
of O
the O
p45 B
gene I
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
GATA B
proteins I
, O
which O
govern O
the O
differentiation O
of O
erythroid O
lineage O
cells O
, O
are O
required O
for O
full O
promoter O
activity O
of O
the O
p45 B
gene I
. O

In O
contrast O
to O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
TNF B
- I
alpha I
did O
not O
activate O
the O
MAP B
kinase I
and O
p70S6 O
kinase O
pathways O
. O

Glucocorticoid B
receptor I
content O
of O
T O
lymphocytes O
: O
evidence O
for O
heterogeneity O
. O

Glucocorticoid B
receptors I
were O
measured O
in O
T O
lymphocytes O
that O
were O
isolated O
from O
peripheral O
blood O
by O
either O
nylon O
wool O
filtration O
or O
E O
- O
rosette O
sedimentation O
. O

These O
findings O
suggest O
that O
T O
cells O
are O
heterogeneous O
with O
respect O
to O
their O
quantity O
of O
glucocorticoid B
receptors I
. O

Isolation O
of O
T O
cells O
by O
E O
- O
rosette O
sedimentation O
enriches O
for O
T O
cells O
that O
have O
a O
greater O
number O
of O
glucocorticoid B
receptors I
, O
and O
isolation O
of O
T O
cells O
by O
nylon O
wool O
filtration O
enriches O
for O
T O
cells O
that O
have O
a O
lesser O
number O
of O
glucocorticoid B
receptors I
. O

Isolation O
of O
T O
cells O
by O
E O
- O
rosette O
sedimentation O
enriches O
for O
T O
cells O
that O
have O
a O
greater O
number O
of O
glucocorticoid B
receptors I
, O
and O
isolation O
of O
T O
cells O
by O
nylon O
wool O
filtration O
enriches O
for O
T O
cells O
that O
have O
a O
lesser O
number O
of O
glucocorticoid B
receptors I
. O

Glucocorticoid B
receptors I
and O
glucocorticoid O
sensitivity O
of O
human O
leukemic O
cells O
. O

We O
have O
established O
optimal O
conditions O
for O
the O
measurement O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
human O
white O
cells O
using O
a O
whole O
- O
cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
as O
the O
ligand O
, O
and O
the O
subsequent O
determination O
of O
the O
GR B
content O
in O
normal O
human O
lymphocytes O
and O
in O
leukemic O
cells O
of O
patients O
with O
various O
forms O
of O
acute O
and O
chronic O
leukemia O
. O

Evidence O
for O
a O
steroid B
receptor I
in O
rheumatoid O
synovial O
tissue O
cells O
. O

Synovium O
, O
obtained O
from O
knee O
joints O
of O
rheumatoid O
patients O
undergoing O
surgery O
, O
was O
incubated O
with O
clostridiopeptidase B
A I
and O
trypsin B
- I
EDTA I
to O
obtain O
cell O
suspensions O
. O

Clinical O
implications O
of O
glucocorticoid B
receptors I
in O
human O
leukemia O
. O

Glucorticoid B
receptors I
were O
studied O
in O
various O
populations O
of O
normal O
human O
peripheral O
blood O
lymphocytes O
and O
leukemic O
lymphoblasts O
. O

Normal O
lymphocytes O
contain O
low O
levels O
of O
glucocorticoid B
receptor I
( O
approximately O
2 O
, O
500 O
sites O
/ O
cell O
) O
which O
are O
identical O
in O
T O
- O
and O
non O
- O
T O
- O
fractions O
. O

Quantitative O
determination O
of O
glucocorticoid B
receptor I
levels O
in O
acute O
lymphoblastic O
leukemia O
may O
be O
of O
value O
both O
as O
an O
independent O
prognostic O
variable O
and O
in O
suggesting O
which O
patients O
should O
receive O
glucocorticoid O
therapy O
. O

Furthermore O
, O
normal B
and I
active I
Fyn I
stimulated O
transcription O
from O
the O
IL B
- I
2 I
gene I
promoter I
when O
transfected O
cells O
were O
stimulated O
by O
concanavalin B
A I
plus O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
. O

Interestingly O
, O
a O
mutant B
Fyn I
, O
which O
has O
deletions O
within O
the O
SH2 B
region I
and O
so O
is O
able O
to O
transform O
chicken O
embryo O
fibroblasts O
, O
did O
not O
stimulate O
either O
the O
c B
- I
fos I
or I
IL I
- I
2 I
promoter I
, O
suggesting O
the O
importance O
of O
this O
region O
in O
T O
- O
cell O
signaling O
. O

Interestingly O
, O
a O
mutant B
Fyn I
, O
which O
has O
deletions O
within O
the O
SH2 B
region I
and O
so O
is O
able O
to O
transform O
chicken O
embryo O
fibroblasts O
, O
did O
not O
stimulate O
either O
the O
c B
- I
fos I
or I
IL I
- I
2 I
promoter I
, O
suggesting O
the O
importance O
of O
this O
region O
in O
T O
- O
cell O
signaling O
. O

A O
novel O
NF B
- I
kappa I
B I
complex I
containing O
p65 B
homodimers I
: O
implications O
for O
transcriptional O
control O
at O
the O
level O
of O
subunit O
dimerization O
. O

The O
predominant O
inducible O
form O
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
is O
a O
heteromeric B
complex I
containing O
two O
Rel B
- I
related I
DNA I
- I
binding I
subunits I
, O
termed B
p65 I
and O
p50 B
. O

The O
predominant O
inducible O
form O
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
is O
a O
heteromeric B
complex I
containing O
two O
Rel B
- I
related I
DNA I
- I
binding I
subunits I
, O
termed B
p65 I
and O
p50 B
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 B
and I
p50 I
subunits I
are O
expressed O
independently O
as O
stable B
homodimers I
, O
p65 B
stimulates O
kappa O
B O
- O
directed O
transcription O
, O
whereas O
p50 B
functions O
as O
a O
kappa O
B O
- O
specific O
repressor O
. O

While O
authentic O
p50 B
homodimers I
( O
previously O
termed O
KBF1 B
) O
have O
been O
detected O
in O
nuclear O
extracts O
from O
nontransfected O
cells O
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 B
homodimers I
in O
vivo O
was O
lacking O
. O

While O
authentic O
p50 B
homodimers I
( O
previously O
termed O
KBF1 B
) O
have O
been O
detected O
in O
nuclear O
extracts O
from O
nontransfected O
cells O
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 B
homodimers I
in O
vivo O
was O
lacking O
. O

We O
now O
provide O
direct O
biochemical O
evidence O
for O
the O
presence O
of O
an O
endogenous O
pool O
of O
inducible O
p65 B
homodimers I
in O
intact O
human O
T O
cells O
. O

We O
compared O
the O
expression O
of O
Egr B
- I
1 I
during O
B O
cell O
stimulation O
with O
Fab B
' I
2 I
and O
IgG B
anti I
- I
immunoglobulin I
( O
anti B
- I
Ig I
) O
, O
since O
it O
is O
known O
that O
Fab B
' I
2 I
anti I
- I
Ig I
is O
mitogenic O
while O
IgG B
anti I
- I
Ig I
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B
cell I
Fc I
gamma I
RII I
to O
membrane B
Ig I
. O

We O
have O
identified O
a O
human B
TNF I
- I
alpha I
promoter I
element I
, O
kappa B
3 I
, O
which O
plays O
a O
key O
role O
in O
the O
calcium O
- O
mediated O
inducibility O
and O
CsA O
sensitivity O
of O
the O
gene O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
an O
oligonucleotide O
containing O
kappa B
3 I
forms O
two O
DNA O
protein O
complexes O
with O
proteins O
that O
are O
present O
in O
extracts O
from O
unstimulated O
T O
cells O
. O

Induction O
of O
the O
inducible O
nuclear B
complexes I
is O
rapid O
, O
independent O
of O
protein O
synthesis O
, O
and O
blocked O
by O
CsA O
, O
and O
thus O
, O
exactly O
parallels O
the O
induction O
of O
TNF B
- I
alpha I
mRNA I
by O
TCR O
ligands O
or O
by O
calcium O
ionophore O
. O

Our O
studies O
indicate O
that O
the O
kappa B
3 I
binding I
factor I
resembles O
the O
preexisting O
component O
of O
nuclear B
factor I
of O
activated O
T O
cells O
. O

Glucocorticoid B
receptors I
and O
sensitivity O
in O
leukemias O
. O

In O
an O
attempt O
to O
investigate O
the O
utility O
of O
glucocorticoid B
receptor I
determination O
to O
predict O
clinical O
responsiveness O
in O
human O
leukemias O
we O
have O
studied O
glucocorticoid B
receptors I
in O
the O
leukemic O
cells O
from O
46 O
patients O
and O
in O
the O
lymphocytes O
from O
18 O
normal O
donors O
. O

In O
an O
attempt O
to O
investigate O
the O
utility O
of O
glucocorticoid B
receptor I
determination O
to O
predict O
clinical O
responsiveness O
in O
human O
leukemias O
we O
have O
studied O
glucocorticoid B
receptors I
in O
the O
leukemic O
cells O
from O
46 O
patients O
and O
in O
the O
lymphocytes O
from O
18 O
normal O
donors O
. O

The O
blasts O
from O
17 O
patients O
with O
ANLL O
had O
on O
average O
higher O
levels O
of O
binding B
sites I
per O
cell O
( O
Median O
= O
7 O
, O
250 O
, O
range O
: O
0 O
to O
15 O
, O
295 O
) O
than O
the O
other O
leukemias O
. O

There O
was O
no O
marked O
correlation O
between O
glucocorticoid B
receptor I
levels O
and O
in O
vitro O
sensitivity O
. O

An O
attempt O
to O
correlate O
receptor O
levels O
with O
clinical O
responsiveness O
demonstrated O
that O
glucocorticoid B
receptor I
determination O
might O
be O
of O
value O
in O
patients O
with O
lymphoid O
malignancies O
but O
probably O
not O
in O
patients O
with O
other O
leukemias O
. O

Munck O
and O
Foley O
have O
shown O
that O
activated B
complexes I
isolated O
from O
thymocytes O
elute O
from O
DEAE O
- O
cellulose O
in O
a O
manner O
identical O
to O
complexes O
activated O
in O
vitro O
. O

We O
report O
here O
that O
DEAE O
- O
cellulose O
chromatography O
of O
steroid B
- I
receptor I
complexes I
from O
CEM O
- O
C7 O
, O
a O
cloned O
human O
leukaemic O
T O
- O
cell O
line O
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid O
- O
resistant O
subclone O
4R4 O
demonstrated O
that O
steroid B
receptors I
of O
clone O
4R4 O
can O
not O
form O
stable O
activated O
complexes O
. O

Identification O
of O
glucocorticoid B
receptors I
in O
monocytes O
and O
macrophages O
. O

Two O
assays O
of O
binding O
were O
used O
- O
- O
an O
assay O
with O
intact O
cells O
in O
suspension O
or O
monolayers O
, O
and O
an O
assay O
of O
cytosol O
and O
nuclear O
forms O
of O
glucocorticoid B
receptors I
. O

The O
binding O
to O
the O
saturable B
sites I
was O
specific O
for O
steroids O
with O
glucocorticoid O
or O
antiglucocorticoid O
activity O
. O

Binding O
of O
dexamethasone O
to O
cytosol O
and O
nuclear O
forms O
of O
the O
receptor B
complex I
and O
temperature O
- O
sensitive O
translocation O
of O
cytosol O
forms O
to O
nuclear O
forms O
were O
shown O
. O

Nitric O
oxide O
signaling O
: O
a O
possible O
role O
for O
G B
proteins I
. O

We O
describe O
a O
novel O
and O
potentially O
important O
mechanism O
of O
nitric O
oxide O
signaling O
- O
through O
direct O
activation O
of O
guanine B
nucleotide I
- I
binding I
proteins I
( O
G B
proteins I
) O
. O

Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs B
alpha I
, O
Gi B
alpha I
1 I
, O
and O
p21ras B
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O

Because O
G B
proteins I
play O
a O
central O
role O
in O
many O
diverse O
signaling O
systems O
, O
activation O
by O
an O
endogenous O
and O
inducible O
oxidant O
may O
represent O
a O
novel O
signaling O
pathway O
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp B
- I
95 I
to I
+ I
27 I
of O
the O
mouse B
GM I
- I
CSF I
promoter I
can O
confer O
inducibility O
to O
reporter B
genes I
in O
the O
human O
Jurkat O
T O
- O
cell O
line O
. O

One O
of O
the O
binding B
factors I
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription B
factor I
AP1 I
. O

As O
an O
initial O
step O
towards O
understanding O
the O
molecular O
basis O
for O
tissue O
- O
specific O
expression O
of O
this O
gene O
, O
we O
surveyed O
the O
surrounding O
chromatin O
structure O
for O
potential O
cis B
- I
acting I
regulatory I
regions I
by O
DNase B
I I
hypersensitivity O
mapping O
and O
found O
four O
hypersensitive O
sites O
, O
three O
of O
which O
were O
T O
cell O
restricted O
. O

DNA O
sequence O
analysis O
of O
the O
minimal B
enhancer I
revealed O
a O
striking O
cluster O
of O
consensus B
binding I
sites I
for O
Ets B
- I
1 I
, I
TCF I
- I
1 I
, I
CRE I
, I
GATA I
- I
3 I
, I
LyF I
- I
1 I
, I
and I
bHLH I
proteins I
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O

Comparison O
of O
the O
CD8 B
alpha I
enhancer I
with O
other O
recently O
identified O
T B
- I
cell I
- I
specific I
regulatory I
elements I
suggests O
that O
a O
common O
set O
of O
transcription B
factors I
regulates O
several O
T B
- I
cell I
genes I
. O

Interleukin B
3 I
( O
IL B
- I
3 I
) O
is O
a O
hematopoietic B
stem I
- I
cell I
growth I
and I
differentiation I
factor I
that O
is O
expressed O
solely O
in O
activated O
T O
and O
NK O
cells O
. O

We O
have O
now O
identified O
DNA B
sequences I
that O
are O
required O
for O
T O
cell O
- O
restricted O
IL B
- I
3 I
gene I
transcription O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49 B
- I
bp I
fragment I
( O
bp B
- I
319 I
to I
- I
270 I
) O
that O
included O
a O
potential B
binding I
site I
for O
AP B
- I
1 I
transcription I
factors I
6 O
bp O
upstream O
of O
a O
binding B
site I
for I
Elf I
- I
1 I
, O
a O
member O
of O
the O
Ets B
family I
of O
transcription B
factors I
. O

We O
conclude O
that O
expression O
of O
the O
human B
IL I
- I
3 I
gene I
requires O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
binding I
sites I
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B
genes I
such O
as O
IL B
- I
2 I
, O
the O
AP B
- I
1 I
and I
Elf I
- I
1 I
factors I
can O
bind O
independently O
in O
the O
IL B
- I
3 I
gene I
. O

A O
[ O
3H O
] O
dexamethasone O
radioligand O
- O
binding O
assay O
was O
used O
to O
measure O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
and O
dissociation O
constant O
( O
Kd O
) O
in O
PBMC O
from O
normal O
donors O
and O
patients O
with O
SR O
asthma O
, O
cultured O
in O
the O
absence O
and O
presence O
of O
these O
cytokines B
. O

Characterization O
of O
the O
human B
CD4 I
gene I
promoter I
: O
transcription O
from O
the O
CD4 B
gene I
core I
promoter I
is O
tissue O
- O
specific O
and O
is O
activated O
by O
Ets B
proteins I
. O

Moreover O
, O
in O
CD4 O
- O
cells O
, O
overexpression O
of O
Ets B
- I
1 I
or O
Ets B
- I
2 I
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B
promoter I
and O
core B
promoter I
. O

Moreover O
, O
in O
CD4 O
- O
cells O
, O
overexpression O
of O
Ets B
- I
1 I
or O
Ets B
- I
2 I
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B
promoter I
and O
core B
promoter I
. O

The O
inactivation O
of O
glucocorticoid B
receptors I
that O
occurs O
when O
cytosol O
from O
normal O
IM O
- O
9 O
cells O
is O
incubated O
at O
25 O
degrees O
C O
is O
inhibited O
by O
molybdate O
, O
vanadate O
, O
fluoride O
, O
ATP O
, O
and O
several O
other O
nucleotides O
. O

The O
experiments O
with O
intact O
human O
lymphoblasts O
suggest O
that O
assays O
of O
specific O
glucocorticoid O
- O
binding O
capacity O
do O
not O
necessarily O
reflect O
the O
cellular O
content O
of O
receptor B
protein I
. O

Cell O
cycle O
- O
dependent O
changes O
in O
glucocorticoid B
receptor I
content O
. O

To O
study O
variations O
in O
glucocorticoid B
receptor I
levels O
during O
the O
cell O
cycle O
, O
we O
have O
separated O
mitogen O
- O
stimulated O
human O
peripheral O
lymphocytes O
and O
rat O
lymph O
node O
cells O
by O
unit O
gravity O
sedimentation O
and O
measured O
glucocorticoid O
binding O
in O
the O
resultant O
fractions O
. O

These O
observations O
together O
with O
those O
from O
other O
studies O
indicate O
that O
formation O
of O
new O
glucocorticoid B
receptors I
near O
the O
S O
phase O
may O
be O
a O
general O
phenomenon O
in O
proliferating O
cells O
. O

We O
propose O
that O
this O
increase O
in O
glucocorticoid B
receptors I
during O
the O
cell O
cycle O
may O
explain O
the O
increase O
in O
glucocorticoid B
receptors I
in O
mitogen O
- O
stimulated O
lymphocytes O
. O

We O
propose O
that O
this O
increase O
in O
glucocorticoid B
receptors I
during O
the O
cell O
cycle O
may O
explain O
the O
increase O
in O
glucocorticoid B
receptors I
in O
mitogen O
- O
stimulated O
lymphocytes O
. O

Glucocorticoid B
receptor I
levels O
and O
steroid O
induced O
inhibition O
of O
nucleic O
acid O
precursors O
have O
been O
examined O
in O
lymphocytes O
from O
27 O
patients O
at O
different O
stages O
of O
chronic O
lymphatic O
leukaemia O
. O

No O
correlation O
can O
be O
found O
between O
the O
level O
of O
glucocorticoid B
receptors I
and O
the O
stage O
of O
the O
disease O
. O

Nuclear O
extracts O
from O
unstimulated O
cells O
of O
the O
human O
monocytic O
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific B
binding I
protein I
( O
complex B
II I
) O
, O
consistent O
with O
a O
constitutive B
p50 I
homodimer I
. O

Stimulation O
of O
Mono O
Mac O
6 O
cells O
with O
LPS O
will O
increase O
complex B
II I
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex B
I I
) O
, O
which O
represents O
the O
p50 B
/ I
65 I
heterodimer I
. O

Stimulation O
of O
Mono O
Mac O
6 O
cells O
with O
LPS O
will O
increase O
complex B
II I
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex B
I I
) O
, O
which O
represents O
the O
p50 B
/ I
65 I
heterodimer I
. O

Treatment O
of O
Mono O
Mac O
6 O
cells O
with O
pyrrolidine O
- O
dithiocarbamate O
( O
PDTC O
) O
at O
300 O
microM O
will O
block O
the O
LPS B
- I
induced I
complex I
I I
almost O
completely O
and O
will O
reduce O
complex B
II I
to O
the O
constitutive O
level O
. O

Binding O
activity O
of O
other O
nuclear B
factors I
that O
recognize O
the O
SP O
- O
1 O
and O
c O
/ O
EBP O
motifs O
of O
the O
human B
TNF I
promoter I
is O
not O
affected O
by O
such O
treatment O
. O

Secreted O
TNF B
protein I
as O
detected O
in O
the O
Wehi O
164S O
/ O
ActD O
bioassay O
and O
in O
a O
sandwich O
immunoassay O
was O
similarly O
reduced O
by O
PDTC O
. O

Kinetic O
analyses O
show O
that O
after O
LPS O
stimulation O
, O
NF B
- I
kappa I
B I
will O
peak O
at O
1 O
h O
, O
TNF O
transcript O
prevalence O
at O
2 O
h O
, O
and O
TNF B
protein I
at O
4 O
h O
. O

PDTC O
did O
not O
shift O
this O
response O
to O
LPS O
to O
a O
later O
time O
, O
but O
suppressed O
NF O
- O
kappa O
B O
mobilization O
, O
TNF B
transcripts I
, O
and O
TNF B
protein I
over O
the O
entire O
8 O
- O
h O
observation O
period O
. O

PDTC O
did O
not O
shift O
this O
response O
to O
LPS O
to O
a O
later O
time O
, O
but O
suppressed O
NF O
- O
kappa O
B O
mobilization O
, O
TNF B
transcripts I
, O
and O
TNF B
protein I
over O
the O
entire O
8 O
- O
h O
observation O
period O
. O

Furthermore O
, O
in O
these O
primary O
cells O
, O
induction O
of O
TNF B
transcripts I
, O
as O
determined O
by O
Northern O
blot O
analysis O
and O
by O
quantitative O
polymerase O
chain O
reaction O
, O
was O
prevented O
by O
PDTC O
as O
was O
TNF B
protein I
production O
. O

Furthermore O
, O
in O
these O
primary O
cells O
, O
induction O
of O
TNF B
transcripts I
, O
as O
determined O
by O
Northern O
blot O
analysis O
and O
by O
quantitative O
polymerase O
chain O
reaction O
, O
was O
prevented O
by O
PDTC O
as O
was O
TNF B
protein I
production O
. O

The O
ZEBRA B
protein I
activates O
expression O
of O
Epstein O
- O
Barr O
virus O
early B
- I
lytic I
- I
cycle I
genes I
in O
human O
B O
lymphocytes O
. O

Two O
of O
the O
three O
regions O
of O
the O
native O
ZEBRA B
protein I
act O
together O
to O
mediate O
activation O
when O
assayed O
on O
ZEBRA B
binding I
sites I
. O

However O
, O
certain O
deletion B
mutants I
of O
ZEBRA B
containing O
mutations O
in O
the O
N B
- I
terminal I
region I
exhibited O
discordant O
behaviors O
in O
S O
. O
cerevisiae O
and O
in O
B O
cells O
. O

The O
discordant O
mutants O
may O
reflect O
interactions O
with O
a O
variable B
domain I
of O
a O
conserved O
component O
or O
unique O
interactions O
with O
specialized O
components O
of O
the O
basal O
transcription O
apparatus O
in O
different O
cells O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B
terminus I
of O
chicken B
c I
- I
Rel I
and O
the O
F9 B
cell I
- I
specific I
activation I
region I
common O
to O
both O
v B
- I
Rel I
and O
c B
- I
Rel I
interact O
with O
the O
TATA B
- I
binding I
protein I
( O
TBP B
) O
and O
transcription B
factor I
IIB I
( O
TFIIB B
) O
in O
vitro O
and O
in O
vivo O
. O

p21ras B
and O
calcineurin O
synergize O
to O
regulate O
the O
nuclear B
factor I
of O
activated O
T O
cells O
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B
cell I
receptor I
( O
TCR B
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B
factor I
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B
binding I
complex I
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B
cell I
growth I
factor I
interleukin B
2 I
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B
regulatory I
domains I
of O
globin B
and O
other O
erythroid B
- I
specific I
genes I
and O
the O
activator B
proteins I
that O
bind O
to O
this O
regulatory B
element I
, O
the O
GATA B
factors I
, O
belong O
to O
a O
multi B
- I
gene I
family I
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

The O
timing O
and O
pattern O
of O
expression O
of O
these O
different O
mRNAs B
during O
avian O
erythroid O
development O
and O
differentiation O
suggests O
that O
temporally O
regulated O
changes O
in O
GATA B
factor I
expression O
are O
required O
for O
vertebrate O
hematopoiesis O
. O

Molecular O
regulation O
of O
human B
interleukin I
2 I
and O
T O
- O
cell O
function O
by O
interleukin B
4 I
. O

The O
two O
major O
types O
and O
their O
principal O
products O
, O
interleukin B
4 I
and O
interferon B
gamma I
( O
IL B
- I
4 I
and O
IFN B
- I
gamma I
) O
, O
are O
reciprocally O
negatively O
interactive O
. O

The O
two O
major O
types O
and O
their O
principal O
products O
, O
interleukin B
4 I
and O
interferon B
gamma I
( O
IL B
- I
4 I
and O
IFN B
- I
gamma I
) O
, O
are O
reciprocally O
negatively O
interactive O
. O

To O
analyze O
the O
molecular O
mechanism O
of O
IL O
- O
4 O
- O
mediated O
suppression O
of O
cell O
- O
mediated O
immunity O
we O
studied O
its O
effects O
on O
expression O
of O
interleukin B
2 I
( O
IL B
- I
2 I
) O
and O
IFN B
- I
gamma I
. O

IL B
- I
4 I
pretreatment O
of O
Jurkat O
cells O
prior O
to O
stimulation O
resulted O
in O
a O
decrease O
in O
transcription O
of O
the O
IL2 B
gene I
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL B
- I
2B I
binding I
site I
indicated O
that O
IL B
- I
4 I
inhibited O
the O
NFIL B
- I
2B I
complex I
and O
that O
the O
NFIL B
- I
2B I
DNA I
binding I
factor I
is O
distinct O
from O
AP B
- I
1 O
. O

These O
results O
suggest O
that O
IL B
- I
4 I
may O
regulate O
development O
and O
function O
of O
T O
- O
cell O
subsets O
involved O
in O
cell O
- O
mediated O
immunity O
in O
part O
by O
inhibiting B
factors I
required O
for O
transcription O
of O
the O
IL2 B
gene I

We O
have O
explored O
the O
possibility O
of O
using O
antibodies B
against O
purified O
rat O
liver O
glucocorticoid B
receptors I
to O
study O
the O
immunochemical O
properties O
of O
glucocorticoid B
receptors I
from O
murine O
and O
human O
malignant O
lymphocytes O
. O

We O
have O
explored O
the O
possibility O
of O
using O
antibodies B
against O
purified O
rat O
liver O
glucocorticoid B
receptors I
to O
study O
the O
immunochemical O
properties O
of O
glucocorticoid B
receptors I
from O
murine O
and O
human O
malignant O
lymphocytes O
. O

Mouse O
thymus O
was O
used O
as O
a O
source O
of O
glucocorticoid B
receptor I
from O
normal O
CS O
lymphocytes O
. O

Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
[ B
3H I
] I
triamcinolone I
acetonide I
- I
receptor I
complexes I
characteristic O
of O
the O
CS O
mouse O
and O
human O
lymphocytes O
, O
it O
failed O
to O
recognize O
the O
27 O
- O
to O
28 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid B
receptor I
present O
in O
corticoid O
- O
resistant O
mouse O
lymphoma O
P1798 O
cells O
. O

Therefore O
, O
under O
appropriate O
experimental O
conditions O
, O
it O
was O
possible O
to O
demonstrate O
cross O
- O
reactivity O
between O
the O
antiserum O
against O
rat B
liver I
glucocorticoid I
receptor I
and O
the O
58 O
- O
to O
62 O
- O
A O
( O
Stokes O
radius O
) O
glucocorticoid B
receptor I
from O
species O
as O
diverse O
as O
mouse O
and O
humans O
. O

In O
leukocyte O
population O
freshly O
isolated O
from O
the O
blood O
of O
26 O
patients O
with O
acute O
leukemia O
, O
we O
have O
measured O
several O
parameters O
including O
glucocorticoid B
receptors I
, O
nucleoside O
incorporation O
, O
percentage O
of O
cells O
in O
S O
phase O
, O
and O
steroid O
- O
induced O
cell O
lysis O
. O

Although O
, O
in O
all O
the O
patients O
studied O
, O
leukocytes O
were O
found O
to O
contain O
glucocorticoid B
receptors I
, O
we O
failed O
to O
demonstrate O
any O
correlation O
between O
the O
level O
of O
binding O
sites O
and O
the O
in O
vitro O
or O
in O
vivo O
response O
to O
glucocorticoids O
. O

Glucocorticoid B
receptors I
in O
cytosol O
and O
nuclear O
extract O
of O
human O
leukocytes O
. O

The O
apparent O
paradox O
of O
heightened O
adrenal O
corticosteroid O
levels O
associated O
with O
reduction O
in O
the O
competence O
of O
the O
body O
' O
s O
defensive O
apparatus O
to O
cope O
with O
exposure O
to O
new O
microbial B
antigens I
is O
considered O
. O

The O
present O
study O
addressed O
the O
role O
of O
different O
protein B
kinases I
in O
the O
LPS O
induction O
of O
cytokines B
. O

In O
addition O
to O
cytokine B
mRNA I
levels O
, O
LPS O
- O
induced O
IL O
- O
6 O
protein O
synthesis O
and O
IL O
- O
6 O
bioactivity O
were O
also O
reduced O
to O
baseline O
levels O
by O
the O
PTK O
inhibitors O
herbimycin O
A O
and O
genistein O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
which O
is O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
cytokine B
genes I
such O
as O
IL B
- I
6 I
and O
TNF B
- I
alpha I
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor B
protein I
I I
kappa I
B I
alpha I
. O

Some O
liberated B
dimers I
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B
kappa I
B I
alpha I
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS O
- O
induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B
kappa I
B I
alpha I
and O
not O
of O
c B
- I
rel I
or O
p65 B
. O

The O
gene O
encoding O
the O
cytolytic B
protein I
perforin B
is O
selectively O
expressed O
by O
activated O
killer O
lymphocytes O
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF B
- I
P1 I
and O
NF B
- I
P2 I
are O
related O
to O
but O
distinct O
from O
Ets B
proteins I
, O
e O
. O
g O
. O
, O
Ets B
- I
1 I
, O
Ets B
- I
2 I
, O
and O
NF B
- I
AT I
/ I
Elf I
- I
1 I
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

This O
potent O
activation O
does O
not O
require O
accessory O
cells O
, O
such O
as O
monocytes O
, O
but O
depends O
on O
persistent O
interleukin B
2 I
( O
IL B
- I
2 I
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25 B
/ I
IL I
- I
2 I
receptor I
alpha I
( I
IL I
- I
2R I
alpha I
) I
chain I
gene I
. O

We O
have O
previously O
observed O
that O
ionizing O
radiation O
induces O
tyrosine O
phosphorylation O
in O
human O
B O
- O
lymphocyte O
precursors O
by O
stimulation O
of O
unidentified O
tyrosine B
kinases I
and O
this O
phosphorylation O
is O
substantially O
augmented O
by O
vanadate O
. O

Influence O
of O
sex B
hormone I
binding I
globulin I
and O
serum B
albumin I
on O
the O
conversion O
of O
androstenedione O
to O
testosterone O
by O
human O
erythrocytes O
. O

Increased O
glucocorticoid B
receptor I
levels O
in O
antigen O
- O
stimulated O
lymphocytes O
. O

Recently O
a O
2 O
- O
to O
3 O
- O
fold O
increase O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
human O
peripheral O
lymphocytes O
has O
been O
noted O
after O
in O
vitro O
mitogen O
stimulation O
. O

Several O
of O
our O
results O
on O
energetics O
and O
kinetics O
of O
hormone O
binding O
to O
glucocorticoid B
receptors I
in O
rat O
thymus O
cells O
seem O
to O
require O
extension O
of O
the O
simplest O
model O
of O
hormone O
- O
receptor O
transformations O
in O
intact O
cells O
. O

ATP O
- O
depletion O
experiments O
suggest O
the O
existence O
of O
a O
nonbinding O
form O
of O
the O
receptor O
; O
` O
` O
chase O
' O
' O
experiments O
suggest O
reaction O
of O
hormone O
directly O
with O
nuclear O
- O
bound O
receptor O
; O
experiments O
on O
depletion O
and O
replenishment O
of O
cytoplasmic B
receptor I
using O
cortisol O
and O
dexamethasone O
suggest O
the O
existence O
of O
at O
least O
two O
subpopulations O
of O
nuclear B
- I
bound I
hormone I
- I
receptor I
complex I
. O

We O
have O
found O
that O
mitogen O
or O
immunologic O
stimulation O
of O
human O
peripheral O
lymphocytes O
in O
culture O
leads O
within O
24 O
h O
or O
so O
to O
a O
striking O
increase O
in O
the O
number O
of O
glucocorticoid B
receptor I
sites O
per O
cell O
. O

Contrary O
to O
the O
widely O
held O
view O
that O
mitogen O
- O
stimulated O
cells O
become O
insensitive O
to O
glucocorticoids O
, O
our O
experiments O
show O
that O
with O
respect O
to O
inhibition O
of O
thymidine O
and O
uridine O
incorporation O
and O
glucose O
uptake O
, O
the O
cells O
are O
highly O
sensitive O
to O
dexamethasone O
at O
24 O
, O
48 O
, O
and O
72 O
h O
after O
stimulation O
with O
concanavalin B
A I
. O

We O
show O
here O
that O
the O
immediate B
upstream I
region I
( O
from O
position O
- O
12 O
to O
- O
270 O
) O
of O
the O
murine B
interleukin I
4 I
( I
Il I
- I
4 I
) I
gene I
harbors O
a O
strong O
cell O
- O
type O
specific O
transcriptional B
enhancer I
. O

DNase O
I O
footprint O
protection O
experiments O
revealed O
six O
sites O
of O
the O
Il B
- I
4 I
promoter I
/ I
enhancer I
to O
be O
bound O
by O
nuclear B
proteins I
from O
lymphoid O
and O
myeloid O
cells O
. O

Three O
of O
the O
Il B
- I
4 I
NFAT I
- I
1 I
sites I
are O
closely O
linked O
to O
weak O
binding O
sites O
of O
Octamer B
factors I
. O

Whereas O
the O
binding O
of O
NFAT B
- I
1 I
and O
Octamer B
factors I
enhance O
the O
activity O
of O
the O
Il B
- I
4 I
promoter I
, O
the O
binding O
of O
HMG O
I O
( O
Y O
) O
suppresses O
its O
activity O
and O
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il B
- I
4 I
transcription O
in O
resting O
T O
lymphocytes O
. O

Induction O
of O
NF B
- I
kappa I
B I
by O
PC B
- I
PLC I
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor B
necrosis I
factor I
or O
interleukin B
1 I
. O

These O
results O
indicate O
that O
a O
cellular O
transduction O
pathway O
, O
dependent O
on O
specific O
PC O
breakdown O
, O
is O
functional O
in O
T O
lymphocytes O
and O
monocytes O
and O
may O
be O
used O
by O
various O
transmembrane O
receptors O
to O
activate O
HIV O
transcription O
through O
NF O
- O
kappa O
B O
- O
dependent O
induction O
of O
the O
HIV B
enhancer I
. O

Inhibition O
of O
T O
cell O
proliferation O
by O
Dex O
was O
associated O
with O
decreased O
IL O
- O
2 O
- O
dependent O
tyrosine O
phosphorylation O
of O
several O
intracellular B
proteins I
and O
decreased O
phosphorylation O
of O
the O
retinoblastoma B
gene I
product I
Rb I
, O
a O
protein O
essential O
for O
controlling O
the O
progression O
of O
cells O
through O
the O
cell O
cycle O
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 B
, I
90 I
, I
and I
100 I
kDa I
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF B
- I
kappa I
B I
site I
within O
the O
PRDII B
domain I
of O
beta B
interferon I
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 B
, I
90 I
, I
and I
100 I
kDa I
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF B
- I
kappa I
B I
site I
within O
the O
PRDII B
domain I
of O
beta B
interferon I
. O

The O
virally O
induced O
90 B
- I
to I
100 I
- I
kDa I
proteins I
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B
domain I
and O
an O
AT B
- I
rich I
sequence I
but O
do O
not O
cross O
- O
react O
with O
NF O
- O
kappa O
B O
subunit O
- O
specific O
antisera O
directed O
against O
NFKB1 B
( O
p105 B
or O
p50 B
) O
, O
NFKB2 B
( O
p100 B
or O
p52 B
) O
, O
RelA B
( O
p65 B
) O
, O
or O
c B
- I
rel I
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

Double O
immunostaining O
with O
the O
anti B
- I
ER I
MAb I
and O
with O
specific B
MAb I
to O
detect O
different O
macrophage B
antigens I
( O
Ber B
- I
MAC3 I
, O
MAC387 B
, O
CD68 B
) O
and O
CD8 O
+ O
T O
cell O
subsets O
( O
CD29 O
+ O
, O
CD45RO O
+ O
and O
CD29 O
- O
, O
CD45RO O
- O
) O
was O
performed O
. O

